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Background: Fatigue is a major problem in rheumatoid arthritis (RA). There is evidence for the clinical
effectiveness of cognitive–behavioural therapy (CBT) delivered by clinical psychologists, but few rheumatology
units have psychologists.
Objectives: To compare the clinical effectiveness and cost-effectiveness of a group CBT programme for
RA fatigue [named RAFT, i.e. Reducing Arthritis Fatigue by clinical Teams using cognitive–behavioural (CB)
approaches], delivered by the rheumatology team in addition to usual care (intervention), with usual care
alone (control); and to evaluate tutors’ experiences of the RAFT programme.
Design: A randomised controlled trial. Central trials unit computerised randomisation in four consecutive
cohorts within each of the seven centres. A nested qualitative evaluation was undertaken.
Setting: Seven hospital rheumatology units in England and Wales.
Participants: Adults with RA and fatigue severity of ≥ 6 [out of 10, as measured by the Bristol Rheumatoid
Arthritis Fatigue Numerical Rating Scale (BRAF-NRS)] who had no recent changes in major RA medication/
glucocorticoids.
Interventions: RAFT – group CBT programme delivered by rheumatology tutor pairs (nurses/occupational
therapists). Usual care – brief discussion of a RA fatigue self-management booklet with the research nurse.
Main outcome measures: Primary – fatigue impact (as measured by the BRAF-NRS) at 26 weeks.
Secondary – fatigue severity/coping (as measured by the BRAF-NRS); broader fatigue impact [as measured
by the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ)]; self-reported
clinical status; quality of life; mood; self-efficacy; and satisfaction. All data were collected at weeks 0, 6,
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26, 52, 78 and 104. In addition, fatigue data were collected at weeks 10 and 18. The intention-to-treat
analysis conducted was blind to treatment allocation, and adjusted for baseline scores and centre.
Cost-effectiveness was explored through the intervention and RA-related health and social care costs,
allowing the calculation of quality-adjusted life-years (QALYs) with the EuroQol-5 Dimensions, five-level
version (EQ-5D-5L). Tutor and focus group interviews were analysed using inductive thematic analysis.
Results: A total of 308 out of 333 patients completed 26 weeks (RAFT, n/N = 156/175; control, n/N = 152/158).
At 26 weeks, the mean BRAF-NRS impact was reduced for the RAFT programme (–1.36 units; p < 0.001)
and the control interventions (–0.88 units; p < 0.004). Regression analysis showed a difference between
treatment arms in favour of the RAFT programme [adjusted mean difference –0.59 units, 95% confidence
interval (CI) –1.11 to –0.06 units; p = 0.03, effect size 0.36], and this was sustained over 2 years (–0.49 units,
95% CI –0.83 to –0.14 units; p = 0.01). At 26 weeks, further fatigue differences favoured the RAFT programme
(BRAF-MDQ fatigue impact: adjusted mean difference –3.42 units, 95% CI –6.44 to – 0.39 units, p = 0.03;
living with fatigue: adjusted mean difference –1.19 units, 95% CI –2.17 to –0.21 units, p = 0.02; and
emotional fatigue: adjusted mean difference –0.91 units, 95% CI –1.58 to –0.23 units, p = 0.01), and these
fatigue differences were sustained over 2 years. Self-efficacy favoured the RAFT programme at 26 weeks
(Rheumatoid Arthritis Self-Efficacy Scale: adjusted mean difference 3.05 units, 95% CI 0.43 to 5.6 units;
p = 0.02), as did BRAF-NRS coping over 2 years (adjusted mean difference 0.42 units, 95% CI 0.08 to
0.77 units; p = 0.02). Fatigue severity and other clinical outcomes were not different between trial arms and
no harms were reported. Satisfaction with the RAFT programme was high, with 89% of patients scoring
≥ 8 out of 10, compared with 54% of patients in the control arm rating the booklet (p < 0.0001); and 96%
of patients and 68% of patients recommending the RAFT programme and the booklet, respectively, to others
(p < 0.001). There was no significant difference between arms for total societal costs including the RAFT
programme training and delivery (mean difference £434, 95% CI –£389 to £1258), nor QALYs gained (mean
difference 0.008, 95% CI –0.008 to 0.023). The probability of the RAFT programme being cost-effective was
28–35% at the National Institute for Health and Care Excellence’s thresholds of £20,000–30,000 per QALY.
Tutors felt that the RAFT programme’s CB approaches challenged their usual problem-solving style, helped
patients make life changes and improved tutors’ wider clinical practice.
Limitations: Primary outcome data were missing for 25 patients; the EQ-5D-5L might not capture fatigue
change; and 30% of the 2-year economic data were missing.
Conclusions: The RAFT programme improves RA fatigue impact beyond usual care alone; this was sustained
for 2 years with high patient satisfaction, enhanced team skills and no harms. The RAFT programme is
< 50% likely to be cost-effective; however, NHS costs were similar between treatment arms.
Future work: Given the paucity of RA fatigue interventions, rheumatology teams might investigate the
pragmatic implementation of the RAFT programme, which is low cost.
Trial registration: Current Controlled Trials ISRCTN52709998.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 23, No. 57. See the NIHR Journals Library website
for further project information.
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Glossary
Cohort 10–14 patients recruited in a centre; the level at which randomisation then occurred.
Reducing Arthritis Fatigue by clinical Teams using cognitive–behavioural approaches (RAFT)
A fatigue self-management programme comprising seven sessions.
Reducing Arthritis Fatigue by clinical Teams using cognitive–behavioural approaches (RAFT) group
A group of 5–7 patients attending the same RAFT programme together.
Self-efficacy The belief or confidence that one can successfully execute an action or master a situation;
a strong predictor of initiating behaviour change and persistence in the face of difficulty.
Session The seven sessions constituting the RAFT programme. Each session covers specific topics.
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Plain English summary
Rheumatoid arthritis (RA) is a lifelong inflammatory condition affecting multiple joints, with fatigue as amajor consequence. Cognitive–behavioural therapy (CBT) helps patients work out links between
symptoms, behaviours and thoughts driving those behaviours (e.g. why someone pushes on when
exhausted), and understanding these links helps patients make changes. A CBT programme for groups of
RA patients, facilitated by a psychologist, reduces fatigue impact. However, few rheumatology teams have
psychologists.
The study tested whether or not rheumatology nurses and occupational therapists (OTs) could facilitate the
programme [named RAFT, i.e. Reducing Arthritis Fatigue by clinical Teams using cognitive–behavioural (CB)
approaches] after brief training. The study compared the RAFT programme with usual care for RA fatigue
(i.e. a short discussion of an arthritis fatigue booklet). All 333 patients received usual care, and then half
of the patients were allocated (by chance) to also attend the seven-session RAFT programme. The study
compared the RAFT programme with usual care for effects on fatigue, quality of life, cost and value for
money. In addition, the rheumatology nurse and OT RAFT tutors were interviewed for their views on the
RAFT programme.
The study found that patients’ fatigue impact was reduced by both the RAFT programme and usual care at
6 months and 2 years, but patients undertaking the RAFT programme improved significantly more than
those receiving usual care alone. Differences were seen for improvements in fatigue impact, fatigue
coping, emotional fatigue and living with fatigue. Patients were very satisfied with the RAFT programme
and attended most of the sessions. The study found no significant difference between the NHS costs of
the RAFT programme and usual care. Neither the RAFT programme nor usual care changed quality of life;
therefore, standard value-for-money tests showed no difference between them. Tutors found that the CB
questioning approach of the RAFT programme was different from their usual problem-solving style, but
helped patients make life changes, and the new CB skills improved tutors’ wider clinical practice.
In conclusion, the trial has shown that the RAFT programme has a small to medium effect on reducing
fatigue impact in patients with RA and is a potentially low-cost intervention that can be delivered by
rheumatology nurses and OTs rather than a psychologist.
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Scientific summary
Background
Fatigue is a major problem in rheumatoid arthritis (RA). Group cognitive–behavioural therapy (CBT) delivered
by a clinical psychologist reduces the impact of RA fatigue on patients’ lives, but few rheumatology units
have psychologists.
Objectives
1. To compare the clinical effectiveness and cost-effectiveness of a group programme for RA fatigue
[named RAFT, i.e. Reducing Arthritis Fatigue by clinical Teams using cognitive–behavioural (CB) approaches],
delivered by the rheumatology team in addition to usual care, with usual care alone. The primary outcomes
were fatigue impact at 6 months (followed up for 24 months), and
2. an evaluation of tutors’ experiences of the RAFT programme.
Design
A randomised controlled trial (RCT) with a nested qualitative evaluation.
Setting
Seven rheumatology units in England and Wales.
Interventions
The RAFT programme consists of group CBT co-delivered by pairs of rheumatology nurses and/or
occupational therapists (tutors), using reflective questioning to enable patients to identify links between
thoughts, feelings, behaviours and fatigue. The group provides role models/peer support for legitimising
fatigue, goal-setting and problem-solving. The RAFT programme comprises six 2-hour sessions (weeks 1–6)
and a 1-hour consolidation session (week 14), covering fatigue validation, pacing, how thoughts drive
boom-and-bust cycles, energisers/drainers, sleep, stress and communication. Patients monitor their activity,
rest and fatigue with charts, which are reviewed in the group sessions to support goal-setting towards
personal priorities for improving quality of life. Tutors were trained together over 4 days and provided with
a RAFT programme manual/material, before delivering a practice programme locally (observed by a trainer).
Tutors delivered four RAFT programmes with clinical supervision for one session in alternate programmes.
Usual care was a short discussion with the research nurse of the Versus Arthritis (formerly Arthritis
Research UK) fatigue self-management booklet, in routine use in UK rheumatology units (written by the
RAFT programme trainers based on an original RCT of the intervention delivered by a psychologist).
Participants
Adults aged ≥ 18 years with RA and fatigue severity score of ≥ 6 [out of 10, as measured by the Bristol
Rheumatoid Arthritis Fatigue Numerical Rating Scale (BRAF-NRS)], which patients considered recurrent.
Any patients who had a recent change in major RA medication or glucocorticoids were excluded.
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Recruitment
Each centre (hospital) delivered four consecutive RAFT programmes over 2 years. In order to randomise
5–7 patients to a RAFT programme, each centre recruited 10–14 patients and then closed that ‘cohort’.
Over a 2-week period, those patients then attended for informed consent and baseline assessment and
received usual care for fatigue. When all visits for patients in that cohort were completed, randomisation
occurred and recruitment commenced for the next cohort.
Randomisation, concealment and blinding
Once a centre completed all baseline visits for a cohort, the clinical trials unit conducted the randomisation
for that centre’s cohort (concealed from the RAFT programme study team and the local research nurse).
Computer-generated randomisation was stratified by the seven centres and by cohort within centres
(four cohorts recruited consecutively over 2 years). Allocation was 1 : 1 within cohorts but, in the event
of an odd number, the CB arm received the extra patient. Patients randomised to the RAFT programme
but unable to attend maintained their allocation and were offered subsequent local RAFT programmes.
If they accepted, the patients had a new baseline assessment performed with that cohort. Blinding of RAFT
programme tutors and patients was not possible, but analysis was performed blind to allocation.
Outcome assessment
Primary clinical outcome
Fatigue impact [measured by the Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scale (BRAF-NRS)
for impact] was measured at 26 weeks.
Secondary clinical outcomes
Fatigue assessments included impact, severity, coping (BRAF-NRS), and overall fatigue impact, physical
fatigue, living with fatigue, emotional fatigue and cognitive fatigue [as measured by the Bristol Rheumatoid
Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ)]. Clinical assessment included mood, pain,
disability, disease activity, quality of life, sleep, valued leisure activities and self-efficacy (belief in ability
to achieve an action), using validated scales. All data were collected at weeks 0, 6, 26, 52, 78 and 104.
In addition, fatigue data were collected at weeks 10 and 18 (i.e. 4 weeks before and 4 weeks after the
consolidation session).
Economic outcomes
The primary economic outcome was quality-adjusted life-years (QALYs) at 26 weeks, using the EuroQol-5
Dimensions, five-level version (EQ-5D-5L) questionnaire (BRAF-NRS impact was a secondary outcome).
Resource use data were collected for RA-related costs, including RAFT programme training and delivery;
RA medications; primary, community and secondary medical and health professional appointments/care;
rheumatology telephone helpline usage; social care; work productivity and patient-incurred expenses for
travelling to appointments and the RAFT programme sessions. Data were collected through staff logs,
hospital computer records and patient questionnaires (at weeks 0, 6, 26, 52, 78 and 104).
Tutor experiences
Individual face-to-face interviews were used to capture tutors’ diverse experiences and a focus group
discussion allowed tutors to discuss clinical implementation. Interviews and focus groups were audio-recorded
and guided by a broad, neutral discussion schedule.
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Sample size
The RAFT programme is delivered by clinical teams rather than psychologists; therefore, the RCT was
powered to be able to demonstrate a difference of 1.46 units on a 0–10 fatigue impact scale (i.e. 75% of
that previously demonstrated by a psychologist). For a two-sided significance of 0.05 and a power of 90%,
73 patients per trial arm were required; allowing for potential clustering of groups within and between
centres increased this to 75 patients per trial arm. Allowing for 50% attrition at 2 years, recruitment aimed
for 150 patients per trial arm.
Analysis methods
Clinical analysis
Descriptive statistics of baseline clinical and sociodemographic characteristics were used to describe the study
sample and ascertain comparability of randomisation arms. The primary analysis of effectiveness was carried
out under the intention-to-treat (ITT) principle and used linear regression to estimate an adjusted mean
difference, comparing fatigue impact at 26 weeks (the primary outcome) between arms as randomised,
adjusted for baseline values of the outcome and recruitment centre. Sensitivity of the primary analysis to the
effect of missing data was explored by imputing missing primary outcome data and repeating the primary
analysis model. A secondary analysis compared arms at follow-up across 26, 52, 78 and 104 weeks using
mixed-effects repeated measures regression. Further secondary analyses of the primary outcome included
repeating the primary analysis model restricted to only baseline-eligible participants (some patients had
dropped below their screening fatigue severity of 6 out of 10 during the time it took to build cohorts); a
complier-average causal-effect analysis to investigate the efficacy of the intervention (based on treatment
compliance status), for comparison with the ITT estimate of the offer of the arm; and investigation of potential
clustering by centre and cohort. The effect of the arm on secondary outcomes, collected at 26 weeks, was also
examined using appropriate regression models (i.e. linear regression for continuous outcomes, logistic
regression for binary outcomes, etc.), adjusted for baseline values of the outcome being investigated and
centre. The secondary outcomes were also subject to repeated measures analysis using data collected at 26,
52, 78 and 104 weeks’ follow-up. Exploratory/subgroup analyses explored further RA fatigue-related questions.
Health economics analyses
The primary economic analysis used QALYs at 26 weeks as the outcome measure and was conducted from
the societal perspective. Secondary analyses investigated the BRAF-NRS impact outcome measure, NHS and
Personal Social Services perspectives, and a 2-year follow-up. All costs are reported in 2015/16 pounds
sterling. Costs and QALYs in the second year of follow-up were discounted at 3.5%.
All analyses were conducted using ITT principles, comparing the trial arms as randomised and including
all patients. Missing data were imputed by the predictive mean-matching method. The incremental mean
differences in total costs and QALYs (adjusted for baseline utility) were estimated between the two arms of
the trial and 95% confidence intervals (CIs) derived. Cost and QALY data were combined to calculate the
incremental cost-effectiveness ratio (ICER) and net monetary benefit statistics. Calculations were made to
investigate whether or not the RAFT programme is cost-effective at the established National Institute for
Health and Care Excellence (NICE) thresholds of £20,000 and £30,000 per QALY gained. One-way
sensitivity analyses were used to judge the potential impact of sources of uncertainty.
Qualitative analyses
Interview and focus group audio-recordings were transcribed and anonymised. All transcripts were analysed
by the qualitative researcher using inductive thematic analysis, with subsets independently analysed by
three co-applicants (two professionals and one patient). Items of interest and their related text were coded,
then patterns of codes identified and their supporting text collated. Related clusters of coded text formed
subthemes, which were then grouped together to form themes. The three independent analyses were
DOI: 10.3310/hta23570 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 57
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hewlett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
incorporated into the final analysis, as there were no substantial differences. The focus group transcript
was analysed by two researchers and used to confirm, challenge or elaborate the themes (triangulation).
Patient and public involvement
Two patient co-applicants brought experiential knowledge of RA fatigue and had undertaken the original
CBT intervention facilitated by a psychologist. The patient co-applicants suggested improvements to the
RAFT programme patient materials, advised on trial outcomes, questionnaire packs and recruitment, talked
with the tutors about fatigue and the intervention, and analysed qualitative data.
Results
Clinical results
A total of 333 participants were recruited (175 participants were randomised to the RAFT programme and
158 participants to the control arm), and participant characteristics were well balanced between the trial
arms at baseline. The RAFT programme participants attended a mean of 5.85 sessions out of their 7 RAFT
sessions (standard deviation 1.63 sessions). Of those participants randomised, 308 participants (92%)
provided primary outcome data. Both trial arms had improved fatigue impact at 26 weeks; however, there
was evidence of a difference between trial arms, with those in the RAFT arm having a BRAF-NRS impact
score that was –0.59 units lower (i.e. better) than those receiving usual care (95% CI –1.11 to –0.06 units;
p = 0.03, effect size 0.36). Repeated measures analysis suggested a sustained effect of the intervention
over the 2 years’ follow-up (adjusted mean difference –0.49 units, 95%CI –0.83 to –0.14 units; p = 0.01).
When restricting analyses to the 262 baseline-eligible participants, a slightly larger effect was observed
both at 26 weeks (adjusted mean difference –0.82 units, 95% CI –1.40 to –0.24; p = 0.01) and over
2 years (adjusted mean difference –0.58 units, 95% CI –0.95 to –0.22 units; p = 0.002). Analysis of
secondary outcomes provided evidence of a between-arm difference in favour of the RAFT programme in
BRAF-MDQ fatigue impact, living with fatigue and emotional fatigue, at both 26 weeks and over 2 years.
There was also evidence of a difference in self-efficacy at 26 weeks and BRAF-NRS coping over 2 years
in favour of the RAFT programme. Fatigue severity and other outcomes were similar between arms at
26 weeks and over 2 years. There were relatively few missing data and the analysis of imputed data
differed very little to complete-case analysis. No harms were reported. The RAFT programme satisfaction
was rated ≥ 8 (out of 10) by 89% of patients, compared with 54% of patients in the control arm rating
the booklet (p < 0.0001).
Health economic results
Participants were relatively low users of primary care and community services, but were regular attenders
in secondary care for RA-related appointments and high users of RA-related medications. At baseline,
76 participants (22.8%) were in work, with no difference between trial arms. There was no statistically
significant difference between trial arms for total societal costs, including the RAFT programme training
and delivery (mean difference £434, 95% CI –£389 to £1258), nor in QALYs gained (mean difference 0.008,
95% CI –0.008 to 0.023). The point estimate of the incremental cost per QALY gained was £55,202 and
the net monetary benefit was –£277 (95% CI –£1212 to £657) at a societal willingness-to-pay threshold
of £20,000 per QALY. The probability that the intervention is cost-effective at the same threshold is 0.28.
The sensitivity analysis without training costs gave an ICER of £31,578 per QALY and a cost-effectiveness
probability of 0.42 at the £20,000 per QALY threshold. Up to 30% of health economics data were missing
at the 2-year follow-up; therefore, imputed data were used throughout (although complete-case analysis
did not alter the primary analysis results). The primary analysis was repeated excluding those individuals who
had fallen below the eligibility criterion of BRAF-NRS severity score of ≥ 6 (out of 10) between screening
and baseline (control, n/N = 24/158; RAFT, n/N = 28/175). For baseline-eligible patients, the ICER was
£17,214 per QALY and the probability of cost-effectiveness was 0.52 at the £20,000 NICE threshold.
Cost-effectiveness analysis using the primary effectiveness outcome gave an ICER of £455 per unit of
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improvement in BRAF-NRS impact, giving a probability of cost-effectiveness of, for example, 0.78,
if society is willing to pay £1000 per unit improvement in BRAF-NRS impact.
Qualitative results
Among the 15 RAFT programme tutors, 14 participated in interviews and eight participated in the focus
group. The following five themes were identified. First, ‘the RAFT programme was a daunting but exciting
undertaking’, as CB approaches and ‘ask don’t tell’ differed from the tutors’ usual advice-giving and
problem-solving approaches. Becoming confident required time and effort. Second, ‘skills practice and
demonstrations were essential’, and training together and expert demonstrations were helpful. Role play
was invaluable, but uncomfortable. Third, ‘developing an individual approach to a standardised intervention’
came through personalising their RAFT programme manuals by paraphrasing sample text. Clinical supervision
helped and tutors developed the dynamics of pair work. Fourth, ‘enhanced clinical practice beyond the RAFT
programme’ was demonstrated as tutors described working with the patient as a whole person in clinic;
their new ‘ask don’t tell’ skills helped them listen, draw things out and confidently discuss fatigue utilising
the RAFT programme material. Fifth, ‘delivering the RAFT programme in clinical practice’ was what tutors
wanted but would require buy-in from managers/colleagues, and NHS restraints mean that models of training
and support need to be explored, perhaps blending online learning with reduced face-to-face training.
Tutors considered the RAFT programme to be life-changing for patients.
Conclusions
The RAFT programme, delivered by clinical rheumatology teams, improved fatigue impact beyond usual
care alone, as well as emotional fatigue, living with fatigue, coping with fatigue and self-efficacy, sustained
over 2 years. Although costs were not statistically significantly different between trial arms, the primary
economic evaluation using QALYs based on EQ-5D-5L suggested that the RAFT programme was unlikely to
be cost-effective at conventional NICE thresholds. Rheumatology clinicians delivering the RAFT programme
acquired new skills that they utilised in patient care beyond the RAFT programme.
Strengths and limitations
Multiple hospitals and tutors were involved in a pragmatic trial, with broad entry criteria incorporating
usual RA management, natural variations in patient attendance and staff ability to deliver clinical services.
In addition, evaluations aimed to capture all relevant outcomes and costs for 2 years, plus qualitative
analysis by multiple researchers.
However, controlling for any social effects of the RAFT programme groups was impractical; seven didactic
information sessions would not reflect usual care and risk high attrition. There were no follow-up data on
25 patients who withdrew before week 26; the economic evaluation had 30% missing data and the
EuroQol-5 Dimensions questionnaire may not capture RA fatigue.
Implications for health care
Although cost-effectiveness was not demonstrated, findings must be reviewed in the context of a low-cost
intervention with sustained clinical effect and no harms, for an important symptom with few treatment
options; analysis of patients with a fatigue severity score of ≥ 6 at baseline and discounting one-off RAFT
programme training costs demonstrated greater effectiveness. Rheumatology teams without clinical
psychologists might thus consider implementation. Increasing RAFT programme groups to 8–10 patients
could be feasible and economically beneficial.
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Implications for future research
The RAFT programme co-delivery by a rheumatology professional–patient tutor pair (combining professional
and experiential knowledge) could be tested, as could delivery to people with physical long-term conditions
with fatigue. The number of RAFT programme sessions required, and contribution of the consolidation
session, could be tested. The amount of change in BRAF-NRS impact that is meaningful for patients needs
clarifying, along with patient values for fatigue (for QALY calculations).
Trial registration
This trial is registered as ISRCTN52709998.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
Rheumatoid arthritis (RA) affects approximately 0.5 million people in the UK,1 with widespread synovitis
leading to joint pain and stiffness in repeated flares of inflammatory activity. Over time this inflammatory
activity can result in multiple joint damage and disability, with major impacts on quality of life, including
social and work life.2 Initiation of very early pharmacological treatment (treat to target) aims to switch off
these inflammatory processes and is combined with multidisciplinary interventions by secondary care
rheumatology teams to support self-management of symptoms and lifestyle.3,4
In the past decade, consultation with people with RA regarding their treatment priorities has highlighted the
importance of fatigue as a symptom.5 For many people with RA, fatigue is present on most days and can
be as extreme as that seen in chronic fatigue syndrome (CFS), and as severe as their RA pain.6,7 Qualitative
research shows that people find RA fatigue to be not only a physical experience, but also to have emotional
and cognitive elements that can have an impact on their work, family roles and relationships.8,9 Quality of
life is reduced by fatigue,10 which patients report as being as difficult as pain to manage. However, fatigue
is often ignored by the rheumatology team,9,11 despite being one of patients’ top priorities.5 People with RA
consider fatigue to be a major feature in work loss,12 which affects two-thirds of working people with RA.
In addition, approximately one-fifth of people with RA become work-disabled within 5 years, resulting in
an annual UK work production loss from RA of around £2 billion.13,14 These findings led to international
consensus that the effect of interventions on RA fatigue should now be reported in all RA clinical trials
alongside the traditional core set.15
Inflammation as a possible mechanism for rheumatoid arthritis fatigue
If the inflammatory processes of RA are the major driver of RA fatigue, either directly or through the effects
of inflammation on pain and function, then pharmacological interventions for RA inflammation should also
significantly improve fatigue. However, systematic review shows that biologic disease-modifying antirheumatic
drugs (bDMARDs) to control RA inflammation yield only a small to moderate improvement in RA fatigue
(32 studies involving 14,628 patients), although the quality of the studies was variable.16 Inflammatory activity,
not fatigue, is the indication for initiating or changing bDMARD therapy; therefore, these studies did not
recruit patients specifically with fatigue.16 The findings are supported by other studies that show that RA
fatigue continues to be problematic even for those patients who achieve disease (i.e. inflammatory)
remission.17 Therefore, it is unlikely that inflammation alone is the single driver for RA fatigue.
Multicausal pathways as a likely mechanism for rheumatoid arthritis fatigue
A systematic review of causal studies relating to RA fatigue could not draw conclusions as a result of the
quality of the evidence, which was largely cross-sectional or longitudinal studies that rarely controlled for
baseline fatigue.18 Therefore, with insufficient studies, and often conflicting results on any single causal
mechanism for fatigue (e.g. inflammation, disability, depression),18 it is postulated that, conceptually,
RA fatigue is likely to have complex and multicausal pathways (see Appendix 1).19 These pathways are
categorised as potentially involving interactions between or within three elements: (1) disease processes
(RA elements); (2) thoughts, feelings and behaviours (cognitive/behavioural elements); and (3) life issues
(personal elements).19 Pathways will vary between patients and potentially even within patients for individual
fatigue episodes. For example, on one occasion fatigue may be driven by inflammation causing pain and
disrupting sleep, interacting with heavy work responsibilities that lead to overactivity (keeping going until
exhausted); however, on another occasion fatigue may be driven by low mood, leading to behavioural
withdrawal (deactivation) and subsequent deconditioning. In this conceptual model, self-management
strategies appear crucial in managing fatigue impact.
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Physical exercise interventions
Physical exercise interventions might address muscle or respiratory deconditioning from inactivity that cause
fatigue. A systematic review of randomised controlled trials (RCTs) of non-pharmacological interventions
reporting RA fatigue identified six physical exercise interventions (five RCTs involving 371 patients), including
pool therapy, yoga, t’ai chi, low-impact aerobics, strength training and stationary cycling.20 Meta-analysis
showed a small effect on fatigue severity. However, none of these studies had fatigue as a primary outcome,
fatigue was not an inclusion criterion and studies were not powered to detect fatigue change.
Psychosocial interventions and underpinning theory
A broader approach of psychosocial interventions for helping people manage their fatigue may address
multiple elements in the conceptual model simultaneously.19 Educational interventions may provide the
information people need to identify and change behaviours that might be stopping their management of
fatigue [e.g. introducing ideas of breaking up periods of activity with rest (pacing)]. Interventions that also
address thoughts or feelings related to fatigue and its management might lead to more beneficial coping
strategies by looking at ways of managing stress, low mood and priorities for a work–life balance.
Rationale for cognitive–behavioural therapy for fatigue in rheumatoid arthritis
Cognitive–behavioural therapy (CBT) aims to help people work out for themselves the links between their
thoughts (cognitions) and feelings and how these may be driving their actions (behaviours), and addresses
these underpinning cognitions as a way of prompting behaviour changes.21 For example, a belief that
it is one’s role to do the household chores may prevent someone asking family members to help, which,
combined with feeling shame or guilt if chores are left undone, may drive persistence in undertaking
chores. This excessive activity leads to episodes of overwhelming fatigue and enforced rest (so-called
‘crashes’), commonly called the ‘boom-and-bust’ cycle. Addressing these previously unchallenged beliefs
about what family members would think about a request for help, and whether or not leaving some
chores undone would be a catastrophe, might prompt behaviour changes that result in less fatigue. The
lack of an existing clear approach to self-management of fatigue from RA professionals may contribute to
a sense of powerlessness and passivity among people with RA fatigue who feel their lives are controlled
by its perceived unpredictability. CBT provides a framework through which a person can better understand
those components of fatigue experiences that are controllable, and, through this, make a shift in core
beliefs towards taking control rather than being passive. On the basis of such a shift a person could
become progressively less passive and more self-confident through better self-management of activity and
fatigue symptoms so that the impact of fatigue is reduced.
A systematic review of group education programmes for general self-management in musculoskeletal
conditions found that a CBT approach is more likely to lead to people making behaviour changes than
information alone,22 and CBT has been shown to be effective for fatigue in CFS and multiple sclerosis.23,24
Problem-solving and goal-setting as routes to enhancing self-efficacy (see Underpinning theory: self-efficacy
and social cognitive theory) are the core self-management skills that patients learn in CBT.
Underpinning theory: self-efficacy and social cognitive theory
Managing daily life with RA in order to minimise fatigue requires changing behaviours that might have been
contributing to fatigue onset, perpetuating it, or limiting its management. Changing habitual behaviours
can be hard, and self-efficacy is the belief or confidence that one can successfully execute an action or
master a situation and is a strong predictor of behaviour change and persistence in the face of difficulty.25
Self-efficacy is cultivated through reinterpretation of symptoms (understanding that fatigue has many causes
that could be tackled), mastering the new behaviours (through progressive goal-setting), and by modelling
and social persuasion (from seeing the successful changes and adaptions of other RA patients).26 Therefore,
learning about fatigue management as part of a group can enhance these self-efficacy processes because
other patients in similar situations act as role models: validating the complexity of fatigue and demonstrating
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more effective ways of mastering it through the efforts they make as fellow participants on the programme
[social cognitive theory (SCT)].25,26 It has been demonstrated that interventions based on SCT and/or CBT
enhance self-efficacy and produce better patient outcomes than simply providing self-management
information.22,27 Learning with others in similar circumstances may be particularly helpful for validating
invisible symptoms, such as fatigue.
Evidence for psychosocial interventions on rheumatoid arthritis fatigue
Three RCTs trialled one-to-one CBT, a group programme (based on SCT) and a group CBT programme
(SCT/CBT) over 11, 16 and 22 hours, respectively, and reported improved fatigue in RA patients.28–30
However, interventions were not primarily aimed at improving fatigue severity; thus, patients were not
recruited because of fatigue, nor were studies powered to detect fatigue change. Furthermore, participation
in the studies was restricted (e.g. to those with early disease, mild disability or psychological distress or
who have a partner). However, RA fatigue occurs in the majority of patients;6,7 therefore, self-management
interventions should be tested across a wide RA population. Therefore, the original 18-week RCT was
conducted to test a fatigue self-management programme in a broad RA population (fatigue score of ≥ 6/10),
using group CBT (13 hours SCT/CBT), led by a clinical psychologist and specialist pain management
occupational therapist (OT), compared with groups receiving fatigue self-management information alone
(n = 127).31 The group CBT intervention improved fatigue impact (effect size 0.77) alongside fatigue severity
and coping with fatigue, as well as disability, sleep and mood (depression, helplessness, self-efficacy).
In the qualitative evaluation undertaken through participant interviews, patients spontaneously raised the
significance of key elements of the CBT used by the clinical psychologist (working links out for themselves,
goal-setting, activity diaries), and SCT components (the value of being in a group).32
A systematic review identified 15 psychosocial interventions reporting RA fatigue, including the previous
study (13 RCTs involving 1556 patients).20 Interventions included expressive writing, CBT, mindfulness,
lifestyle management, self-management, energy conservation and group education, and showed an overall
small benefit on RA fatigue severity. The overall quality of trials was rated as being low, largely accounted for
by small patient numbers and the difficulty of blinding participants in interventions that require engagement
for behaviour change. Within the systematic review, the RCTs detailed above, which were the only
interventions in which improving fatigue was an aim or inclusion criterion,28,30,31 had stronger methodological
qualities and stronger effects on fatigue.
Rationale for programme delivery by rheumatology clinical teams
The fatigue self-management programme using CBT and SCT was delivered by a CBT-trained clinical
psychologist.31 However, only 8% of rheumatology units have a clinical psychologist on their team;33
therefore, implementation in routine NHS care is currently difficult. Enabling people with long-term
conditions to self-manage is a key government target,34 and RA-specific guidelines by rheumatology
professional bodies and the National Institute for Health and Care Excellence (NICE)3,4,35 highlight the
need to address self-management, including fatigue. Given the success of psychological therapies but
the shortage of clinical psychologists, Improving Access to Psychological Therapies is also a government
health policy.36 This is being achieved through manualisation of psychological interventions and training
non-clinical assistants to deliver them, often by telephone and under the supervision of a psychologist,
adhering closely to the intervention stipulated and referring those cases that are not straightforward to
the psychologist. It might be that RA fatigue self-management programmes do not need to be delivered
by trained CBT psychologists, but could be delivered by, for example, Improving Access to Psychological
Therapies practitioners guided by a manual. However, in people with RA fatigue, thoughts, feelings and
behaviours will also interact with their need to manage a complex, lifelong and fluctuating chronic physical
illness that in itself requires managing the interactions between pain, inflamed joints, disrupted sleep,
multiple medications and their accumulative effects on overall well-being. Therefore, in order to address
these issues, psychological therapies need to be provided by clinicians who understand the multiple
interactions between fatigue and the patient’s wider self-management of fluctuating RA symptoms.
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The multidisciplinary team, particularly rheumatology nurse specialists (RNSs) and OTs, routinely support RA
patients in self-management and understand these interactions; therefore, with appropriate training and
support RNSs and OTs are ideally placed to deliver a group fatigue intervention using cognitive–behavioural
(CB) approaches, thus embedding fatigue management within usual care.
Development of the RAFT programme intervention for delivery by
clinical teams
The original group CBT fatigue intervention delivered by a clinical psychologist and specialist OT to people
with RA31 was developed from clinical experience of chronic pain and CFS self-management programmes,
using the Medical Research Council’s framework for complex interventions.37 The intervention was grounded
in qualitative data about RA patients’ experiences of fatigue9 and clinical RA experience. The intervention
comprised six 2-hour sessions, running once per week (weeks 1–6), and a 1-hour consolidation session
(week 14), and was delivered to groups of approximately 5–7 patients. For delivery by clinical teams, a tutor
manual was produced, and the intervention given the acronym RAFT (Reducing Arthritis Fatigue by clinical
Teams using CB approaches).
The RAFT programme delivery: cognitive–behavioural and social cognitive
theory approaches
The CB approach used was one of reflective discovery through Socratic questioning, in which tutors ask simple
questions to enable patients to identify the links between their thoughts, feelings, behaviours and symptoms
(i.e. fatigue).21 This was in contrast to the more didactic information- or advice-giving by the tutors, in which
the patients were passive recipients of information. Self-monitoring (daily activity/rest charts) and goal-setting
are the most effective tools in bringing about behavioural change,38 and the use of metaphors helps turn
abstract or difficult therapeutic concepts into a form that can be more easily understood and remembered.39
The value of group CB programmes is that fellow patients are a credible source to legitimise or validate
invisible symptoms, such as fatigue, and provide role models and peer support in the goal-setting and
problem-solving processes.25
The RAFT programme content
The RAFT programme addresses the potential interactive drivers of fatigue (see Appendix 1)19 and its
management, with the tutors facilitating topic discussions for the first hour, then splitting after a short tea
break into two groups for detailed goal-setting. Topics, goal-setting and homework build on earlier sessions
over the weeks (see Appendix 2).40 The group initially validates this invisible symptom of fatigue and the
problem of managing it, then explores pacing and how underpinning thoughts drive boom-and-bust cycles
(week 1). Between sessions patients are asked to monitor their patterns of activity, rest and fatigue crashes
by colouring in an hourly chart. In week 2, things that energise or drain are the topic, and personal priorities
to improve overall life balance then feed into goal-setting, when each participant’s daily activity chart is
discussed to elucidate behaviour patterns and their consequences (fatigue). These charts are the focus of
the small group discussions each week and give a visual overview of a changing balance of rest, activity,
sleep and relaxation/energisers and, hopefully, fewer fatigue crashes because of improvements in pacing
as the programme progresses. Subsequent topics are sleep (week 3), with its links to stress (week 4), and
the struggle to communicate what can and cannot be done because of fatigue (week 5). Week 6 looks
at dealing with setbacks (using a metaphor of ‘falling into the pit’ that is fatigue), and reviews the skills
introduced in weeks 1–5. The consolidation session (week 14) helps participants reflect on their progress in
acceptance and self-management of fatigue (using the metaphor of leaving the ‘isolation of a desert island’
that is fatigue), and finishes with longer-term goals.
The RAFT programme training and materials for tutors
The RAFT programme was manualised for the tutors, including a detailed guide for each session, sample
texts, diagrams and patient handouts (these were piloted and refined).41 The RAFT programme was
co-facilitated by a pair of tutors, who were clinical rheumatology nurses and/or OTs. A 4-day training
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programme was delivered to all the RAFT programme tutors together, covering RA fatigue and the conceptual
model, information on CB principles, Socratic questioning (used to help patients identify thoughts that
drive behaviours), self-efficacy, goal-setting and group management, and each RAFT programme session
was discussed and demonstrated or rehearsed. To complete their training, tutor pairs delivered a practice
programme to patients and were observed and given feedback by a trainer (a clinical psychologist, specialist
OT or a rheumatology nurse specialising in fatigue: NA, BK and SH). As tutors were experienced rheumatology
clinicians, little clinical supervision was required; thus, one session in each of programmes 2 and 4 was
supervised by a trainer.
Aims and objectives
The objectives are reproduced from Hewlett et al.40 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The text includes minor additions and formatting changes
to the original text.
The overall aim of this study was to test a group CB intervention for RA fatigue (the RAFT programme)
that can be routinely delivered by clinical rheumatology teams across the NHS, using a manualised
programme with all supporting materials, delivered by the rheumatology team after brief training and with
minimal clinical supervision.40 The objectives were to:
l assess whether or not there is a clinically important difference in the impact of fatigue at 6 months between
patients participating in a group CB self-management programme for RA fatigue, delivered by the clinical
rheumatology team using a detailed manual (in addition to usual care), and patients receiving usual care
alone (which includes written fatigue self-management information)
l compare differences between trial arms for secondary outcomes of fatigue severity, coping, mood, sleep,
helplessness, pain, disability, valued activities, quality of life, work, health service use, acceptability, and
cost-effectiveness for the NHS, patients and society
l evaluate and control for potential demographic, psychological and clinical predictors of fatigue change
l evaluate persistence of effect (if any) over 2 years
l explore whether or not clinical teams trained in CB approaches perceive any positive or negative outcomes,
particularly on their wider clinical practice.
The study comprised:
l a RCT in which the RAFT programme in addition to usual care was compared with usual care alone
l an evaluation of the cost-effectiveness of providing the fatigue intervention
l a nested qualitative study to explore the tutors’ (RNSs and OTs) experiences of CB approach training and
any positive or negative effects on their wider clinical practice beyond the RAFT programme delivery.
As a process evaluation of the RAFT programme from the patients’ perspectives had been undertaken
in the original trial with a qualitative study,32 this was not repeated. Instead, in this RCT, the process
evaluation concentrated on understanding the perspectives of rheumatology clinicians who were being
asked to learn new skills and deliver the RAFT programme in the nested qualitative study.
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Chapter 2 Trial design and methods
Trial design
This trial evaluated the RAFT programme self-management intervention for fatigue plus usual care compared
with usual care alone, through a pragmatic RCT delivered by seven hospital teams across the UK, a setting
that reflected clinical practice. Clinical care, including medication change, continued as normal and without
restrictions for all participants throughout the trial. In addition to clinical effectiveness (see Chapter 3),
a health economic evaluation (see Chapter 4) and a qualitative evaluation of the RNS and OT tutors’
experiences (see Chapter 5) were undertaken. The protocol has been published.40
Ethics and registration
The trial and qualitative study were approved by the East of England – Cambridgeshire and Hertfordshire
Research Ethics Committee (reference number 13/EE/0310), after which each centre obtained the necessary
local research and development approvals. The RCT was registered with the International Standard
Randomised Controlled Trial Number registry as ISRCTN52709998.
Participants
Inclusion criteria
In order to reflect pragmatic clinical practice, in which the majority of RA patients experience fatigue,
inclusion criteria were very broad. Patients aged ≥ 18 years with confirmed RA42 were eligible if they had a
fatigue severity score of ≥ 6 (out of 10) on the Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scale
(BRAF-NRS),43,44 which they perceived was a recurrent problem.
Exclusion criteria
Patients were excluded if they had recently changed major RA medication (within 16 weeks) or glucocorticoids
(within 6 weeks), as that might influence fatigue. Patients were ineligible if they had insufficient English to
participate in group discussions or lacked capacity for informed consent.
Setting
Rheumatoid arthritis is managed in secondary care; therefore, the RAFT programme was delivered by pairs
of local hospital rheumatology clinicians (i.e. nurses/OTs, band 6 or 7), who understand how RA symptoms
interact with fatigue in the self-management of a long-term, fluctuating condition that requires adaptation
and acceptance. In order to test the generalisability of the RAFT programme, the seven participating
rheumatology units encompassed a range of large and small departments, academic and non-academic,
covering city and rural areas in England and Wales (Bristol, North Bristol, Cardiff, Chertsey, Poole, Torbay
and Weston-super-Mare).
Recruitment procedures
Patients with RA were invited to complete the BRAF-NRS to screen for fatigue severity, either when
attending clinic or by mailshot to departmental lists in the seven participating hospitals. If fatigue was
scored as ≥ 6 and the patient was interested, other eligibility criteria were then checked, and an
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information sheet provided with a pre-paid envelope to return to the local research nurse. Each centre
recruited to and delivered four consecutive RAFT programmes over 2 years. In order to randomise 5–7
patients to a RAFT programme, each centre recruited 10–14 patients and then closed that ‘cohort’. Over a
2-week period, those patients attended for informed consent and baseline assessment, and then received
usual care for fatigue. When all patients had completed this, randomisation occurred and recruitment
commenced for the next cohort. Delays between screening and baseline assessment were inevitable,
as baseline assessments could not be performed until a centre had accrued a large enough cohort of
10–14 interested and eligible patients (which often took several months). Therefore, any changes to
eligibility at baseline assessment (e.g. fatigue less severe, medication changed) were noted for potential
subgroup analysis; however, the patient proceeded to randomisation, reflecting the pragmatic way in
which this intervention would be delivered in practice to a population with fluctuating, recurrent fatigue
and frequently changing medication regimens. Patients who were randomised to a RAFT programme but
were then unable to attend the dates offered maintained their randomisation allocation and were offered
the subsequent RAFT programmes being run in that centre; if they accepted then they had a new baseline
assessment performed with the others in that cohort.
Interventions
The RAFT programme intervention
The RAFT programme is a CB fatigue self-management programme delivered to groups of 5–7 RA patients
in six 2-hour sessions (weeks 1–6) and a 1-hour consolidation session (week 14) by a pair of local RNSs
and/or OTs (see Chapter 1). Taking a pragmatic approach, if one of the tutors was unable to deliver a session,
perhaps because of illness, the remaining tutor delivered the session alone. Patients were asked to attend
all seven sessions if possible; however, some patients inevitably missed some sessions as RA is a fluctuating
condition, in which case tutors offered to explain some of what had been missed, prior to the next session.
Fidelity to the RAFT programme during delivery
Quality and homogeneity of the RAFT programme were facilitated by standardised training and a standardised
manual, with programme delivery by the same tutor pairs in each centre. However, unlike a pharmacological
RCT, in a group CB intervention it is not possible to adhere to a rigid protocol in every session, as tutors
must respond to the individual issues raised by patients. Therefore, fidelity evaluation was pragmatic and
involved monitoring in one randomly selected session of each of the four programmes run in each centre.
An independent clinical psychologist observer (Richard Cheston) used a template to record evidence of CB
approaches (e.g. reflective questioning, group management, goal-setting), delivery of the RAFT programme
as planned (adherence to session plans), use of the RAFT programme materials (handouts, metaphors) and
any unhelpful delivery styles (e.g. didactic teaching) (see Report Supplementary Material 1).41
Control intervention (usual care alone)
Unlike pain, RA fatigue is not routinely addressed in usual care in great detail and patients are generally
given written fatigue information by the RNS. Most rheumatology units supply the free Versus Arthritis
(formerly Arthritis Research UK) fatigue booklet,45 a comprehensive fatigue self-management booklet for
arthritis authored by Hewlett et al. and based on their original RCT.31 It contains information on all the
topics in the RAFT programme, includes a pull-out sample activity and rest chart to complete and could be
considered ‘usual care’. Usual care (i.e. provision of the Versus Arthritis fatigue booklet) was given to patients
in both the control and intervention arms of the trial at the baseline visit, after consent and assessment but
before randomisation. The research nurse spent approximately 5 minutes showing their patient the sections
in the booklet, using a brief standardised guideline and pointing out that the booklet suggests patients might
wish to request specific support from the rheumatology team to help them try the fatigue self-management
activities described (generally requested via the local RNS helpline). Seeking help is thus an intended outcome
of the booklet, which was captured within health-care use data collected in the trial. In order to minimise the
risk of contamination between the trial arms, the helpline RNS were asked not to book in a control patient
requesting fatigue support to see a clinician who was also a RAFT programme tutor if there was an alternative
health professional available, and tutors recorded any control patients seen for fatigue support.
TRIAL DESIGN AND METHODS
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Outcomes of clinical effectiveness
Primary outcome measure (26 weeks)
As the impacts of fatigue are wide-ranging and personal to individuals’ lives, the perceived impact of
fatigue was the primary outcome measure, rather than fatigue severity.8–11 Fatigue impact was measured
by a single NRS item, ‘Please circle the number that describes the effect fatigue has had on your life in the
last 7 days’, with anchors of ‘No effect’ to ‘A great deal of effect’ (0–10), using the BRAF-NRS for impact
(see Report Supplementary Material 2).43,44
Secondary outcome measures (clinical)
The secondary fatigue outcomes were fatigue severity and coping (as measured using the BRAF-NRS severity,
BRAF-NRS coping questionnaires) (see Report Supplementary Material 2) and a RA fatigue multidimensional
questionnaire [i.e. Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ)] (see
Report Supplementary Material 2), which measures overall fatigue impact and includes subscales for physical
fatigue, living with fatigue, emotional fatigue and cognitive fatigue.43,44 Each of these fatigue variables might
respond differently to interventions. Other components of the RA fatigue conceptual model19 evaluated were
mood [via the Hospital Anxiety and Depression Scale (HADS)],46 pain (via the NRS), disability [via the modified
Health Assessment Questionnaire (MHAQ)],47 quality of life [global arthritis impact question from the Arthritis
Impact Measurement Scale (AIMS)],48 sleep quality (via a single question from the Pittsburgh Sleep Quality
Index),49 and returning to important leisure activities previously lost to fatigue [via the discretionary activity
subscale of the Valued Life Activities scale for rheumatoid arthritis (VLA)].50 Beyond pain, disability and fatigue,
remaining items from the RA core set51 were an objective assessment of painful joints and swollen joints, an
inflammatory marker (i.e. C-reactive protein) and patient global opinion of disease activity [visual analogue
scale (VAS)], forming a single disease activity score [Disease Activity Score (DAS28)] through a weighted
algorithm.52 As the DAS28 requires a hospital visit to the research nurse, it was measured at weeks 0 and 26
only, and replaced at all other time points by a patient self-reported version [i.e. the simplified Patient-derived
Disease Activity Score (sPDAS2)].53,54 Social contact questions (unvalidated) were added for weeks 52 and 104.
Secondary outcome measures (processes)
To understand what key processes may relate to behavioural change, helplessness [via the Arthritis
Helplessness Index (AHI)]55 and self-efficacy [via the Rheumatoid Arthritis Self-Efficacy (RASE) scale]56 were
measured. The RASE scale contains questions on self-efficacy beliefs for managing RA covered in both the
RAFT programme and the usual-care Versus Arthritis fatigue booklet.45
Secondary outcome measures (acceptability and feasibility)
Acceptability of the RAFT programme and the usual-care booklet45 was assessed at week 26 by patient
satisfaction and the likelihood that patients would recommend the programme or booklet to others,
and by programme attendance. Feasibility of delivery in the NHS was captured through monitoring of
programme scheduling and delivery, and the tutor qualitative evaluation.
Follow-up time points, data collection and management
Baseline assessments (and usual care) for each cohort were conducted over a 2-week period. The cohort
was then randomised, and those patients randomised to the RAFT programme commenced their local
programme within a few weeks. To standardise data collection across all cohorts and centres, the date of
each cohort’s first RAFT programme session was designated as week 1 for both trial arms. Outcomes were
then measured at weeks 6 (end of the RAFT programme), 26 (primary end point), 52, 78 and 104, apart
from DAS28 and social contact as described in Secondary outcome measures (clinical). Only fatigue data
were collected at weeks 10 and 18 (via the BRAF-NRS for impact, severity and coping and BRAF-MDQ),43,44
to capture outcomes 4 weeks before and after the week 14 consolidation session. Data were collected
DOI: 10.3310/hta23570 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 57
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hewlett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
primarily by patient self-report questionnaire, except for objective measures of disease activity, which were
evaluated by the local research nurse (after standardised training) at weeks 0 and 26. Patients completed
their self-report questionnaire pack during those visits, but at all other time points questionnaire packs
were posted to patients from the central trial team in Bristol, with pre-paid envelopes. In order to maximise
data returns, the trial co-ordinator or trial administrator (ZP and CA), with ethics approval, telephoned each
patient at each assessment point to collect the primary outcome (i.e. the BRAF-NRS impact) and inform the
patient that the questionnaire pack was being posted (participants were contacted once more if packs
were not returned within 2 weeks). Data were returned direct to the managing centre (University of the
West of England, Bristol, UK) and entered onto an Microsoft Access® database (Microsoft Corporation,
Redmond, WA, USA) that was created by the Bristol Randomised Trials Collaboration (BRTC) unit. Data
entry was then checked by a second researcher against the original questionnaires (100% of entries were
checked) (Table 1).
TABLE 1 The RAFT programme outcome assessments and time points
Assessment Measure Score range
Week
0 6 10 18 26 52 78 104
Nurse led
Demographic data n/a ✓
Disease activity DAS2852 0.96+a ✓ ✓
Primary outcome
By telephone BRAF-NRS43,44 0–10 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Questionnaire (self-reported)
Fatigue severity BRAF-NRS43,44 0–10 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Fatigue coping BRAF-NRS43,44 0–10b ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Fatigue overall impact BRAF-MDQ43,44 0–70 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Physical fatigue BRAF-MDQ43,44 0–22 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Emotional fatigue BRAF-MDQ43,44 0–12 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Cognitive fatigue BRAF-MDQ43,44 0–15 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Living with fatigue BRAF-MDQ43,44 0–21 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Pain NRS 0–10 ✓ ✓ ✓ ✓ ✓ ✓
Disability MHAQ47 0–3 ✓ ✓ ✓ ✓ ✓ ✓
Quality of life AIMS VAS48 0–100 ✓ ✓ ✓ ✓ ✓ ✓
Disease activity sPDAS253,54 2.4–7.9 ✓ ✓ ✓ ✓ ✓ ✓
Anxiety HADS46 0–21 ✓ ✓ ✓ ✓ ✓ ✓
Depression HADS46 0–21 ✓ ✓ ✓ ✓ ✓ ✓
Sleep quality Pittsburgh item49 1–4 ✓ ✓ ✓ ✓ ✓ ✓
Valued life activities VLA50 0–3 ✓ ✓ ✓ ✓ ✓ ✓
Helplessness AHI55 5–30 ✓ ✓ ✓ ✓ ✓ ✓
Self-efficacy RASE56 28–140b ✓ ✓ ✓ ✓ ✓ ✓
Satisfaction and acceptability ✓
Social contact ✓ ✓
n/a, not applicable.
a No upper limit: C-reactive protein level in the algorithm has no maximum.
b High score = better outcome.
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Protocol amendments during the trial
Prior to the first baseline assessment, the global impact of arthritis question48 was added (amendment 1,
January 2014). Amendment 2 (February 2015) comprised the addition of the social contact questions
(at weeks 52 and 104), following reflection by the Study Management Group that the RAFT programme
promotes resisting the desire to isolate oneself. In addition, the qualitative evaluation of tutor experiences
through focus groups was expanded to offer one-to-one interviews in order to allow easier discussion of
individual opinions. Amendment 3 (September 2015) allowed for the possibility of an additional RAFT
programme to run in the case of low levels of recruitment or high levels of attrition (but this was not
needed).
Sample size
The sample size calculation has previously been published.40 In the original trial of CBT delivered by a clinical
psychologist, the baseline-adjusted difference in fatigue impact between trial arms was 1.95 units on a VAS
(0–10) [95% confidence interval (CI) −2.99 to −0.90 units; p < 0.001], giving an effect size of 0.77.31 As the
RAFT programme is delivered by clinical teams using CB approaches rather than by a CB therapist, the RCT
reported here was powered to be able to demonstrate 75% of that (1.46 units, effect size 0.54). For a
two-sided significance of 0.05 and a power of 90%, 73 patients per trial arm were required. The study was
interested in the average effect across all centres; therefore, no loss of power from randomising patients by
centre was considered.57,58 In the RAFT programme arm there was potential for clustering effects from the
seven centres (including the one tutor pair per centre), and from the CB group within centres. In the original
RCT, the intraclass correlation coefficient (ICC) for the CBT group and the primary outcome was < 0.00001,
with no data for centre/tutor effects as it was a single-centre study.31 In the present RCT, an overall ICC
value of 0.01 was employed for groups clustered within and between centres, and was used for estimating
a design effect,59 increasing the sample size to 75 per trial arm.
In the original RCT,31 most attrition was not from the intervention but from loss to questionnaire completion;
therefore, to maximise data returns in this RCT the primary outcome was collected by telephone by the
central RAFT programme team as described above, and patients who wished to withdraw were asked if
they might continue providing a fatigue impact NRS by telephone (ethics approval given). It was intended
to achieve 80% of primary outcome data at week 26, but longer-term attrition was unknown. Therefore,
we assumed 50% retention and thus capacity was planned to recruit up to 150 patients per trial arm.
A pragmatic approach took account of the need to form viable RAFT programme groups and natural
variations in group size; therefore, a target of seven centres each running four RAFT programmes, with
an average of six participants per RAFT programme group and six participants randomised to usual care
(n = 336), provided contingency for smaller groups.
Minimising attrition
In order to reduce attrition prior to starting a RAFT programme, patients were consented and randomised as
close to the dates of the CB programmes as possible and the local research nurse kept patients informed of the
potential programme dates. Three-quarters of participants in the original RCT attended most of their seven CBT
sessions, suggesting that the RAFT programme would be acceptable.31 In this RCT a 2-year follow-up potentially
risked significant loss to questionnaire completion over time; therefore, to maximise questionnaire returns,
the primary outcome data (i.e. fatigue impact NRS scores) were collected by the central trial team by telephone
each time (see Follow-up time points, data collection and management). To enhance feelings of community,
engagement and responsibility, all RAFT programme study materials included the study logo; questionnaire
packs were accompanied by a short newsletter highlighting overall questionnaire return rates, and thank-you
notelets were sent at major time points.
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Randomisation, concealment and blinding
After consent at the baseline visit, the local research nurse allocated each patient the next consecutive
study identification number; as patients chose from several available baseline visit dates and times, this
allocation was unlikely to be influenced by the research nurse. When a centre had finished all baseline
visits for that cohort (10–14 participants, assessed over a 2-week period), the research nurse sent the
unique study numbers to the trial co-ordinator in Bristol, which requested that the BRTC unit conduct the
randomisation for that centre’s cohort (concealed from the RAFT programme study team and the research
nurse). Computer-generated randomisation (using a specially created Access database) was performed for
each cohort (1, 2, 3 and 4) in each centre (1, 2, 3, 4, 5, 6 and 7) consecutively over 2 years as each cohort
was finalised and all its participants had attended for consent, baseline assessment and delivery of usual
care. Allocation was 1 : 1 within cohorts but, in the event of an odd number, the RAFT programme trial
arm received the extra patient on the grounds that risk of attrition was likely to be higher in that arm.
The BRTC unit informed the trial co-ordinator of the arm allocations, and the trial co-ordinator informed
the local research nurse, who subsequently telephoned each consented patient using a brief, standardised
guideline to ensure that no suggestion other than equipoise between the arms was communicated.
Those randomised to the RAFT programme trial arm had the dates, times and venue confirmed. Blinding
of clinicians delivering the RAFT programme was not possible, nor could patients be blind because of the
need to engage them in making behavioural and cognitive changes and attend or not attend the RAFT
programme sessions. However, most outcome measures used were validated tools and analysis was
performed blind to allocation.
Overview of evaluation methods
Clinical and health economic analysis followed the predefined statistical and health economics analysis
plan (SAP) [see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1111201/#/documentation (accessed
12 April 2019)], which was agreed in discussion with the Trial Steering Committee (TSC) and Data
Management and Ethics Committee (DMEC). Detailed methods and results are presented separately for
the clinical, health economic and qualitative evaluations (see Chapters 3–5).
Study management
The project was managed and co-ordinated centrally in Bristol by the chief investigator (SH), trial co-ordinator
(ZP) and trial administrator (CA), with all outcome assessments (apart from baseline and week 26) being sent
out by, and returned to, the central study team, thereby enabling careful monitoring of timelines and returns.
Each centre employed a research nurse to manage local recruitment, cohort building and closure, visits for
consent and baseline assessment, and week 26 assessment. The trial co-ordinator maintained the overall site
documentation and a local study file for each site and liaised with all sites and with the BRTC randomisation
service. The central co-ordinating team (i.e. SH, ZP and CA) held weekly meetings to set up the trial, with other
key trial staff, co-applicants and patient partners attending as appropriate. Monthly Trial Management Group
meetings of the researcher co-applicants were held and the wider group of rheumatologist co-applicants (local
principal investigators) attended when appropriate. The independent TSC and DMEC convened at key time
points to support the trial development and review progress. All meetings were reduced in frequency once the
trial was established, but resumed more frequently during database closure, data analysis and interpretation.
The RCT was sponsored by the University Hospitals Bristol NHS Foundation Trust.
Patient and public involvement
Patient involvement occurred throughout the project and was provided by two patients who had participated
in the original trial (Clive Rooke and Frances Robinson).31 The aim of a joint enterprise with patient partners
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was for them to bring experiential knowledge of RA fatigue and receiving the original CBT intervention from
a psychologist. The patient partners advised on outcomes to be evaluated, questionnaire pack design,
recruitment processes and all trial patient materials. The patient partners suggested improvements to the
patient handouts used in the RAFT programme and advised that the relaxation CD be re-recorded to improve
sound quality. The patient partners attended the tutor training days to talk with the tutors and the principal
investigators about their experience of fatigue. Continued involvement (by Clive Rooke) included advising
on the formatting of the tutor manual, attendance at major project review meetings and analysis of the
qualitative data.
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Chapter 3 Clinical evaluation: analysis methods
and results
Statistical analysis methods
The analysis and reporting of this trial was undertaken in accordance with Consolidated Standards of
Reporting Trials (CONSORT) guidelines.60 All statistical analyses were undertaken using Stata version 14.1.1
(StataCorp LP, College Station, TX, USA), following a predefined SAP [see URL: www.journalslibrary.nihr.
ac.uk/programmes/hta/1111201/#/documentation (accessed 12 April 2019)], which was agreed with the
TSC and the DMEC. The primary comparative analyses between randomised trial arms were conducted on
an intention-to-treat (ITT) basis without imputation of missing data.
Preliminary analyses (baseline comparability)
Descriptive statistics of key clinical and sociodemographic characteristics were used to compare randomisation
trial arms at baseline and to inform any additional adjustment of the primary and secondary analyses when
appropriate.
Primary analysis
The primary analysis used linear regression to compare BRAF-NRS impact score at 26 weeks (the primary
outcome) between trial arms as randomised and adjusted for baseline values of the outcome and
recruitment centre (stratification variable). The result of the linear regression model is presented as an
adjusted difference in means between the RAFT programme and control arms, alongside the associated
95% CI and p-value for the comparison. A standardised effect size for the primary outcome was also
calculated as the adjusted difference in mean divided by the pooled baseline standard deviation (SD).
Secondary analyses
Primary outcome measure
Secondary analyses of the primary outcome included additional adjustment of the primary analysis for any
prognostic variables demonstrating a marked imbalance at baseline (ascertained using descriptive statistics).
There was a gap in time between eligibility screening and baseline measurement. Owing to this time gap,
some individuals who had a BRAF-NRS severity score of ≥ 6 points (out of 10 points) at screening (an eligibility
criterion) subsequently had a lower BRAF-NRS severity score of < 6 points at the time of randomisation.
For this reason, the primary analysis was repeated and restricted to those individuals who had a BRAF-NRS
severity score of ≥ 6 points at randomisation (analysis not prespecified).
A repeated measures mixed-effects model was used to examine the effect of the intervention over time by
including up to four follow-up BRAF-NRS impact scores (at weeks 26, 52, 78 and 104), adjusted for baseline
values of the outcome and for recruitment centre. This analysis provided an estimate of the average effect size
over the duration of follow-up. A potential convergence or divergence between trial arms was investigated
by repeating the analysis with the inclusion of a time-by-treatment group interaction term. The repeated
measures analysis was repeated on those individuals with a BRAF-NRS severity score of ≥ 6 points at
randomisation.
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Secondary outcome measures
The effect of the intervention on the secondary outcomes collected at 26 weeks was also examined using
appropriate regression models adjusted for baseline values of the outcome being investigated and for
recruitment centre. The secondary outcomes were also subject to repeated measures analysis using data
collected at the 26-, 52-, 78- and 104-week follow-ups.
A potential difference between trial arms in the changes in major RA medications that might influence
the primary outcome was investigated using a chi-squared test. A change in major RA medications was
defined as stopping, starting or changing the dose of one or more disease-modifying antirheumatic drugs
(DMARDs), bDMARDs or glucocorticoid medications during a single time period. Acceptability of the RAFT
programme or the usual-care booklet to patients was measured by the RAFT programme attendance rates,
satisfaction and recommendation to others, and is summarised using descriptive statistics.
Potential clustering effects
Owing to the hierarchical nature of the data (i.e. participants nested within centres and then within cohorts),
there is potential for clustering effects in the trial. To investigate this, a linear mixed-effects model, which
included centre and cohort as cluster-level variables, was compared with the linear regression primary
analysis model by means of the likelihood ratio test.
Missing data
The sensitivity of the primary analysis to the impact of missing data was examined. The method of multiple
imputation by chained equations using predictive mean matching was used to impute missing data. The
imputation model included all variables that were part of the ITT primary analysis, variables identified from
the previous trial as being related to fatigue impact (fatigue severity, pain and both self-reported and
nurse-rated disease activity), and baseline variables that were associated with missingness of the primary
outcome. In total, 20 imputed data sets were generated and combined using Rubin’s rules. The primary
analysis model was then repeated using the imputed data.
Treatment efficacy
Complier-average causal effect (CACE) analysis was used to investigate the efficacy of the RAFT programme
intervention in reducing fatigue impact at 26 weeks. The CACE methodology compares outcomes among
those who ‘complied’ with the intervention and a comparable group of ‘would be compliers’ in the control
arm.61 (The word ’compliance’ is used here as a statistical term; clinically the word adherence is used to describe
active rather than passive decisions to participate.) CACE analysis provides an estimate of the efficacy of
the intervention for comparison with the ITT estimate of the offer of the intervention, while respecting
randomisation and avoiding biases inherent to crude per-protocol analyses, in which only individuals in the
RAFT programme arm are included. In this trial ‘compliance’ was defined as attending at least two sessions
of the RAFT programme (session 1 plus any other session). However, those individuals randomised to
the RAFT programme intervention arm but who did not attend (i.e. withdrew and did not attend the first
RAFT programme session) had no follow-up data collected. This is problematic as it meant that outcome
information was not available for a group of individuals who would be considered ‘non-compliant’ and
have contributed information to the CACE analysis. It also potentially violated the exclusion restriction
assumption: if individuals in the RAFT programme intervention arm were considered participants only if they
attended the first CB session (which might then have an impact on their outcome), then the offer of the
intervention does affect outcome. To address this issue, the two stages of the two-stage least squares (2SLS)
CACE estimation were carried out separately to allow for loss to follow-up that was dependent on compliance.
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The first-stage regression uses all individuals randomised to predict compliance. The second stage involved only
those with non-missing outcomes, but modelled these using the predicted values of compliance obtained from
the ‘complete’ first stage.
Interpretation of findings
When designing the trial it was stated that the traditional effect size of > 0.5 would be considered to reflect
a clinically meaningful effect.40 During the discussions to interpret the findings, the Trial Management
Group, with input from the TSC statistician, discussed the issue of effect sizes in terms of their clinical
importance. Over the years, concerns have been raised in the literature as to whether only an effect size
≥ 0.5 must be considered clinically meaningful, or if smaller effect sizes might be considered by patients to
have had an effect. For example, Sloan et al.62 argue that this cut-off point is only a broad guideline and
that clinical meaningfulness must be related to each specific health issue under investigation (i.e. it would
be different for different patient outcomes). They recommend that, if supported by additional data related
to that specific health issue, ‘small’ effect sizes of 0.2 can also be considered clinically meaningful. Although
there are no data on clinically meaningful change in RA fatigue impact, Khanna et al.63 demonstrated that
patients reported that they experienced a noticeable improvement in RA fatigue severity at effect sizes 0.27
to 0.39. It was therefore decided to take a broader view when interpreting the findings and also to consider
additional data to inform consideration of clinically meaningful change and effect sizes (a departure from
the protocol).
Subgroup and exploratory analyses
Number of sessions attended
It was hypothesised a priori that those individuals attending a greater number of the RAFT programme sessions
would show a greater improvement than those who attended fewer sessions. The theoretical justification was
that greater exposure to the RAFT programme intervention should improve self-management skills. A structural
mean model 2SLS instrumental variable approach, which respects randomisation,64 was used to investigate
the impact of number of sessions of the RAFT programme attended on BRAF-NRS impact score. As with the
treatment efficacy CACE analysis, the non-follow-up of those individuals randomised to the RAFT programme
intervention arm but who did not attend the first session of the RAFT programme is problematic. The same
approach (i.e. a separate two-stage approach) was used to address this issue. A further assumption of this
model was that of a linear relationship between session attendance and BRAF-NRS impact score, that is, that
the impact of an increase in attendance of one session was the same across all the different sessions (i.e. all
sessions had a similar effect on patient outcome).
Consolidation session (week 14)
The RAFT programme intervention was delivered in seven sessions: sessions 1–6 delivered weekly over
weeks 1–6, followed by session 7 at week 14 to consolidate skills and behaviours. Separate linear regression
models were used to examine the effect of the RAFT programme on BRAF-NRS impact score at 6 weeks
(immediately after the final RAFT programme session), at 10 weeks (4 weeks before the consolidation
session) and at the 18-week follow-up (4 weeks after the consolidation session).
Predictors of fatigue impact change
Certain clinical and demographic characteristics were examined as potential predictors of fatigue impact
change. All of these variables of interest were first added as covariates to the primary analysis model and
then removed from the model one by one in a process of stepwise deletion until only covariates with
a p-value of < 0.05 were retained (i.e. the covariate with the highest p-value from the initial model was
removed, the model was then repeated without this covariate and the variable with the highest p-value
in this second model was then removed, etc.). The starting model comprised the primary analysis model
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additionally adjusted for baseline pain (i.e. NRS score), disease activity (i.e. DAS28 score), BRAF-NRS coping
score, age, comorbidity, work status, disease duration and sex.
Self-efficacy
The RASE scale has 28 items that ask about beliefs regarding self-management tasks, many of which are
discussed during the RAFT programme. To examine the impact of the RAFT programme intervention on
particular components of self-efficacy, the change in RASE scale item scores from 0 to 26 weeks in the
control and the RAFT programme intervention trial arms was compared using t-tests.
Tutor delivery over time
It was hypothesised that the size of the effect of the RAFT programme intervention may differ between
cohorts as tutors within each centre may have improved in their delivery of the intervention over time. To
explore this, the mean change in fatigue, impact from 0 to 26 weeks, is presented by intervention arm and
cohort. The difference in mean change (between trial interventions) by cohort is also presented (this was
not in the SAP but was prespecified before any analysis commenced).
Social contact
Group work may enhance the seeking of social support (see Chapter 2, Protocol amendments during the
trial). The social contact data are analysed using simple percentages.
Results
The key clinical findings from the RAFT programme trial presented here have been previously published.65
Participant flow
Recruitment commenced in December 2013, with the first patient consent received in February 2014
and the last in October 2015, and the trial completed as planned with the final follow-up questionnaires
returned in January 2018. The flow of eligible patients with RA and a fatigue severity score of ≥ 6 points
from invitation to participation through to week 104 is detailed in Figure 1. Over the 2 years a total of
333 patients were randomised, comprising four consecutive cohorts in each of the seven centres (see
Chapter 2, Recruitment procedures), with similar numbers across centres (see Appendix 3). All patients
accepted their randomised allocation.
After consent and baseline assessment, all patients received usual care before randomisation, i.e. the
Versus Arthritis fatigue booklet.45 Of the 175 patients randomised to additionally receive the RAFT
programme, 14 did not receive the intervention because of an inability to find suitable programme dates.
Of the 161 patients who received the RAFT programme, five patients withdrew for personal/health reasons
(four patients during programme delivery, having received up to three of the seven sessions, and one
patient withdrew before the week 10 assessment). Therefore, 156 of the 175 RAFT programme patients
provided primary outcome data at week 26, and 153 patients provided data at week 104 (89.9% and
87.4% of those patients randomised, respectively). Of the 158 patients randomised to usual care only,
six patients withdrew before week 26, leaving 152 patients providing primary outcome data at week 26
and 147 patients providing data at week 104 (96% and 93.0%, respectively).
Follow-up data completion
The majority of patients provided primary outcome fatigue impact data (BRAF-NRS impact data were
collected by telephone), with 308 and 296 patients completing BRAF-NRS impact at weeks 26 and 104,
respectively (see Appendix 4). Therefore, the 50% attrition allowed for at 2 years did not materialise
and the follow-up numbers exceeded the required total sample size of 150. Secondary outcome data
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Invited to participate
(n = 1113)
(RA + fatigue ≥ 6)
Not interested/no reply
(n = 742)
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(n = 371)
Eligible
(n = 353)
Declined
(n = 20)
Randomised
(n = 333)
Control arm
(n = 158)
CBT intervention arm
(n = 175)
Ineligible
(n = 18)
• Medication changes/steroids, n = 18
Did not receive treatment as allocated
(n = 0)
Did not receive treatment as allocated
(n = 14)
• Unable to attend course, n = 14
Received control
(n = 158)
Lost to follow-up
(n = 1)
• Health issues/personal reasons, n = 1
Lost to follow-up
(n = 4)
• Health issues/personal reasons, n = 4
Lost to follow-up
(n = 1)
Lost to follow-up
(n = 0)
Lost to follow-up
(n = 0)
Lost to follow-up
(n = 0)
• Health issues/personal reasons, n = 1
Lost to follow-up
(n = 1)
• Misinformed, n = 1
Lost to follow-up
(n = 1)
• Died, n = 1
Lost to follow-up
(n = 3)
26-week primary outcome point
(n = 152)
26-week primary outcome point
(n = 156)
104-week secondary outcome point
(n = 147)
104-week secondary outcome point
(n = 153)
• Health issues/personal reasons, n = 2
• Died, n = 1
Lost to follow-up
(n = 2)
• Health issues/personal reasons, n = 1
• Died, n = 1
Lost to follow-up
(n = 1)
• Health issues/personal reasons, n = 1
Lost to follow-up
(n = 3)
• Health issues/personal reasons, n = 3
Lost to follow-up
(n = 1)
• Health issues/personal reasons, n = 1
Lost to follow-up
(n = 1)
• Died, n = 1
Received CBT intervention
(n = 161)
n = 157 n = 157
n = 156 n = 156
n = 156
n = 154
n = 154
n = 155
n = 151
n = 148
6 weeks
10 weeks
18 weeks
52 weeks
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FIGURE 1 Participant flow chart. Reproduced from Hewlett et al.65 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the
original text.
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questionnaire packs were returned by > 88% of patients at 26 weeks and 78% of patients at 104 weeks
(lowest completion rate was 72% for sleep quality at week 78, see Appendix 4). Six patients who were
randomised to a RAFT programme but could not attend their planned programme dates attended a later
programme, when a fresh baseline assessment was made. However, at the end of RAFT programme
delivery in the seven centres, 14 patients randomised to the RAFT programme had been unable to attend
any local programme dates and the 26-week primary outcome data were not obtained from them.
The RAFT programme delivery and tutor adherence
All seven rheumatology centres were able to provide at least two clinicians for training and, of those 15
who were trained, 14 went on to deliver the RAFT programme. One tutor pair comprised OTs, two tutor
pairs were nurses and four pairs were mixed nurse and OT. They had a mean of 5.3 years’ rheumatology
experience (range 0–17 years) and had been qualified for a mean of 18 years (range 6–30 years) and 10
had some experience of running patient groups, of whom four also reported some prior relevant
knowledge such as goal-setting or CBT (data not detailed to preserve anonymity).
All seven hospitals were able to deliver all four 14-week RAFT programmes as planned and on time,
indicating feasibility to deliver in the NHS, which is explored further in the qualitative evaluation (see
Chapter 5). Tutor pairs remained unchanged throughout the RAFT programmes, apart from one centre
where tutor absence for two programmes was covered by the remaining tutor co-delivering one programme
with a trainer and one with a locum tutor who had observed the previous programme. There were 196
RAFT sessions (28 programmes comprising seven sessions), of which seven (3.6%) were delivered by a single
tutor due to absence. Independent monitoring for tutor adherence (fidelity) to the RAFT programme delivery
and CB principles was carried out as planned and no remedial teaching was deemed necessary.
The RAFT programme attendance
At randomisation, the RAFT programme group sizes averaged six patients (with a range of five to eight
patients). The RAFT programme patients attended a mean of 5.85 of their 7 RAFT programme sessions
(SD 1.63 sessions). Most of the 156 patients had high attendance rates, with 87.2% (n = 136) attending
5–7 sessions (Table 2).
All 156 RAFT programme patients attended their first session and each of the subsequent sessions
(i.e. sessions 2–7) was attended by ≥ 75% of the randomised patients (Table 3).
TABLE 2 Total number of RAFT sessions attended by patients
Total number of sessions attended Patients (N= 156), n (%)
1 7 (4.5)
2 6 (3.8)
3 4 (2.6)
4 3 (2.0)
5 20 (12.8)
6 42 (26.9)
7 74 (47.4)
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Adverse events
No related serious adverse events were reported by tutors.
Preliminary analyses (baseline comparability)
The 25 patients who did not complete to 26 weeks were very similar to the 308 patients who did
complete to this primary end point in terms of baseline demographic data (age, sex, disease duration,
comorbidity), and fatigue severity (entry criterion) and impact (primary outcome) (see Appendix 5).
They had similar clinical status to those who completed the study (see Appendix 6).
Baseline demographic data were similar between trial arms, with the majority of patients being female,
as reflects the RA population (Table 4). The patients were aged > 60 years, on average, with a wide range
of disease duration. The majority of patients were of moderate to high socioeconomic status and white,
and a small proportion had previously attended a general rheumatology self-management programme
many years earlier.
Baseline clinical data were similar between arms and were therefore well balanced (Table 5). On average,
patients had high fatigue impact scores (i.e. a BRAF-NRS impact score of > 7/10), which were slightly
higher than fatigue severity scores, and had a low perceived ability to cope with fatigue (measured via the
BRAF-NRS coping questionnaire). The participants had relatively high levels of disease activity (inflammation)
with DAS28 scores of > 4.2 (> 5.1 is the eligibility criterion for starting bDMARDs). On average, participants
had moderate pain, low disability and moderate self-efficacy and helplessness at baseline. The distribution
of the primary outcome, fatigue impact, is shown in Figure 2.
Participants had eligible fatigue scores at screening (i.e. a BRAF-NRS severity score of ≥ 6/10), but often
had to wait for a sufficient number of participants to be recruited in order to close their cohort ready for
consent, baseline assessment and randomisation. At the later baseline assessment, the fatigue severity
scores of 23 out of 152 control patients and 23 out of 156 RAFT programme patients had fallen below the
inclusion criterion (15.1% and 14.6%, respectively); however, as this was a pragmatic trial aiming to
reflect how the RAFT programme would be delivered in clinical practice, the participants proceeded to
randomisation.
TABLE 3 Attendance at individual RAFT programme sessions 1–7
Individual session Patients (N= 156), n (%)
1 156 (100)
2 137 (87.8)
3 129 (82.7)
4 125 (80.1)
5 129 (82.7)
6 119 (76.3)
7 118 (75.6)
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TABLE 4 Baseline demographic data
Demographic variable
Trial arm, n (%)
Control (N= 152) RAFT (N= 156)
Female 121 (79.6) 125 (80.1)
Age (years)a 61.8 (54.4, 69.6) 63.7 (54.2, 69.9)
Disease duration (years)a 10 (3, 20) 10 (5, 19)
Socioeconomic status: Englandb
Deprived 28 (21.1) 23 (17.2)
Moderate 60 (45.1) 65 (48.5)
Affluent 45 (33.8) 46 (34.3)
Socioeconomic status: Walesb
Deprived 7 (41.2) 7 (35.0)
Moderate 3 (17.7) 5 (25.0)
Affluent 7 (41.2) 8 (45.0)
Ethnicity
White 147 (98.0) 151 (96.8)
Asian/Asian British/other 3 (2.0) 5 (3.1)
Other self-management programmes 21 (14.0) 16 (10.3)
Years since previous programmea 8 (5, 11) 5 (3, 10)
a Median (lower and upper quartile).
b The top three deciles of the national scores for England and Wales were labelled ‘affluent’, the middle four deciles were
labelled ‘moderate’ and the bottom three deciles were labelled ‘deprived’.
TABLE 5 Baseline outcome data
Clinical variable
Trial arm
Control (N= 158) RAFT (N= 175)
n (%)a Mean (SD) n (%)a Mean (SD)
Fatigue
BRAF-NRS impact (0–10) 152 (96.2) 7.23 (1.6) 156 (89.1) 7.10 (1.7)
BRAF-NRS severity (0–10) 142 (89.9) 6.85 (1.57) 152 (86.9) 6.89 (1.57)
BRAF-NRS coping (0–10)b 142 (89.9) 4.84 (2.09) 152 (86.9) 5.16 (2.08)
BRAF-MDQ overall impact (0–70) 142 (89.9) 40.39 (12.99) 152 (86.9) 40.42 (12.70)
BRAF-MDQ physical (0–22) 142 (89.9) 16.19 (3.21) 152 (86.9) 16.12 (3.39)
BRAF-MDQ emotional (0–12) 142 (89.9) 6.71 (3.31) 152 (86.9) 6.55 (3.18)
BRAF-MDQ cognitive (0–15) 142 (89.9) 7.58 (4.04) 152 (86.9) 7.54 (4.00)
BRAF-MDQ living (0–21) 142 (89.9) 9.90 (5.18) 152 (86.9) 10.21 (5.05)
Pain: NRS (0–10) 142 (89.9) 5.57 (2.10) 152 (86.9) 5.70 (2.12)
Disability: MHAQ (0–3) 142 (89.9) 0.76 (0.51) 151 (86.3) 0.75 (0.53)
Quality of life: AIMS VAS (0–100) 141 (89.2) 49.89 (20.44) 152 (86.9) 49.16 (22.27)
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TABLE 5 Baseline outcome data (continued )
Clinical variable
Trial arm
Control (N= 158) RAFT (N= 175)
n (%)a Mean (SD) n (%)a Mean (SD)
Disease activity
Assessed: DAS28 (0.96+) 145 (91.8) 4.23 (1.11) 147 (84.0) 4.22 (1.30)
Self-reported: sPDAS2 (2.4–7.9) 142 (89.9) 4.36 (0.99) 151 (86.3) 4.44 (1.06)
Anxiety: HADS (0–21) 142 (89.9) 8.01 (4.45) 151 (86.3) 7.29 (4.08)
Depression: HADS (0–21) 142 (89.9) 6.79 (3.94) 151 (86.3) 7.18 (3.59)
Valued life activities: VLA (0–3) 142 (89.9) 1.08 (0.60) 151 (86.3) 1.16 (0.61)
Helplessness: AHI (5–30) 142 (89.9) 18.98 (4.74) 152 (86.9) 19.03 (4.67)
Self-efficacy: RASE scale (28–140)b 142 (89.9) 104.38 (11.34) 151 (86.3) 102.49 (11.51)
Sleep quality 142 (89.9) 149 (85.1)
Very goodc 5 (3.5%) 9 (6.0%)
Fairly goodc 58 (40.9%) 48 (32.2%)
Fairly badc 51 (35.9%) 56 (37.6%)
Very badc 28 (19.7%) 36 (24.2%)
a Percentage of the total number of patients randomised (control, n = 158; RAFT, n = 175).
b Higher score = better outcome.
c Percentage of questionnaires returned.
Note
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FIGURE 2 Distribution of baseline BRAF-NRS impact scores, by trial arm. (a) Control; and (b) the RAFT programme.
DOI: 10.3310/hta23570 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 57
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hewlett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Primary analysis
There was no difference between the trial arms for fatigue impact at baseline and both arms had improved
fatigue impact at week 26 (Table 6). Patients in the control arm improved by a mean of –0.88 (SD 2.4,
Wilcoxon signed-rank test statistic –3.560; p < 0.001), and those in the RAFT programme improved by a
mean of –1.36 (SD 2.7, Wilcoxon signed-rank test statistic –5.666; p < 0.001).
The primary outcome was the BRAF-NRS impact score at 26 weeks (ranging from 0 to 10, with the lower score
representing the better outcome). Linear regression was used to investigate the impact of the intervention
on the primary outcome, adjusted only for baseline score and centre as other factors were similar between
trial arms (see Table 5). Individuals in the RAFT programme had a BRAF-NRS impact score at 26 weeks that
was, on average, –0.59 units lower (better) than that of those in the usual-care arm, with a 95% CI ranging
from a 1.11 to a 0.06 reduction in fatigue impact (p = 0.03). The adjusted mean difference between arms
equated to a standardised effect size of 0.36.
Secondary analysis
Primary outcome measure
Analysis adjusting for variables imbalanced at baseline was not required as no variables were imbalanced.
Baseline eligibility and 26-week outcome
The primary analysis was repeated excluding those individuals who had fallen below the eligibility criterion
of BRAF-NRS severity of ≥ 6.0 points between screening and baseline (n/N = 3/152 control patients and
n/N = 23/156 RAFT programme patients). For baseline-eligible patients, the fatigue impact score at 26 weeks
was lower in the RAFT programme than in the control arm, with an adjusted mean difference between
arms in fatigue impact of –0.82, a slightly larger effect than observed in the primary complete-case
(screening-eligible) analysis (Table 7).
Primary outcome at 26–104 weeks
The BRAF-NRS impact score differed between trial arms over weeks 0–104 (Figure 3). Based on repeated
measures analysis and using data from the 26-, 52-, 78- and 104-week follow-up time points, the group
TABLE 6 Primary outcome of fatigue impact scores at 26 weeks
Primary
outcome
Trial arm
Adjustedb mean
difference (95% CI) p-value
Control RAFT
n (%)a
Week, mean (SD)
n (%)a
Week, mean (SD)
0 26 0 26
BRAF-NRS
impact score
152
(96.2)
7.23
(1.6)
6.36
(2.42)
156
(89.1)
7.10
(1.7)
5.74
(2.41)
–0.59 (–1.11 to –0.06) 0.03
a Percentage of the total number of patients randomised (control, n = 158; RAFT, n = 175).
b Linear regression adjusted for baseline BRAF-NRS impact score and centre.
Note
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receiving the RAFT programme intervention had a BRAF-NRS impact score that was, on average, 0.49 units
lower (i.e. better) than in the control arm over the 2 years, on a scale of 0–10 (adjusted mean difference –0.49)
(Table 8).
When a treatment arm-by-time interaction term was added to the model there was no evidence that
the difference between the RAFT programme and the control arm varied over time (interaction between
treatment and time, p = 0.52). The estimated treatment effects at each of the follow-up time points were
similar and in favour of the RAFT programme, with the exception of that at the 78-week follow-up time
point, which was non-significant (see Appendix 7).
Baseline eligibility and 2-year follow-up
The repeated measures analysis was repeated excluding those individuals who had fallen below the
eligibility criterion of a BRAF-NRS severity score ≥ 6.0 between screening and baseline (n/N = 23/152
control patients and n/N = 23/156 RAFT programme patients). For baseline-eligible patients, the RAFT
programme patients had a BRAF-NRS impact score that was, on average, 0.58 lower (i.e. better) than
those in the control arm over the 2 years (adjusted mean difference –0.58) (Table 9). This represents a
slightly larger treatment effect than observed when analysing all screening-eligible participants.
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FIGURE 3 The BRAF-NRS impact scores over weeks 0–104, by trial arm. Reproduced from Hewlett et al.65 This is
an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor
additions and formatting changes to the original text.
TABLE 7 Primary outcome at 26 weeks on patients eligible for RCT at baseline
Eligibility n
BRAF-NRS impact score, adjusted
mean differencea (95% CI) p-value
Screening-eligible patients 308 –0.59 (–1.11 to –0.06) 0.03
Baseline-eligible patients 262 –0.82 (–1.40 to –0.24) 0.01
a Linear regression adjusted for baseline score and centre.
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TABLE 8 Repeated measures analysis of BRAF-NRS impact score at 26, 52, 78 and 104 weeks
Trial arm
Time point
Repeated measures (N= 308)26 weeks (N= 308) 52 weeks (N= 305) 78 weeks (N= 300) 104 weeks (N= 296)
n
BRAF-NRS impact
score, mean (SD) n
BRAF-NRS impact
score, mean (SD) n
BRAF-NRS impact
score, mean (SD) n
BRAF-NRS impact
score, mean (SD)
Adjusted mean
differencea (95% CI) p-value
Control 152 6.36 (2.42) 151 6.38 (2.19) 146 6.38 (2.23) 145 6.05 (2.14) –0.49 (–0.83 to –0.14) 0.01
RAFT 156 5.74 (2.41) 154 5.72 (2.23) 154 6.17 (2.24) 151 5.54 (2.28)
a Adjusted for baseline score and centre.
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
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additions and formatting changes to the original text.
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Secondary outcome measures
Secondary outcomes at 26 weeks
Both trial arms appeared to demonstrate improvement in some secondary outcomes at 26 weeks, particularly
overall fatigue impact score (BRAF-MDQ overall) and its fatigue subscales, self-efficacy (RASE scale score) and
sleep (see Appendix 8). There appeared to be little change in disease activity measures (DAS28 and sPDAS2),
pain, disability or mood.
After adjusting for baseline scores and centre, there was evidence of a difference between arms in overall
fatigue impact score (BRAF-MDQ overall), and the subscales emotional fatigue and living with fatigue, as
well as the process measure of self-efficacy for managing RA (i.e. RASE scale score), with the adjusted
mean differences in favour of the RAFT programme intervention (Table 10). Standardised effect sizes
calculated for these variables ranged from 0.23 to 0.28. There was no evidence of a difference between
the trial arms for any other secondary outcome, including fatigue severity. Over the 26 weeks, 20 out of
141 control patients reported seeking extra appointments for fatigue help, compared with 8 out of 152
RAFT programme patients (14.2% vs. 5.2%; p < 0.01).
Secondary outcomes at 26–104 weeks
Based on repeated measures analysis using data from the 26-, 52-, 78- and 104-week follow-up time
points (see Appendix 9), the patients in the RAFT programme had, on average, a better outcome than
those patients in the control arm over the 2 years, with respect to fatigue coping (BRAF-NRS coping),
overall fatigue impact (BRAF-MDQ overall), emotional fatigue and living with fatigue (BRAF-MDQ
emotional, BRAF-MDQ living) (Table 11). There was no evidence of a difference between trial arms over
the 2-year duration of follow-up with respect to fatigue severity (BRAF-NRS severity, BRAF-MDQ physical),
cognitive fatigue (BRAF-MDQ cognitive) or any other variable.
Patients making medication changes
During the trial, as reflects the clinical management of RA, many patients had changes to their RA
medication, defined as starting, stopping or changing the dose of a DMARD, bDMARD or glucocorticoid
medication, which might have influenced fatigue. However, the proportion of patients making at least one
change was not different between the trial arms (see Appendix 10).
The RAFT programme acceptability
Patient acceptability of the RAFT programme was indicated by high levels of attendance with little attrition
(see Tables 2 and 3). At 26 weeks, patients reported high levels of satisfaction with the usual-care fatigue
booklet and the RAFT programme (Table 12). However, there was evidence of a difference between
the trial arms for satisfaction, with 89% of RAFT programme patients rating satisfaction ≥ 8 out of 10
(including 62% rating 10/10), compared with 54% of control patients rating satisfaction ≥ 8 out of 10
(including 26% rating 10/10, p < 0.0001). Similarly, 96% of RAFT programme patients were very likely to
recommend the programme to others compared with 68% of control patients who were very likely to
recommend the booklet (i.e. scoring ≥ 8/10; p < 0.001) (see Table 12).
TABLE 9 Primary outcome over 2 years on patients eligible for the RCT at baseline
Eligibility n
BRAF-NRS impact score, adjusted
mean differencea (95% CI) p-value
Screening-eligible participants 308 –0.49 (–0.83 to –0.14) 0.01
Baseline-eligible participants 262 –0.58 (–0.95 to –0.22) 0.002
a Repeated measures analysis adjusted for baseline score and centre.
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TABLE 10 Adjusted mean difference between trial arms in secondary outcomes at 26 weeks
Clinical outcome
Trial arm
Adjusted mean
differenceb (95% CI) p-value Effect size
Control RAFT
n (%)a Mean (SD) n (%)a Mean (SD)
Fatigue
BRAF-NRS severity (0–10) 142 (89.9) 6.13 (2.30) 152 (86.9) 5.91 (2.22) –0.24 (–0.75 to 0.27) 0.35
BRAF-NRS coping (0–10)c 142 (89.9) 5.32 (2.42) 152 (86.9) 5.25 (2.33) –0.15 (–0.69 to 0.39) 0.58
BRAF-MDQ overall impact (0–70) 142 (89.9) 34.74 (16.41) 152 (86.9) 31.51 (16.02) –3.42 (–6.44 to –0.39) 0.03 0.27
BRAF-MDQ physical (0–22) 142 (89.9) 14.40 (5.23) 152 (86.9) 13.72 (4.91) –0.68 (–1.78 to 0.42) 0.23
BRAF-MDQ emotional (0–12) 142 (89.9) 5.36 (3.79) 152 (86.9) 4.37 (3.51) –0.91 (–1.58 to –0.23) 0.01 0.28
BRAF-MDQ cognitive (0–15) 142 (89.9) 6.55 (4.16) 152 (86.9) 5.89 (4.35) –0.66 (–1.45 to 0.13) 0.10
BRAF-MDQ living (0–21) 142 (89.9) 8.43 (5.68) 152 (86.9) 7.53 (5.43) –1.19 (–2.17 to –0.21) 0.02 0.23
Pain: NRS (0–10) 142 (89.9) 5.24 (2.41) 152 (86.9) 5.47 (2.32) 0.16 (–0.33 to 0.65) 0.51
Disability: MHAQ (0–3) 142 (89.9) 0.70 (0.51) 151 (86.3) 0.71 (0.54) 0.02 (–0.06 to 0.10) 0.67
Quality of life: AIMS VAS (0–100) 141 (89.2) 47.70 (23.04) 152 (86.9) 47.22 (23.46) –0.33 (–5.13 to 4.65) 0.90
Disease activity
Assessed: DAS28 (0.96+) 145 (91.8) 4.10 (1.31) 147 (84.0) 4.13 (1.38) 0.02 (–0.21 to 0.24) 0.88
Self-reported: sPDAS2 (2.4–7.9) 142 (89.9) 4.33 (1.04) 151 (86.3) 4.44 (1.13) 0.05 (–0.16 to 0.26) 0.63
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Clinical outcome
Trial arm
Adjusted mean
differenceb (95% CI) p-value Effect size
Control RAFT
n (%)a Mean (SD) n (%)a Mean (SD)
Anxiety: HADS (0–21) 142 (89.9) 7.56 (4.48) 151 (86.3) 6.65 (4.36) –0.33 (–0.95 to 0.29) 0.30
Depression: HADS (0–21) 142 (89.9) 6.42 (4.06) 151 (86.3) 6.22 (3.76) –0.50 (–1.14 to 0.14) 0.13
Valued life activities: VLA (0–3) 142 (89.9) 1.07 (0.62) 151 (86.3) 1.09 (0.67) –0.05 (–0.15 to 0.05) 0.34
Helplessness: AHI (5–30) 142 (89.9) 17.47 (5.46) 152 (86.9) 16.92 (5.06) –0.61 (–1.65 to 0.43) 0.25
Self-efficacy: RASE (28–140)c 142 (89.9) 104.67 (13.31) 151 (86.3) 106.26 (14.78) 3.05 (0.43 to 5.66) 0.02 0.27
Sleep quality
Very goodd 9 (6.3%) 17 (11.4%) 0.75 (0.47 to 1.17)e 0.21
Fairly goodd 65 (45.8%) 64 (43.0%)
Fairly badd 51 (35.9%) 51 (34.2%)
Very badd 17 (12.0%) 17 (11.4%)
a Percentage of the total number of patients randomised (control, n = 158; RAFT, n = 175).
b Linear regression adjusted for baseline measure of outcome and centre.
c Higher score = better outcome.
d Number of patients (percentage of questionnaires returned).
e Proportional odds ratio from ordinal regression.
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original text.
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Potential clustering effects
A likelihood ratio test was used to compare the primary analysis model (standard linear regression) to a
linear mixed model that included centre (1–7) and the RAFT programme cohort (i.e. group) within centres
(1–4) as cluster variables. No evidence of clustering was demonstrated: the log-likelihood of linear mixed
model was –696.444 and the log-likelihood of model not adjusting for clustering was –696.489 (p = 0.96).
The ICC for the correlation of the outcome in cohorts within centre was also very low (0.009).
Missing data
Analysis on 20 sets of imputed data was almost identical to the results of the primary ‘complete-case’ analysis,
with an adjusted mean difference between the trial arms in fatigue impact at 26 weeks of 0.58 in favour of
the RAFT programme (Table 13). Consequently, no further analyses were conducted on imputed data sets.
TABLE 11 Mixed models examining the effect of the RAFT programme on secondary outcomes over 2 years
Secondary outcome Adjusted mean differencea 95% CI p-value
Fatigue
BRAF-NRS severity (0–10) –0.17 –0.54 to 0.20 0.38
BRAF-NRS coping (0–10)b 0.42 0.08 to 0.77 0.02
BRAF-MDQ overall impact (0–70) –2.98 –5.39 to –0.57 0.02
BRAF-MDQ physical (0–22) –0.64 –1.45 to 0.17 0.12
BRAF-MDQ emotional (0–12) –0.90 –1.44 to –0.37 0.001
BRAF-MDQ cognitive (0–15) –0.53 –1.14 to 0.08 0.09
BRAF-MDQ living (0–21) –0.93 –1.75 to –0.10 0.03
Pain: NRS (0–10) 0.01 –0.38 to 0.40 0.94
Disability: MHAQ (0–3) 0.01 –0.07 to 0.08 0.86
Quality of life: AIMS VAS (0–100) –0.02 –3.91 to 3.86 0.99
Disease activity: sPDAS2 (2.4–7.9) 0.03 –0.15 to 0.20 0.77
Anxiety: HADS (0–21) –0.40 –0.96 to 0.15 0.16
Depression: HADS (0–21) –0.49 –1.06 to 0.08 0.09
Valued life activities: VLA (0–3) –0.06 –0.14 to 0.03 0.22
Helplessness: AHI (5–30) –0.27 –1.12 to 0.58 0.54
Self-efficacy: RASE scale (28–140)b 1.31 –0.80 to 3.42 0.23
Sleep quality 0.74c 0.44 to 1.27 0.28
a Adjusted for baseline measure of outcome and centre.
b Higher score = better outcome (for all other scales lower score = better outcome).
c Proportional odds ratio.
Note
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Treatment efficacy
The CACE analysis suggested that there was a larger effect of the RAFT programme intervention in those
who ‘complied’ with the intervention than in the ITT estimate of the ‘offer’ of the intervention (CACE
treatment effect estimate –0.69 vs. primary ITT analysis treatment effect estimate –0.59; see Appendix 11).
However, the CACE analysis method could be considered inappropriate as 14 participants randomised to,
but not attending, the RAFT programme had no follow-up data; therefore, although an attempt was made
to address this issue in the analysis, the results should be interpreted with caution.
Subgroup and exploratory analysis
No patient was deemed to have violated the protocol; therefore, an additional per-protocol analysis was
unnecessary.
Number of sessions attended
As with the CACE analysis (see Appendix 11), a structural mean model 2SLS instrumental variable
approach62 was used to investigate the effect of the total number of RAFT programme sessions attended
on the BRAF-NRS impact score. The results suggest that the more RAFT sessions attended, the greater the
TABLE 12 Satisfaction with and recommendation of usual-care booklet or the RAFT programme
Rating
Acceptability, n (%)a
Satisfactionb Recommendationc
Control (N= 139) RAFT (N= 150) Control (N= 139) RAFT (N= 150)
0 2 (1.4) 0 (0) 2 (1.4) 0 (0)
1 2 (1.4) 0 (0) 2 (1.4) 0 (0)
2 1 (0.7) 0 (0) 2 (1.4) 0 (0)
3 10 (7.2) 0 (0) 6 (4.3) 0 (0)
4 5 (3.6) 0 (0) 3 (2.2) 0 (0)
5 12 (8.6) 3 (2.0) 7 (5.0) 1 (0.7)
6 12 (8.6) 6 (4.0) 8 (5.8) 1 (0.7)
7 20 (14.4) 8 (5.3) 14 (10.1) 4 (2.7)
8 19 (13.7) 17 (11.3) 14 (10.1) 8 (5.3)
9 19 (13.7) 23 (15.3) 15 (10.8) 14 (9.3)
10 37 (26.6) 93 (62.0) 66 (47.5) 122 (81.3)
a Percentage of returned questionnaires.
b Very dissatisfied to very satisfied (0–10).
c Not at all likely to recommend to yes, definitely recommend (0–10).
TABLE 13 Regression model of change in BRAF-NRS impact with imputed data
Trial arm
Complete casesa (N= 308) Imputed dataa (N= 333)
Adjusted mean difference (95% CI) p-value Adjusted mean difference (95% CI) p-value
RAFT –0.59 (–1.11 to –0.06) 0.03 –0.58 (–1.11 to –0.05) 0.03
a Linear regression adjusted for baseline score and centre.
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reduction in fatigue impact at 26 weeks, with each additional RAFT session attended giving a decrease
of approximately 0.1 BRAF-NRS impact units (95% CI –0.21 to –0.01 BRAF-NRS impact units; p = 0.03).
However, the model assumes a linear relationship between session attendance and BRAF-NRS impact score
and that the impact of an increase in attendance at any one of the seven sessions is the same across all
sessions (i.e. each of sessions 1–7 has a similar effect on patient outcome, even though each session
covers a different topic that may or may not hold personal relevance for individual patients). This analysis is
exploratory and assumptions of linearity may not hold.
Consolidation session (week 14)
Additional data were collected at the end of the intensive six sessions of the RAFT programme (week 6) and
4 weeks before and after the week 14 consolidation session (i.e. weeks 10 and 18), to provide preliminary
data on the possible impact of the consolidation session. Week 6 data are shown in Appendices 12 and 13
and fatigue data collected at weeks 10 and 18 are provided in Appendices 14–17. After adjusting for
baseline score and centre, there was evidence of a difference between trial arms at week 6 in favour of
the RAFT programme for the primary outcome (BRAF-NRS impact, –0.65), as well as coping with fatigue
(BRAF-NRS coping), overall fatigue impact (BRAF-MDQ overall) and living with fatigue, cognitive fatigue
and emotional fatigue, plus sleep quality and the process measure self-efficacy (RASE scale) (Table 14).
Effect sizes for these variables ranged from 0.21 (cognitive fatigue) to 0.6 (coping with fatigue).
TABLE 14 Adjusted mean difference between arms for secondary outcomes at 6 weeks
Clinical outcome
Trial arm, n (%)a
Adjusted mean
differenceb (95% CI) p-value Effect sizeControl RAFT
Fatigue
BRAF-NRS impact (0–10) 156 (98.7) 156 (89.1) –0.65 (–1.07 to –0.23) < 0.01 0.40
BRAF-NRS severity (0–10) 139 (88.0) 144 (82.3) –0.37 (–0.78 to 0.04) 0.07
BRAF-NRS coping (0–10)c 139 (88.0) 144 (82.3) 1.23 (0.75 to 1.71) < 0.01 0.60
BRAF-MDQ overall Impact (0–70) 139 (88.0) 143 (81.7) –4.78 (–7.14 to –2.42) < 0.01 0.37
BRAF-MDQ physical (0–22) 139 (88.0) 144 (82.3) –1.56 (–2.39 to –0.73) < 0.01 0.48
BRAF-MDQ emotional (0–12) 139 (88.0) 143 (81.7) –1.06 (–1.66 to –0.45) 0.01 0.33
BRAF-MDQ cognitive (0–15) 139 (88.0) 143 (81.7) –0.82 (–1.50 to –0.15) 0.01 0.21
BRAF-MDQ living (0–21) 139 (88.0) 143 (81.7) –1.33 (–2.26 to –0.41) 0.01 0.26
Pain: NRS (0–10) 139 (88.0) 144 (82.3) –0.02 (–0.45 to 0.40) 0.92
Disability: MHAQ (0–3) 139 (88.0) 142 (81.1) 0.03 (–0.05 to 0.10) 0.50
Quality of life: AIMS VAS (0–100) 138 (87.3) 144 (82.3) –3.01 (–7.53 to 1.51) 0.19
Disease activity: sPDAS2 (2.4–7.9) 139 (88.0) 141 (80.6) 0.07 (–0.13 to 0.27) 0.49
Anxiety: HADS (0–21) 139 (88.0) 143 (81.7) –0.24 (–0.88 to 0.40) 0.46
Depression: HADS (0–21) 139 (88.0) 143 (81.7) –0.31 (–0.86 to 0.25) 0.28
Valued life activities: VLA (0–3) 139 (88.0) 142 (81.1) –0.002 (–0.08 to 0.08) 0.97
Helplessness: AHI (5–30) 139 (88.0) 143 (81.7) –0.65 (–1.51 to 0.20) 0.13
Self-efficacy: RASE scale (28 to 140)c 138 (87.3) 143 (81.7) 3.94 (1.67 to 6.20) < 0.01 0.35
Sleep qualityd 136 (86.1) 139 (79.5) 0.49 (0.30 to 0.80) < 0.01
a Percentage of the total number of patients randomised (control, n = 158; RAFT, n = 175).
b Linear regression adjusted for baseline outcome scores and for centre.
c Higher score = better outcome.
d Proportional odds ratio.
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At 10 weeks, the adjusted mean difference between the arms for the primary outcome was maintained
in favour of the RAFT programme, but was lower than that at 6 weeks (BRAF-NRS impact score –0.51 vs.
–0.65). In addition, there was no longer evidence of a difference between arms for coping with fatigue.
At 18 weeks, 4 weeks after the consolidation session 7, the adjusted mean difference in BRAF-NRS impact
score was again similar to that at week 6, at –0.64, and coping with fatigue was once again significantly
different between arms (Table 15). However, these were exploratory analyses and any differences between
effect sizes at these time points may reflect random variation in treatment effect as the trial progressed.
Predictors of fatigue impact change
Certain clinical and demographic characteristics were examined as potential predictors of fatigue impact.
The starting model comprised the primary analysis model additionally adjusted for baseline pain (NRS),
disease activity (DAS28), BRAF-NRS coping score, age, comorbidity, work status, disease duration and sex.
After the process of stepwise deletion, the only additional variables retained (i.e. variables other than those
in the primary analysis model) were sex and disease activity (DAS28) score. The final linear regression model
(primary analysis model plus additional adjustment for sex and baseline DAS28) suggested that a worse
outcome was predicted by being female and having a higher baseline DAS28 score: being female was
associated with a 0.75 unit of scale increase in BRAF-NRS impact score at 26 weeks (95% CI 0.08 to 1.41;
p = 0.03), whereas a 1 unit of scale increase in baseline disease activity (DAS28) was associated with a
0.25 unit of scale increase in BRAF-NRS impact score at 26 weeks (95% CI 0.02 to 0.49; p = 0.04).
Self-efficacy
The RASE scale addresses beliefs about RA self-management behaviours56 and most of the 28 items are
touched on during the RAFT programme, except the final three medication items (see Appendix 18). At
26 weeks, six RASE scale items demonstrated evidence of a difference between trial arms for change
over weeks 0–26 in favour of the RAFT programme (Table 16). Avoiding doing things that cause pain,
relaxation, pacing, acceptance of fatigue, asking for help and using relaxation tapes were all covered
during RAFT programme sessions.
TABLE 15 Adjusted mean difference between arms for fatigue outcomes at 10 and 18 weeks
Fatigue outcome
Time point
Week 10a Week 18b
Adjusted mean
differencea (95% CI) p-value
Effect
size
Adjusted mean
differencec (95% CI) p-value
Effect
size
BRAF-NRS impact (0–10) –0.51 (–0.97 to –0.05) 0.03 0.31 –0.64 (–1.11 to –0.17) 0.01 0.39
BRAF-NRS severity (0–10) –0.04 (–0.52 to 0.45) 0.88 –0.32 (–0.81 to 0.18) 0.21
BRAF-NRS coping (0–10)d 0.46 (–0.05 to 0.98) 0.08 0.75 (0.20 to 1.29) 0.01 0.36
BRAF-MDQ overall impact (0–70) –2.22 (–5.00 to 0.57) 0.12 –2.93 (–6.09 to 0.22) 0.07
BRAF-MDQ physical (0–22) –0.64 (–1.65 to 0.36) 0.21 –0.89 (–1.96 to 0.18) 0.10
BRAF-MDQ emotional (0–12) –0.76 (–1.44 to –0.08) 0.03 0.24 –0.87 (–1.57 to –0.18) 0.01 0.27
BRAF-MDQ cognitive (0–15) –0.34 (–1.06 to 0.38) 0.36 –0.74 (–1.53 to 0.06) 0.07
BRAF-MDQ living (0–21) –0.55 (–1.55 to 0.45) 0.28 –0.44 (–1.56 to 0.68) 0.44
a Control, n = 103–153; RAFT, n = 137–155.
b Control, n = 137–151; RAFT, n = 137–154.
c Linear regression adjusted for baseline outcome scores and for centre.
d Higher score = better outcome.
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original text.
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Tutor delivery over time
It was hypothesised that tutors might increase in skills and confidence to deliver the RAFT programme over
time, which might be reflected in improved outcomes in the later RAFT programmes (i.e. from cohort 1
through to cohort 4). Although it appears that the difference between trial arms in mean change in
BRAF-NRS impact score was greatest in cohort 4, the study was not powered to formally test this (Table 17).
TABLE 16 Rheumatoid Arthritis Self-Efficacy Scale item changes at 0–26 weeks (N= 293)
RASE scale itema
Trial arm, mean change
Difference in
mean change p-value
Control
(n= 142)
RAFT
(n= 151)
Use relaxation techniques to help with pain –0.07 0.11 0.18 0.10
Think about something else to help with pain 0.04 0.16 0.12 0.34
Use my joints carefully to help with pain 0.20 0.18 –0.02 0.87
Think positively to help with pain 0.06 0.23 0.17 0.16
Avoid doing things that cause pain 0.25 –0.05 –0.30 0.03
Wind down, relax before bed, to improve sleep 0.10 0.17 0.07 0.56
Hot drink before bed to improve sleep 0.14 0.19 0.05 0.69
Use relaxation before bed to improve sleep –0.11 0.17 0.28 0.02
Pace myself, take RA into account to deal with fatigue –0.08 0.33 0.41 < 0.01
Accept fatigue as part of my arthritis 0.07 0.40 0.33 0.01
Use gadgets to help with mobility, tasks, personal care –0.01 0.19 0.20 0.06
Ask for help to deal with difficulties of doing everyday things –0.01 0.25 0.26 0.02
Do exercises to deal with difficulties of doing everyday tasks 0.01 0.09 0.08 0.50
Plan/prioritise to deal with difficulties doing everyday tasks –0.01 0.17 0.19 0.07
Educate family/friends about my RA to help relationships 0.01 0.15 0.14 0.25
Explain to friends and family when I do or do not need help –0.02 0.04 0.06 0.61
Discuss any problems with my partner or family 0.00 0.10 0.10 0.38
Make time for leisure activities, hobbies or socialising –0.01 0.05 0.05 0.58
Save energy for leisure activities, hobbies or socialising 0.08 0.14 0.06 0.66
Focus on the positive when I am feeling down 0.01 0.15 0.14 0.21
Use relaxation to deal with worries 0.07 0.03 –0.04 0.75
Allocate time for relaxation –0.05 0.04 0.09 0.39
Use relaxation tape or instructions to help me relax –0.22 0.18 0.40 < 0.01
Use regular exercise 0.02 0.14 0.12 0.27
Be aware of my limits in exercise –0.07 0.05 0.11 0.23
Manage medication, knowing how and when to take it –0.01 0.07 0.07 0.42
Look out for and avoid side effects of medication –0.08 0.01 0.09 0.42
Seek help with persistent side effects –0.04 0.00 0.04 0.66
a High score means greater self-efficacy (1–5).
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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TABLE 17 Change in BRAF-NRS impact score at 26 weeks for each RAFT programme cohort (1–4)
Cohort
Trial arm
Difference in
mean change
Control RAFT
n
Time point, mean (SD)
Mean change (95% CI) n
Time point, mean (SD)
Mean change (95% CI)0 weeks 26 weeks 0 weeks 26 weeks
1 39 7.56 (1.31) 6.72 (1.92) –0.85 (–1.43 to –0.26) 37 6.95 (1.70) 5.73 (2.58) –1.22 (–2.17 to –0.26) –0.37
2 39 7.54 (1.54) 6.44 (2.82) –1.10 (–1.90 to –0.30) 38 7.21 (1.58) 5.76 (2.62) –1.45 (–2.34 to –0.56) –0.35
3 39 6.69 (1.81) 6.15 (2.62) –0.54 (–1.45 to 0.37) 42 7.26 (1.89) 6.31 (2.42) –0.95 (–1.77 to –0.13) –0.41
4 35 7.11 (1.75) 6.09 (2.27) –1.03 (–1.76 to –0.29) 39 6.95 (1.50) 5.10 (1.90) –1.85 (–2.51 to –1.18) –0.82
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original text.
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Social contact
Both the usual-care booklet and the RAFT programme highlight the value of obtaining support. At 52 and
104 weeks, 7–13% of patients across both trial arms reported making contact with other patient(s) for
support with fatigue or arthritis (see Appendix 19). In addition, at 52 weeks, 20% of RAFT programme
patients (n = 35) had made contact with patient(s) in their RAFT programme group after their programme
had finished and 12.6% (n = 22) had maintained contact during the year. At 104 weeks, 9% of RAFT
programme patients (n = 16, including 12 of the original 35 patients) had made contact and 5.6% of RAFT
programme patients (n = 10) maintained contact during this second year.
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Chapter 4 Economic evaluation: methods and
results
Introduction
The economic evaluation aimed to determine the cost-effectiveness of delivering the RAFT CB programme
alongside usual care (intervention) to RA patients with fatigue, compared with patients receiving usual care
alone (control). The primary economic cost–utility analysis was conducted from the societal perspective,
including costs incurred by the NHS, Personal Social Services (PSS) and the individual, and costs arising
from loss of productivity, comparing the costs and benefits of each trial arm over the first 26 weeks’
follow-up, in line with the clinical effectiveness analysis. A secondary analysis restricted the perspective to
NHS and PSS costs to conform to the NICE reference case.66 Longer-term cost-effectiveness was assessed
through a secondary analysis conducted after 2 years’ follow-up.
Methods
The cost-effectiveness analyses were conducted in accordance with the SAP [see URL: www.journalslibrary.
nihr.ac.uk/programmes/hta/1111201/#/documentation (accessed 12 April 2019)] and agreed with the TSC
and the DMEC. Minor deviations from the plan were required (see Report Supplementary Material 3).
Measurement and valuation of economic outcomes
The primary economic outcome measure was quality-adjusted life-years (QALYs). Measurements were
recorded at baseline and at 6, 26, 52, 78 and 104 weeks post randomisation, using the EuroQol-5 Dimensions
(EQ-5D) health-related quality-of-life descriptive system [most recently the EuroQol-5 Dimensions, five-level
version (EQ-5D-5L)]67 in the main questionnaire package (see Chapter 2, Follow-up time points, data collection
and management). As recommended by the recent position statement from NICE,68 utility scores were derived
from the EQ-5D-5L measurements using the van Hout crosswalk method69 and, when relevant, were set to
zero at death. The utility scores were used to calculate QALYs using linear interpolation and the area under
the curve method, and were discounted at 3.5% in the second year of follow-up.
A secondary economic outcome measure was fatigue impact at 26 weeks (the primary effectiveness
outcome of the trial). Fatigue impact was measured using the BRAF-NRS impact score collected by the
central trial team by telephone at the same major time points as the utility measures.
Identification of relevant resource use
Data were collected for resource use associated with RA or RA-related fatigue only. Routine monthly blood
monitoring visits were excluded, whether performed in primary or secondary care, as these were considered
to be unrelated to the intervention. For the NHS and PSS perspectives, data were collected on arthritis
medication, primary and community medical care, physiotherapy, occupational therapy, podiatry or nursing
care, secondary care, use of a rheumatology telephone helpline and use of social care by the patient. Staff
time and other expenses incurred during the training and delivery of the RAFT programme were recorded.
For the primary analysis from the societal perspective, we additionally collected data on work productivity
(presenteeism and absenteeism), and patient-incurred expenses for travel to a general practitioner (GP) and
hospital appointments, including the RAFT programme itself.
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Measurement of resource use
Time logs and expense forms were used to track all resources used in the delivery of the 4-day RAFT
training programme, including trainee and trainer time (preparation time and observation of the practice
programme), travel costs and programme materials, to calculate the fixed cost of training (Table 18).
For the delivery of the RAFT programme CB sessions, NHS resources were captured in staff time logs
recording session preparation, delivery, debriefing, supervision time and materials.
NHS community care and emergency care, and patient personal resource use, during the 2-year follow-up
period were captured using patient-reported questionnaires at baseline and at weeks 6, 26, 52, 78 and
104, with patients completing the questionnaires at their research nurse visits at baseline and week 26,
and by post at all other time points. Medications were recorded by the research nurse at the baseline visit
and patients were asked to indicate changes from the previous record at each follow-up questionnaire.
Secondary care data on outpatient appointments, inpatient stays and day-case attendances were extracted
from hospital computer records by research nurses.
The research nurse documented the patient’s normal transport method for hospital and GP appointments
and the cost (for public transport) or mileage (for private or hospital transport) at the baseline visit, to use
as a multiplier for calculating costs. Work disability, presenteeism and absenteeism were captured using
the Work Productivity and Activity Impairment (WPAI) scale, which measures hours worked or lost over the
past 7 days.70
Valuation of resource use
All costs are reported in pounds sterling at 2015/16 rates. Unit costs for community care, primary care and
NHS staff time to train for and deliver the intervention were based on the Unit Costs of Health and Social
Care 2016.71 Actual expenses incurred for training materials, refreshments and staff travel were recorded.
The costs of medications used during follow-up were based on data in the prescriptions cost analysis for
England.72 Secondary care (including routine RA care) costs were derived from the NHS Reference Costs
2015 to 2016.73 Private care costs were estimated from the median of three quotes or by using data from
national bodies. The WPAI scale responses were combined to derive an estimate of the overall work
impairment due to RA or RA-related fatigue.70 The impairment factor was applied to average weekly
earnings stratified by age.74 Productivity losses were estimated as changes in productivity from baseline.
Unit costs used in the analysis are given in Table 19. Costs occurring during the second year of follow-up
were discounted in line with NICE guidance (currently 3.5%).66
Missing data
All analyses were conducted using ITT principles, comparing the two interventions as randomised and
including all patients in the analysis. Multiple imputation by chained equations was conducted to impute
NHS and PSS costs, travel costs, productivity losses and utility values. All missing data were imputed by the
predictive mean-matching method using the five nearest neighbours and 33 imputations. The intervention arm
fatigue impact up to week 26 and baseline pain and fatigue severity scores were included in the model,
along with sex, age at baseline and centre.
Analysis of costs and economic outcomes
The cost of each resource item was calculated by multiplying the number of resource units used by the
unit cost. The total cost for each individual patient was estimated as the sum of the cost of resource use
items consumed. Overall mean costs, stratified by NHS, PSS, patient and productivity costs, and standard
errors (SE) for both interventions of the trial, were calculated. The incremental mean difference in total
costs was estimated between the two interventions of the trial and derived 95% CIs derived using SEs
from linear regressions.
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TABLE 18 The RAFT programme health economic outcome variables, measures and time points
Variable Measure
Time point
0 weeks 6 weeks 26 weeks 52 weeks 78 weeks 104 weeks
Fatigue impact (primary outcome) BRAF-NRS (telephone) ✓ ✓ ✓ ✓ ✓ ✓
RA-related medicationsa Nurse collected ✓
Travel costs to all appointmentsb Nurse collected ✓
QALYs EQ-5D-5L64 self-reported ✓ ✓ ✓ ✓ ✓ ✓
Work productivity (last 7 days) WPAI scale68 self-reported ✓ ✓ ✓ ✓ ✓ ✓
Days of sick leave (last 6 months) Self-report ✓ ✓ ✓ ✓ ✓ ✓
Primary care RA appointments Self-report ✓ ✓ ✓ ✓ ✓ ✓
Secondary care RA helpline telephone call Self-report ✓ ✓ ✓ ✓ ✓ ✓
Social care (by whom/hours) Self-report ✓ ✓ ✓ ✓ ✓ ✓
Private community care Self-report ✓ ✓ ✓ ✓ ✓ ✓
Medication changes Self-report ✓ ✓ ✓ ✓ ✓
RA-related outpatient appointments Hospital computer ✓ ✓ ✓ ✓ ✓ ✓
RA-related day cases Hospital computer ✓ ✓ ✓ ✓ ✓ ✓
RA-related inpatient stays Hospital computer ✓ ✓ ✓ ✓ ✓ ✓
RA-related emergency department visits Self-report ✓ ✓ ✓ ✓ ✓ ✓
RAFT programme training; observed practice programmes; and RAFT
programme delivery × 28
Tutor/trainer time, travel costs and
materials
Logged as they occurred
a Subsequent questionnaires listed last medications reported and asked patients to report changes.
b Usual cost to travel to a GP/hospital appointment used as multiplier for calculating total visit costs.
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TABLE 19 Unit costs
Service Unit cost (£) Source
Rheumatology nurse helpline (hospital) 22.00 Unit Costs of Health and Social Care 201671
NHS podiatry (community) 16.00 Unit Costs of Health and Social Care 201671
NHS physiotherapy (community) 16.00 Unit Costs of Health and Social Care 201671
NHS OT (community) 16.00 Unit Costs of Health and Social Care 201671
NHS orthotist (community) 16.00 Unit Costs of Health and Social Care 201671
GP appointment 27.00 Unit Costs of Health and Social Care 201671
GP telephone call 21.18 Unit Costs of Health and Social Care 201671
Nurse appointment (community) 9.30 Unit Costs of Health and Social Care 201671
Social home care provided by social services 24.00 Unit Costs of Health and Social Care 201671
Home care provided by private provider 13.00 Paying for Home Care Costs in 2019 – Your Ultimate
Guide75
Home care provided by family 7.20 UK government76
Private podiatry 38.00 Three estimatesa
Private physiotherapy 50.00 Three estimatesb
Private reflexology 45.00 Three estimatesc
Private acupuncture 32.50 Three estimatesd
Private osteopathy 42.00 Three estimatese
Private OT 55.00 Three estimatesf
Private counselling 40.00 Three estimatesg
Private massage therapy 45.00 Three estimatesh
Personal trainer 40.00 Three estimatesi
Private chiropractor 55.00 Chiropractic77
Rheumatology outpatient CL 137.00 NHS Reference Costs 2015 to 201673
Rheumatology outpatient NCL 87.00 NHS Reference Costs 2015 to 201673
Trauma and orthopaedics outpatient CL 110.00 NHS Reference Costs 2015 to 201673
Trauma and orthopaedics outpatient NCL 98.00 NHS Reference Costs 2015 to 201673
Pain management outpatient CL 131.00 NHS Reference Costs 2015 to 201673
Pain management outpatient NCL 109.00 NHS Reference Costs 2015 to 201673
Orthotics outpatient CL 62.00 NHS Reference Costs 2015 to 201673
Orthotics outpatient NCL 121.00 NHS Reference Costs 2015 to 201673
Diagnostic imaging outpatient CL 51.00 NHS Reference Costs 2015 to 201673
Diagnostic imaging outpatient NCL 35.00 NHS Reference Costs 2015 to 201673
Podiatry outpatient NCL 37.00 NHS Reference Costs 2015 to 201673
Physiotherapy outpatient NCL 45.00 NHS Reference Costs 2015 to 201673
OT outpatient NCL 60.00 NHS Reference Costs 2015 to 201673
Dietetics outpatient NCL 68.00 NHS Reference Costs 2015 to 201673
Ophthalmology outpatient CL 87.00 NHS Reference Costs 2015 to 201673
Inpatient stay in rheumatology 1567.00 NHS Reference Costs 2015 to 201673
Day case 389.00 NHS Reference Costs 2015 to 201673
DEXA scan 71.00 NHS Reference Costs 2015 to 201673
Ultrasound scan 57.00 NHS Reference Costs 2015 to 201673
MRI scan 153.00 NHS Reference Costs 2015 to 201673
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The incremental mean difference in QALYs between the two interventions of the trial and 95% CIs were
calculated, adjusting for any imbalances in baseline utility scores.78 Pearson’s correlation coefficients
between the change in BRAF-NRS impact score and the change in utility, and the EQ-5D score between
baseline and 2 years, were examined.
Analysis of relative costs and outcomes
Primary cost-effectiveness analysis
Cost and QALY data were combined to calculate the incremental cost-effectiveness ratio (ICER) and
incremental net monetary benefit (INMB) statistics:
INMB = λΔE –ΔC. (1)
The INMB statistic is given as the societal willingness to pay (WTP) for a QALY, λ, multiplied by the difference
in patient outcomes, E (i.e. QALYs), from which the difference in total costs, C, is subtracted. In the primary
analysis, INMB was estimated to see whether or not the RAFT programme intervention is cost-effective at
the established NICE thresholds of £20,000 and £30,000 per QALY gained.
The probability that the RAFT programme intervention is cost-effective at various ‘WTP-for-a-QALY’
thresholds was explored using cost-effectiveness acceptability curves.79 All cost-effectiveness statistics
(i.e. ICERs, cost-effectiveness acceptability curves and INMB) and CIs were estimated parametrically from
the output of seemingly unrelated regression analysis, using the Stata ‘sureg’ command to allow for
the correlation between costs and outcomes. Differences in baseline utility (or BRAF-NRS impact score)
between the arms were controlled for. Study centre was included as an independent variable in the
regression analysis.
TABLE 19 Unit costs (continued )
Service Unit cost (£) Source
Productivity losses per hour (age 22–29 years) 10.52 Annual Survey of Hours and Earnings: 2016 Provisional
Results74
Productivity losses per hour (age 30–39 years) 13.57 Annual Survey of Hours and Earnings: 2016 Provisional
Results74
Productivity losses per hour (age 40–49 years) 13.92 Annual Survey of Hours and Earnings: 2016 Provisional
Results74
Productivity losses per hour (age 50–59 years) 13.18 Annual Survey of Hours and Earnings: 2016 Provisional
Results74
Productivity losses per hour (age ≥ 60 years) 11.26 Annual Survey of Hours and Earnings: 2016 Provisional
Results74
CL, consultant led; DEXA, dual-energy X-ray absorptiometry; MRI, magnetic resonance imaging; NCL, non-consultant led.
a www.bupa.co.uk/health/bupa-on-demand/muscles-bones-joints; Hilton Foot Care, personal communication, 2 June 2016;
www.feetinfocus.com/payment-insurance/prices-of-treatments.
b www.nuffieldhealth.com/physiotherapy/faqs; www.birdwellclinic.co.uk/physiotherapy; www.whatclinic.co.uk/physiotherapy/
uk/surrey/runnymede/cobham-and-weybridge-physiotherapy.
c www.pure-reflexology.org/cost-price-for-reflexology.html; www.mkjreflexology.co.uk/fees-and-charges.html;
www.feetinfleet.co.uk/phdi/p1.nsf/supppages/2698?opendocument&part=7
d www.acupuncture.org.uk.
e www.osteopathy.org.uk/news-and-resources/research-surveys/statistics.
f www.which.co.uk/later-life-care/home-care/organising-home-care/occupational-therapy-a7bty0s71xz8.
g www.nhs.uk/conditions/counselling.
h www.findatherapy.org/massage_therapy/louise_powell_28.html; www.findatherapy.org/massage_therapy/agatka_angel_
warsza_7004.html; www.findatherapy.org/massage_therapy/antoinette_atuah_4315.html
i www.benandrewsfitness.co.uk/prices; https://ollielawrencepersonaltrainer.co.uk/prices; www.motivatept.co.uk/prices.
All URLs were accessed in February 2018.
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Sensitivity analyses
One-way sensitivity analyses were used to judge the potential impact of sources of uncertainty. A sensitivity
analysis was conducted in which rare high-cost events thought unlikely to be related to fatigue by two
clinicians (unaware of randomised treatment allocation) were excluded. A sensitivity analysis dropping
training costs was also conducted to estimate the impact of training becoming routine in a roll-out situation.
Although it was possible to restrict the primary statistical (clinical) analysis to complete cases, the number of
missing data was higher for the economic analysis and so data were imputed and a complete-case analysis
was conducted as a sensitivity analysis. There was an inevitable delay between screening assessment and
formal baseline assessment as the cohorts (i.e. 10–14 patients sufficient for randomisation) took time
to accrue (see Chapter 2, Recruitment procedures). This meant that 24 out of the 158 randomised control
patients and 28 out of the 175 randomised RAFT programme patients had a baseline BRAF-NRS fatigue severity
score that fell below the eligibility criterion of ≥ 6 points. A further post hoc subgroup analysis therefore
investigated only those patients who were eligible to participate in the trial at baseline, as was performed
for the primary clinical outcome (see Chapter 3).
Results
Missing data
Complete sets of data were available for the intervention costs (which were recorded by staff) and
secondary care costs (which were extracted from medical records). Participants did not always fully complete
questionnaires, leading to missing data at some time points in the medication, emergency care, social care,
community care, work productivity, travel and private care cost categories, and in the utility measurements.
For the primary 26-week analysis, one or more data points were imputed for 59 participants (17.7%),
comprising 24 patients in the control arm (15.2%) and 35 patients in the RAFT programme arm (20.0%)
(p = 0.25). At the 2-year follow-up, one or more data points were imputed for 107 participants (32.1%),
comprising 51 patients in the control arm (32.3%) and 56 patients in the RAFT programme arm (32.0%)
(p = 0.96). Data were imputed for a mean of 9.9 out of 18 items in the RAFT programme arm and a mean
of 8.0 out of 18 items in the control arm over weeks 0–26 (p = 0.03); and a mean of 15.8 out of 48 items in
the control arm and a mean of 20.8 out of 48 items in the RAFT programme arm over weeks 0–104 (p = 0.07).
Resource use and costs of health-care services at 0–26 weeks
Disaggregated data showing the mean number of contacts in the first 26 weeks for each participant (based
on all available data) are given in Table 20. The participants were relatively low users of primary care and
community services for their arthritis, but were regular attenders in secondary care for arthritis-related
appointments. They were high users of RA-related medications, with participants in both trial arms taking
an average of 5.9 different medications to manage their RA. At baseline, 76 (22.8%) participants were in
work, with no difference between trial arms (see Appendix 20). At the 26-week follow-up, participants in
the control arm had lost 0.25 weeks of work productivity, whereas participants in the RAFT programme arm
gained 0.04 weeks from their baseline status (mean difference –0.29 weeks, 95% CI –1.17 to 0.59 weeks).
Only the number of hours of social care related to RA that the participant paid for themselves differed
significantly between the trial arms, with participants in the control arm using more than three times as
much private care (mean difference –8.11 hours, 95% CI –15.39 to –0.82 hours; p = 0.03).
The mean costs for each type of care at 26 weeks are given in Table 21. Medication costs were by far the
highest, driven by the use of very costly bDMARDs by some patients. Other substantial NHS cost categories
were the secondary care outpatient and day-case costs. Social care costs were also high, whether provided
by social services or by family or paid for privately, although private social care was the only category to
differ significantly between trial arms. Travel costs were higher in the RAFT programme arm because of
the additional travel required to attend the sessions. However, overall mean costs (including the RAFT
programme training and delivery) were not different between the trial arms. Costs associated with the
RAFT programme are given in Table 22.
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Quality-adjusted life-years
The mean EQ-5D-5L utility scores and QALYs after 26 weeks and across the 2 years of follow-up are given
in Table 23. Participants in the control trial arm had slightly higher utility scores at baseline, and this
persisted at each time point except at 6 weeks. There were no differences between QALYs gained in each
arm at either 26 weeks or 2 years.
There was a weak to moderate negative correlation between the change in utility score and the change
in BRAF-NRS impact score at 26 weeks (correlation coefficient –0.4, n = 293; p < 0.001) and at 2 years
(correlation coefficient –0.38, n = 259; p < 0.001). Correlation coefficients between the change in the
five individual dimensions of the EQ-5D and the change in BRAF-NRS impact score ranged between 0.21
for the self-care dimension and 0.41 for usual activities (see Appendix 21).
TABLE 20 Resource use: contacts from weeks 0 to 26
Type of resource
Trial arm
Difference in mean
change (95% CI)b p-value
Control RAFT
na Mean SE na Mean SE
GP visits 142 0.86 0.15 152 0.80 0.12 –0.06 (–0.44 to 0.31) 0.74
Nurse visits (community) 142 0.27 0.11 152 0.19 0.07 –0.08 (–0.33 to 0.18) 0.55
OT visits (community) 142 0.06 0.03 152 0.11 0.05 0.04 (–0.07 to 0.15) 0.47
Physiotherapist visits
(community)
142 0.32 0.12 152 0.20 0.08 –0.11 (–0.39 to 0.17) 0.43
Podiatrist visits (community) 142 0.44 0.10 152 0.41 0.09 –0.03 (–0.29 to 0.23) 0.83
Hospital day cases 152 0.30 0.08 156 0.20 0.07 –0.10 (–0.31 to 0.12) 0.37
Hospital outpatient
appointments (all professions)
152 2.02 0.15 156 2.35 0.19 0.33 (–0.15 to 0.81) 0.17
Hospital inpatient stays 152 0.01 0.01 156 0.00 0.00 –0.01 (–0.03 to 0.00) 0.15
Helpline calls 142 0.68 0.11 152 0.53 0.07 –0.15 (–0.40 to 0.10) 0.24
Emergency care visits 143 0.03 0.02 152 0.03 0.01 –0.01 (–0.05 to 0.03) 0.67
Medications (RA related) 143 5.91 0.20 152 5.88 0.21 –0.03 (–0.60 to 0.54) 0.92
Social care (NHS, hours) 134 6.54 3.80 142 5.29 3.94 –1.26 (–12.04 to 9.53) 0.82
Community care (private,
hours)
142 0.53 0.22 152 0.42 0.18 –0.11 (–0.66 to 0.44) 0.70
Family help (hours) 134 94.99 12.97 142 138.19 21.87 43.20 (–7.59 to 93.98) 0.09
Social care (private, hours) 134 11.46 3.59 142 3.35 1.21 –8.11 (–15.39 to –0.82) 0.03
Work productivity losses
(weeks)
134 0.25 0.33 142 –0.04 0.30 –0.29 (–1.17 to 0.59) 0.51
a Counts based on available data, not imputed data.
b CIs calculated using SEs from linear regressions.
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TABLE 21 Mean service costs by arm (weeks 0–26)
Cost category
Trial arm
Difference in mean
cost (£) change
(95% CI)b p-value
Control RAFT
na Mean (£) SE (£) na Mean (£) SE (£)
GP 142 23 4 152 22 3 –2 (–12 to 9) 0.76
Nurse (community) 142 2 1 152 2 1 –1 (–3 to 2) 0.55
OT (community) 142 1 1 152 2 1 1 (–1 to 2) 0.47
Physiotherapist (community) 142 5 2 152 3 1 –2 (–6 to 3) 0.43
Podiatrist (community) 142 7 2 152 7 1 –0 (–5 to 4) 0.83
Hospital day cases 152 115 33 156 77 26 –38 (–121 to 45) 0.37
Hospital outpatients 152 204 14 156 233 18 28 (–16 to 73) 0.21
Hospital inpatients 152 51 42 156 0 0 –51 (–132 to 30) 0.22
Helpline calls 142 15 2 152 12 2 –3 (–9 to 2) 0.24
Emergency care visits 143 5 2 152 10 5 5 (–5 to 15) 0.35
Medications (RA related) 143 1764 261 152 1714 232 –50 (–736 to 636) 0.89
RAFT programme training 158 0 0 175 186 5 186 (176 to 196)
RAFT programme delivery 158 0 0 175 322 9 322 (303 to 340)
Social services 134 157 91 142 127 94 –30 (–289 to 229) 0.82
Private community care 142 22 10 152 18 8 –5 (–30 to 21) 0.73
Travel costs 142 15 1 152 55 4 40 (33 to 48) 0.00
Family help 134 684 93 142 995 157 311 (–55 to 677) 0.09
Private social care 134 149 47 142 44 16 –105 (–200 to –11) 0.03
Productivity losses 134 96 150 142 –20 135 –116 (–512 to 280) 0.56
Total NHS/PSS costs 134 2377 304 142 2797 267 421 (–374 to 1215) 0.30
Total costs from the patient
perspectivec
134 871 110 142 1111 158 240 (–143 to 624) 0.22
a Counts based on all available data.
b CIs calculated using SEs from linear regressions.
c Patient perspective includes private community and social care, travel costs and family help.
TABLE 22 Intervention costs for participants who received the RAFT programme intervention
Cost variable Mean cost per person (£) (N= 161)a SE
Printed programme materials 2.00 0.12
Refreshments 2.77 0.13
CD handouts 1.97 0.04
Staffingb 342.95 5.65
Trainingc 201.77 2.68
Patient travel (for up to seven sessions) 36.94 2.56
CD, compact disc.
a Includes all patients who attended any RAFT programme sessions; excludes 14 patients who withdrew beforehand.
b Unit costs for research nurses (£15.03), trainers (£34.22) and tutors (£21.97) taken from mid-point of relevant NHS/
university pay scales.
c Training costs include staff costs/travel time, clinical observations and costs of running the practice (training) cohorts.
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Primary cost-effectiveness analysis
The cost-effectiveness statistics for the primary analysis at 26 weeks, from a societal perspective, are based
on an imputed data set of all participants as randomised (Table 24). The point estimate of the incremental
cost per QALY gained is £55,202, and the net monetary benefit is –£277 (95% CI –£1212 to £657) at a
societal WTP threshold of £20,000 per QALY. The probability that the RAFT programme is cost-effective at
the same threshold is 0.28. Figure 4 shows the variation in the probability that the RAFT programme is
cost-effective at different WTP thresholds.
TABLE 23 EuroQol-5 Dimensions, five-level version utility scores and QALYs, by trial arm (all available data)
Outcome
Trial arm
Difference in mean
change (95% CI)a p-value
Control RAFT
n Mean SE n Mean SE
Baseline utility 158 0.554 0.018 175 0.540 0.018 –0.014 (–0.063 to 0.036) 0.59
6-week utility 139 0.535 0.020 143 0.546 0.019 0.011 (–0.044 to 0.066) 0.70
26-week utility 144 0.561 0.020 151 0.553 0.020 –0.008 (–0.063 to 0.048) 0.78
52-week utility 128 0.556 0.020 138 0.530 0.024 –0.026 (–0.088 to 0.035) 0.40
78-week utility 120 0.552 0.021 130 0.528 0.024 –0.024 (–0.086 to 0.038) 0.45
104-week utility 125 0.534 0.021 138 0.502 0.025 –0.033 (–0.097 to 0.032) 0.32
QALYs after 26 weeks of
follow-up
135 0.275 0.009 140 0.275 0.009 –0.001 (–0.026 to 0.024) 0.96
QALYs after 2 years of follow-up 108 1.115 0.037 120 1.058 0.041 –0.057 (–0.168 to 0.053) 0.31
a CIs calculated using SEs from linear regressions.
TABLE 24 Cost-effectiveness statistics from a societal perspective at 26 weeks based on imputed data
Costs and outcomes
Trial arm
Mean difference (95% CI) p-value
Control (n= 158) RAFT (n= 175)
Mean SE Mean SE
Unadjusted costs from the societal
perspective (£)
3279 317 3756 295
Adjusted costs from the societal
perspective (£)a
3301 301 3736 293 434 (–389 to 1258) 0.30
Unadjusted QALYs over 26 weeks of
follow-up
0.269 0.009 0.272 0.008
Adjusted QALYs over 26 weeks of
follow-upb
0.267 0.006 0.274 0.006 0.008 (–0.008 to 0.023) 0.32
ICERb 55,202
Net monetary benefit at £20,000 (£) –277 (–1212 to 657)
Net monetary benefit at £30,000 (£) –198 (–1220 to 823)
Probability that the RAFT programme is cost-effective at £20,000 per QALY 0.28
Probability that the RAFT programme is cost-effective at £30,000 per QALY 0.35
a Adjusted for centre.
b QALYs adjusted for baseline utility and centre.
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Sensitivity analyses
Data from one individual who had a costly inpatient stay, which was deemed potentially unrelated to RA
fatigue, were removed in a sensitivity analysis. This resulted in an ICER of £51,893 per QALY gained, with
the probability of cost-effectiveness 0.29 at a £20,000 per QALY threshold. The sensitivity analysis without
training costs gave an ICER of £31,578 per QALY and a cost-effectiveness probability of 0.42 at £20,000.
The complete-case sensitivity analysis did not alter the conclusions as to the probability of cost-effectiveness
(see Appendix 22).
The primary analysis was repeated excluding those individuals who had fallen below the eligibility criterion
of BRAF-NRS severity ≥ 6.0 between screening and baseline (24/158 patients randomised to the control
arm and 28/175 patients randomised to the RAFT programme). For baseline-eligible patients, using
imputed data, the ICER was £17,214 per QALY and the probability of cost-effectiveness was 0.52 at the
£20,000 NICE threshold (Table 25).
Secondary cost-effectiveness analyses
The results of the three secondary cost-effectiveness analyses (from an NHS/PSS perspective, a longer-term
analysis with 2 years of follow-up and an analysis based on the primary effectiveness outcome of BRAF-NRS
impact) are given in Tables 26–28. The RAFT programme had a similar likelihood of cost-effectiveness from
the NHS/PSS perspective as from the societal perspective (see Table 26). After 2 years of follow-up, the RAFT
programme had higher costs and slightly poorer health-related quality-of-life outcomes (see Table 27).
However, the CIs on costs and outcomes included zero and the uncertainty around the cost and outcome
estimates results in a similar probability of cost-effectiveness. The cost-effectiveness analysis using the primary
effectiveness outcome gave an ICER of £455 per unit improvement in the BRAF-NRS impact score (see Table 28).
The variation in probability of the RAFT programme cost-effectiveness thresholds (see Appendix 23)
suggests, for example, a probability of cost-effectiveness of 0.78 if society was willing to pay £1000 per unit
of improvement in the BRAF-NRS impact score.
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FIGURE 4 Cost-effectiveness acceptability curve: variation in probability of the RAFT programme cost-effectiveness
at a range of societal WTP thresholds – primary analysis.
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TABLE 26 Cost-effectiveness secondary analysis: NHS/PSS perspective after 26 weeks of follow-up
Costs and outcomes
Trial arm
Mean difference (95% CI) p-value
Control (n= 158) RAFT (n= 175)
Mean SE Mean SE
Unadjusted costs from the
NHS/PSS perspective (£)
2310 271 2620 233
Adjusted costs from the NHS/PSS
perspective (£)a
2326 250 2605 238 279 (–393 to 950) 0.42
Unadjusted QALYs over 26 weeks
of follow-up
0.269 0.009 0.272 0.008
Adjusted QALYs over 26 weeks of
follow-upb
0.266 0.006 0.274 0.006 0.008 (–0.008 to 0.024) 0.31
ICER 34,878
Net monetary benefit at £20,000 (£) –119 (–879 to 641)
Net monetary benefit at £30,000 (£) –39 (–884 to 806)
Probability that the RAFT programme is cost-effective at £20,000 per QALY 0.38
Probability that the RAFT programme is cost-effective at £30,000 per QALY 0.46
a Adjusted for centre.
b QALYs adjusted for baseline utility and centre.
TABLE 25 Cost-effectiveness statistics from a societal perspective at 26 weeks restricted to patients eligible at
baseline
Costs and outcomes
Trial arm
Mean difference (95% CI) p-value
Control (n= 134) RAFT (n= 147)
Mean SE Mean SE
Unadjusted costs from the
societal perspective (£)
3380 364 3644 327
Adjusted costs from the societal
perspective (£)a
3417 341 3611 328 194 (–746 to 1134) 0.69
Unadjusted QALYs over
26 weeks of follow-up
0.261 0.01 0.265 0.009
Adjusted QALYs over 26 weeks
of follow-upb
0.257 0.007 0.268 0.006 0.011 (–0.007 to 0.029) 0.22
ICER 17,214
Net monetary benefit at £20,000 (£) 31 (–1029 to 1092)
Net monetary benefit at £30,000 (£) 144 (–1014 to 1302)
Probability that the RAFT programme is cost-effective at £20,000 per QALY 0.52
Probability that the RAFT programme is cost-effective at £30,000 per QALY 0.60
a Adjusted for centre.
b QALYs adjusted for baseline utility and centre.
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TABLE 28 Cost-effectiveness secondary analysis: NHS/PSS perspective after 26 weeks of follow-up (BRAF-NRS impact
outcome)
Costs and outcomes
Trial arm
Difference (95% CI) p-value
Control (n= 158) RAFT (n= 175)
Mean SE Mean SE
Unadjusted costs from the NHS/PSS
perspective (£)
2310 271 2620 233
Adjusted costs from the NHS/PSS
perspective (£)a
2326 250 2605 238 279 (–393 to 950) 0.42
Unadjusted BRAF-NRS impact score over
26 weeks of follow-up
3.622 0.195 4.279 0.191
Adjusted BRAF-NRS impact score over
26 weeks of follow-upb
3.645 0.187 4.258 0.184 0.613 (0.10 to 1.126) 0.02
ICER (£ per unit of BRAF-NRS impact score improvement) 455
Net monetary benefit at £1000 per unit of improvement in BRAF-NRS impact
score (£)
334 (–527 to 1195)
Net monetary benefit at £5000 per unit of improvement in BRAF-NRS impact
score (£)
2787 (112 to 5461)
Probability that the RAFT programme is cost-effective at £1000 per unit of
improvement in BRAF-NRS impact score improvement
0.78
Probability that the RAFT programme is cost-effective at £5000 per unit of
improvement in BRAF-NRS impact score improvement
0.98
a Adjusted for centre.
b BRAF-NRS impact outcome adjusted for baseline score and centre.
TABLE 27 Cost-effectiveness secondary analysis: societal perspective after 2 years of follow-up
Costs and outcomes
Trial arm
Mean difference (95% CI) p-value
Control (n= 158) RAFT (n= 175)
Mean SE Mean SE
Unadjusted costs from the societal
perspective (£)
12,784 1259 13,972 1231
Adjusted costs from the societal
perspective (£)a
12,877 1220 13,888 1193 1012 (–2318 to 4341) 0.55
Unadjusted QALYs over 2 years of
follow-up
1.064 0.032 1.038 0.034
Adjusted QALYs over 2 years of
follow-upb
1.056 0.024 1.046 0.023 –0.010 (–0.075 to 0.054) 0.75
ICER Control has lower costs,
higher QALYs
Net monetary benefit at £20,000 (£) –1217 (–4981 to 2546)
Net monetary benefit at £30,000 (£) –1320 (–5438 to 2798)
Probability that the RAFT programme is cost-effective at £20,000 per QALY 0.26
Probability that the RAFT programme is cost-effective at £30,000 per QALY 0.26
a Adjusted for centre.
b QALYs adjusted for baseline utility and centre.
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Chapter 5 Qualitative evaluation: methods and
results
Reproduced from Dures et al.80 This is an Open Access article distributed in accordance with theterms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and formatting
changes to the original text.
Background and aims
Qualitative studies nested within RCTs can facilitate exploration of the views and experiences of individuals
who have participated in the research and offer an opportunity to capture unintended or unexpected
outcomes.81 Implementing successful RCT interventions into clinical practice can prove challenging, and a
qualitative evaluation of the experiences of those clinicians delivering the intervention (i.e. RAFT programme
tutors) can provide useful insights.82 Experience of patients receiving the programme delivered by a clinical
psychologist were explored in the original RCT;31,32 therefore, aims of the qualitative evaluation in the
current RCT were to:
l understand RAFT programme tutors’ experiences of RAFT programme training and delivery
l collect tutors’ ideas about the potential future roll-out of the RAFT programme intervention.
The RAFT programme qualitative study was led by co-applicant Emma Dures (ED), with support from the
chief investigator Sarah Hewlett (SH), co-applicant and patient research partner Clive Rooke (CR) and
co-applicant Alison Hammond (AH).
The key qualitative findings from the RAFT programme trial presented here have been previously published.80
Methods
Protocol amendment to data collection
In the original protocol [see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1111201/#/documentation
(accessed 12 April 2019)], the study design included two focus groups with RAFT programme tutors to
evaluate the impact of learning CB approaches and delivering the RAFT programme intervention. The first
focus group with approximately half of the RAFT programme tutors (as available) would then be followed by a
focus group with the remaining tutors to confirm, challenge or elaborate those findings. Focus groups allow
for discussion and reflection of a common experience, which can help participants to clarify their own thoughts
and so provide a collective consideration of the topic under investigation.83 However, the RAFT programme
tutor feedback immediately after the training and clinical supervision during delivery indicated great variation
in individual tutor experiences, even though the RAFT programme tutors participated in the training together
and all delivered the RAFT programme from a standard manual. The RAFT programme study team concluded
that individual face-to-face interviews would be the most appropriate method of data collection to capture
this diversity, as these types of interviews allow for in-depth exploration of a single viewpoint and facilitate
discussion of sensitive topics.84 Therefore, the final qualitative study design was individual tutor interviews
followed by a single focus group (see Chapter 2, Protocol amendments during the trial).
Recruitment and sampling
All RAFT programme tutors, comprising nurses and OTs who delivered RAFT programme sessions at the
seven participating sites (see Chapter 3, RAFT programme delivery and tutor adherence), were invited to
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take part in a one-to-one, face-to-face semistructured interview. This included a locum tutor who had
not attended RAFT programme training, but had co-delivered one RAFT programme after observing the
previous programme delivered at that site. Fourteen tutors accepted and the one tutor who declined did
not offer a reason. At least one RAFT programme tutor from each RAFT programme site participated in an
interview (nine nurses and five OTs).
In addition to the individual interviews, the same 15 RAFT programme tutors were invited to take part in a
focus group, of whom eight agreed to participate. Reasons cited for declining included clinical commitments,
the focus group taking place on a non-work day and the time needed to travel to Bristol. At least one RAFT
programme tutor from five of the seven RAFT programme sites participated in the focus group (three nurses
and five OTs).
Data collection
Data collection occurred after the completion of the last of the four RAFT programmes in a centre. On
average the tutor interview or focus group occurred 9 weeks later (range 4–13 weeks), apart from the
interview with the locum tutor who had delivered an early RAFT programme, resulting in a longer time
period of 39 weeks.
Interviews
Interviews were conducted face to face by ED between July 2015 and March 2016 at the tutors’ local
hospital where they had delivered the RAFT programme. Prior to the start of the interview, each RAFT
programme tutor signed a consent form. Interviews were audio-recorded and lasted between 52 and
82 minutes (an average of 62 minutes). An interview schedule was used to guide discussions and to
ensure that key topics were discussed in all interviews (see Report Supplementary Material 1), including
previous experience of group work/CB techniques; content and structure of RAFT programme training and
manual; practical, personal and professional challenges and benefits of delivering the RAFT programme;
and ideas for the RAFT programme intervention in the future.
Focus group
The focus group was held at the central RAFT trial team’s institution (i.e. Bristol Royal Infirmary) and was
facilitated by ED and SH. Prior to the start of the focus group, each RAFT programme tutor signed a
consent form. The focus group was audio-recorded and lasted for 84 minutes. Discussions were guided by
a focus group schedule (see Report Supplementary Material 1), including feedback on the RAFT programme
training and manual, delivery of the RAFT programme and ideas for the RAFT programme implementation
into clinical practice.
Data analysis
Interview and focus group audio-recordings were transcribed by a professional service and then transcripts
checked for accuracy against the original audio-recordings and anonymised (ED). The interview and focus
group transcripts were analysed using an inductive thematic approach.85 Two main characteristics of
thematic analysis made it appropriate for the RAFT programme qualitative study:
1. It is a useful method when researchers want to stay close to the data and ensure that the findings are
recognisable to participants.
2. It can summarise the key features of a large body of data, highlighting both similarities and differences
across participants.86
First, ED read through all the interview transcripts and coded items of interest and chunks of text that
related to the research topic. These initial codes were made in the margins of the transcript itself. ED then
re-read the transcripts to identify patterns of codes. Codes and their supporting text that appeared to be
addressing similar topics or ideas were copied from the transcript and placed together in a Microsoft Word
document (Microsoft Corporation, Redmond, WA, USA). This sorting process formed the basis of the
analysis. Related clusters of coded text formed subthemes, which were then grouped together to form a
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smaller number of higher-order themes that were more generic and described broader, and often more
abstract, elements in the data set. Two transcripts were independently coded by SH and AH, and a single
transcript by CR. These independent analyses were incorporated into the final analysis by ED, as there were
no substantial differences or inconsistencies between the interpretations of the data. The focus group
transcript was analysed by ED and AH. Owing to the overlap in the topics discussed in the interviews and
the focus group, the RAFT trial team decided to use the focus group data as a form of triangulation (i.e. to
confirm, challenge or elaborate the themes identified in the interviews, and to present a single, integrated
analysis). In this final analysis presented here, each theme has three parts: the label, the summary and the
supporting subthemes. These subthemes are supported by data excerpts from the RAFT programme tutors
to ensure that data interpretation remains directly linked to their words.87 Tutor excerpts are identified using
arbitrarily allocated numbers not linked to the RAFT programme site or tutor pairing (INT 1–14 for interview
participants, FG 1–8 for focus group participants).
Results
Five themes, each with subthemes, were identified in the data (Table 29): theme 1 (the RAFT programme
was a daunting but exciting undertaking) reflected the mixture of excitement and anxiety in the training
and delivery of the RAFT programme; theme 2 (skills practice and demonstrations were essential) captured
the value of learning and practising together, even though practice could be uncomfortable; theme 3
(developing an individual approach to a standardised intervention) showed how tutors dealt with delivering
from a manual; theme 4 (enhanced clinical practice beyond the RAFT programme) captured tutors’ views
on how the RAFT programme might have influenced their wider clinical practice; and theme 5 (delivering
the RAFT programme in clinical practice) highlighted potential ways forward for implementing the RAFT
programme outside the RCT.
TABLE 29 Themes and subthemes arising from analysis of tutors’ data
Theme Subtheme
The RAFT programme was a daunting but exciting undertaking A different way of working
Requiring time and effort
Feeling challenged
Not as easy as it looks
Skills practice and demonstrations were essential Being new to the RAFT programme together
Learning from expert demonstrations
Role play: invaluable despite the discomfort
Developing an individual approach to a standardised intervention Personalising the RAFT programme manual
Delivery improved through clinical supervision
Using the dynamics of pair work
Enhanced clinical practice beyond the RAFT programme Working with the whole person
Knowing how to draw things out, sit back and listen
More confident talking about fatigue
Delivering the RAFT programme in clinical practice Buy-in from managers and clinical colleagues
Models of training and support
Wonderful seeing how patients can benefit
DOI: 10.3310/hta23570 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 57
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hewlett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
Theme 1: the RAFT programme was a daunting but exciting undertaking
Participants described starting the group training without a clear idea of what the RAFT programme comprised
or what to expect from those 4 days. Participants had been sent the manual beforehand but, as anticipated,
they had not looked at it in detail. As the complexity of the intervention emerged and the challenges of
delivery became apparent, the RAFT programme was perceived as a novel and exciting intervention as well as
a daunting undertaking.
A different way of working
To differing degrees, participants identified elements of the RAFT programme intervention that required
a different way of working and for some it was ‘completely unfamiliar territory’ (INT4). In particular, the
use of CB approaches and the ‘ask don’t tell’ approach contrasted with participants’ usual clinical practice,
which involved giving advice and problem-solving for patients. Group work was also a new way of working
for several participants:
I think it was really interesting and of course, I guess, the complexity of it was, there was all of those
things to go through as somebody that was learning.
INT2
I wasn’t used to that kind of role, the cognitive–behavioural role rather than, just, as a nurse you just
want to help them and say ‘Yes, I’ll do that for you’ so it was changing my kind of way of thinking.
INT3
I found it quite hard to change my way of thinking to follow it as the ‘ask don’t tell’ sort of process
I found very difficult. Just purely from the way I’d worked over the years really.
INT7
. . . it’s the techniques because we’re used to giving information aren’t we and obviously we have
to deliberately not do that and reflect things all the time and that wouldn’t come naturally to
most practitioners.
FG1
. . . the fact that it could be delivered by an OT and somebody within rheumatology, it was quite
exciting to be able to do that.
INT11
Requiring time and effort
At the start of the study, participants had not anticipated the high levels of time and effort that would be
expended during training and delivery of the RAFT programme intervention. The amount of hard work
required was due to the challenge of becoming familiar and confident with a large amount of material,
delivered using a new approach, to patients in a group setting. Participants described a sense of
responsibility and commitment to delivering the RAFT programme to the best of their ability:
It wasn’t something you were just going to be able to go away with and think ‘I could just do this’ . . .
you really did need to know your material. You needed to be well read . . . before you delivered . . .
and it made you realise that it, there was quite a lot of preparation to be done and it wasn’t just
something you could run off on a whim.
INT6
I remember just taking it very seriously, that it wasn’t a practice run at all and putting as much effort
and time as I could just to try and understand the manual and get it across.
INT9
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We spent hours, hours and hours sitting and going through it and going through it again and writing
it out on to cards.
INT12
Feeling challenged
Along with being enthusiastic about the RAFT programme, participants reported feeling challenged as they
started to engage with the training and intervention:
. . . interested, enthusiastic, I just wanted to try and do it.
INT12
. . . it was a bit scary actually and I felt quite challenged.
INT1
I did feel very daunted starting it. I was very nervous delivering the groups as it first began.
INT7
. . . it was the managing the group and actually when to try to stop somebody or try and include
somebody else and the actual feeling at one point . . . you know the group can change and there are
dynamics and sometimes it can feel quite . . . certainly, intimidating sometimes.
INT14
Not as easy as it looks
When the RAFT programme trainers demonstrated sessions during training, the delivery flowed and the
interaction appeared natural and almost effortless. When participants practised, they found it difficult
to emulate this sense of being at ease with the material and with the group. Although, initially, this
diminished participants’ confidence as they compared their performance to that of the RAFT programme
trainers, it also helped to get a sense of what participants were aiming for with the intervention:
I didn’t feel particularly confident in delivering it as well because you’ve got professionals who have
shown us how to do it, they’re so good at what they do you know it’s quite daunting to think
‘Oh crikey how can you do that?’
INT3
I mean they made it look so easy and then when you try and do it yourself it is like ‘Let’s have a look
at my card again and I’ll just have a look at the manual again’. Whereas they were just able to do it.
INT7
[RAFT programme trainers] made it look so simple, so easy. I just think ‘why can’t I do it like that?’
they’ve made it look so easy.
FG2
Theme 2: skills practice and demonstrations were essential
The opportunity to train with other nurses and OTs was valued greatly, as a range of common concerns
and shared experiences emerged during the four central training days. When reflecting on learning, it was
acknowledged that skills practice and role play were an essential part of preparing to deliver to patients,
even though practising could be difficult and uncomfortable at times.
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Being new to the RAFT programme together
Participants felt sufficiently comfortable with each other and with the training team to engage and take
part in the training. They found it helpful to realise that they were all new to the RAFT programme and to
be able to share their thoughts and concerns:
. . . you definitely have that camaraderie and that you can continue to bounce things off each other a
little bit or whatever, I personally like that environment, and I like to learn in that way.
INT2
It’s reassuring in a way to know that you have people with the same mind-set and obviously finding
that opportunity to explore this territory further helps us because it’s like putting a blank canvas and at
the end of the day it’s like painting it together.
INT4
. . . having the group dynamics of different nurses, allied health professionals, I think we fed off
each other.
INT6
Learning from expert demonstrations
Observing the RAFT programme trainers demonstrate sessions brought the RAFT programme intervention
to life, adding depth and detail to the manual. Demonstrations were very helpful for facilitating
participants’ learning and understanding of what the intervention should look like in action:
I thought it was quite good when they demonstrated, they demonstrated how to use the CB
[cognitive–behavioural] approach in the group setting using the manual. That was good because I
work best by being able to observe and sort of see how you do things rather than reading it off
a page.
INT7
We sat back and observed didn’t we and we actually watched them do a session. That was really
helpful when we didn’t know how it was going to do anyway, to actually see it happen that was
really helpful.
FG6
Role play: invaluable despite the discomfort
Participants acknowledged role play as one of the most useful aspects of the central training. Practising
parts of the sessions out loud then getting feedback from the RAFT programme trainers was invaluable in
the process of becoming familiar with the intervention, although it could be uncomfortable at times:
I mean I hate role play; I absolutely detest it. It is just not in my nature to do it. I just think ‘God’, but it
was good because it gave us the chance to practise it, and to get feedback.
INT7
For me to actually have a go and to practise . . . I found that was very useful even though I didn’t like
it, I would say one of the most valuable things of the course. I think we should have more of it,
although people will hate me for saying that.
INT8
I think you need to have that practice, that . . . it’s not until you realise the benefit, I said this before,
about the role play and that and actually practising saying things and scenarios.
FG2
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I didn’t enjoy the role plays at all but if we had to do some more training that is what I would want is
what I’m saying and I would know the benefits of it and that’s probably . . . for me it was the only
way that I could actually practise and be semi-confident going out for the pilot [practice run].
FG4
Theme 3: developing an individual approach to a standardised intervention
The RAFT programme manual was seen as invaluable and ‘my bible all the way through’ (INT9), because it
contained the information and guidance needed to deliver the intervention. However, participants described
the tension between adhering to the sample text and staying true to the concepts and content, compared
with using their own words to deliver in a natural and easy manner. In addition to finding their own way of
working from the manual, participants developed individual approaches and styles of delivery through
feedback during clinical supervision and through the relationship with their co-tutor.
Personalising the RAFT programme manual
Participants described consolidating and deepening their understanding of the RAFT programme
intervention through adapting their manual, including writing summaries and rephrasing text. This was
done with great care to ensure that delivery stayed true to the underpinning CB approach. Participants
explained that this was a difficult but essential part of the process of becoming a competent RAFT
programme tutor:
I was worried about if I changed it in certain ways that actually the fundamental way of interacting
with the patients wouldn’t have been right, do you see what I mean? So because you’re trying to use
that cognitive–behavioural approach, I was conscious that maybe if I alter it too much, I wouldn’t be
doing that and therefore you wouldn’t get where you wanted to with it, but at the same time, the
language, for me, didn’t sound familiar for me, so it’s trying to get that balance of extracting the
essence of what you’re getting from it and putting it across in a way that feels comfortable for you as
a practitioner.
INT2
FG2: That was one of the hardest things I think we’ve found. Is actually putting it in our words
because . . .
FG1: We really struggled to start with because we were trying to learn it as a script and it wasn’t how
we would say things. So, yeah, we spent hours didn’t we . . . Hours taking it all apart.
FG2: Sort of changing it. Changing bits to how we would speak.
FG1: And we had to have crib sheets for every session.
Delivery improved through clinical supervision
In addition to the 4 days of central training, participants reported that ‘you need the feedback on your
performance’ (INT13) when delivering to patients. The RAFT programme trainers’ ongoing support, comprising
clinical supervision and feedback on observed sessions, was described as very helpful. Feedback was perceived
as constructive and a mechanism for enhancing participants’ confidence and skills. Occasionally, participants
sought specific guidance, aware of the RAFT programme trainers’ high level of skills and familiarity with the
intervention:
[RAFT programme trainer] said ‘You really need to get up and get the people engaged more, and you
were struggling to get the information from them’ and that was really, although it was a bit of
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criticism it was really useful because the next time we did that session we did it differently and it was
much better.
INT1
I think it gave us more confidence that they are there, we can actually ask questions afterwards and
then they can give us feedback on how we could have delivered it better or what are we lacking in
terms of explanations or something.
INT4
. . . just please give me an answer and then I can decide whether that’s what I would do or not, but I
want to know what you think I should do.
INT8
I think the feedback after the pilots [practice run] was essential, as much as it was really scary to have
someone observe you the feedback and the debrief afterwards was really good to just give you focus,
direction and just reassurance that you were doing something right.
FG5
Using the dynamics of pair work
In addition to the work that participants did to consolidate their individual understanding of the
intervention, the participants developed ways of working with their co-tutor that were mutually supportive
and allowed them to each play to their strengths:
. . . you need two people, if you’re delivering stuff and you can’t, you listen to what is going on but
sometimes you can miss other things that are going on in the room and having the other person there
just reminds you to pick it up as well and should you get stuck or lost, it’s good to have the other
person there because they could always pick it up for you, it was back up, it was reassurance to have
two of them there and I think that worked really well.
INT8
. . . you’re helping each other out, aren’t you, you’re writing things up on the board and even if the
one is struggling a bit, then we would, we tried, you have to be careful not to take over each other’s
little roles, but we did just support each other.
INT10
I think it’s really important that you do it in pairs, really important because we helped each other
didn’t we?
FG3
Theme 4: enhanced clinical practice beyond the RAFT programme
As a consequence of taking part in the RAFT programme, participants described changes in how they
interacted with patients in their wider, everyday clinical practice. They identified being more equipped to
support patients’ self-management compared with before the RAFT programme study. They valued the
‘ask don’t tell’ approach and their increased confidence to discuss fatigue. Their experience of the RAFT
programme study ‘has certainly improved me, definitely, as a therapist’ (INT10), with participants having
‘benefited in ways that I didn’t appreciate at the time’ (INT14). It was rewarding to then see the positive
impact of these new approaches on patients beyond those who took part in the RAFT programme
intervention.
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Working with the whole person
During delivery of the intervention, participants explored with patients ways in which fatigue can permeate
all spheres of patients’ lives and well-being. This heightened the tutors’ awareness of the importance of
looking at all of the individual and contextual factors that might be impacting on patients’ health in their
wider clinical practice, and not focusing solely on a set of symptoms:
. . . it’s like you become more sensitive of the person that you’re seeing all the time and you sort of
separate it slightly different in a way that am I just going to be focusing on treatments or am I going
to prompt them to say something about, you know more on how they feel, how they live their life
and how they do their day to day, so it helps in a way.
INT4
. . . that’s been so helpful just in day-to-day treatment with patients, just being able to get a bit more
out of them and . . . yeah, it’s a really, really useful skill.
INT11
I feel I’m a better practitioner, I feel I’m more compassionate and empathetic. I think I look at them
much more holistically as opposed to ‘Right what drug can I throw at them now?’
INT13
Knowing how to draw things out, sit back and listen
Participants contrasted using new approaches to support self-management in their clinical practice, such as
‘ask don’t tell’, with their previous ways of working, such as advice-giving. In particular, they identified that
eliciting patients’ thoughts and feelings and letting them come up with answers to challenges was beneficial:
I think as nurses you tend to often want to give the answer all the time and give advice and it’s very
nursey to do that, but it’s learning when to listen and stand back and try and get the patients to find
the answers more rather than you delivering the answers to them and the solutions all the time.
INT6
Confidence that you have the knowledge, but you question them to bring up the answer, I do that a
lot more.
INT10
It’s so easy and quick to see, say a hand deformity and think that’s clearly the problem, but it’s
actually establishing ‘Why is that causing the problem, how is that affecting you functionally’ and it’s,
yeah it’s just drawing out the, yeah a better insight really and getting that more out of a patient . . .
getting them to open up a bit more which still does often require a box of tissues sometimes.
INT11
More confident talking about fatigue
Participants noted an increased confidence to discuss fatigue in their everyday clinical practice, in the
knowledge that they had some ideas, skills and tools for supporting patients. Often these discussions
involved adapting or distilling parts of the RAFT programme session:
I got used to using the [activity] diaries quite happily with those and trying to set goals from those was
quite useful as well. So, used them a lot more in practice now with people which is good. I feel a lot
more happy to talk about fatigue and that with patients on a one-to-one session now rather
than before.
INT7
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I liked the communication one [session] and I’ve used some of those concepts a lot in clinic because I
feel that it’s quite useful even in, a few sentences in the clinic we have got somebody who has got
fatigue and they’re isolating themselves, you can talk to them about communicating with family
and friends.
INT12
Theme 5: delivering the RAFT programme in clinical practice
Participants expressed enthusiasm for the RAFT programme intervention, a sense of professional fulfilment
seeing how patients can benefit and an interest in delivering it in routine clinical practice. However, they
also identified generic and local challenges to implementation. These include having sustainable models of
training, the need to gain support from management and clinical colleagues, and ‘just how you would fit
it in with the other things that are going on’ (INT2). There was a clear sense that a pragmatic and flexible
approach would be necessary and that ‘if it’s over prescriptive, it won’t happen, because the constraints of
the NHS will just bury it’ (INT13).
Buy-in from managers and clinical colleagues
At an individual level, participants would be delighted if they could deliver the RAFT programme
intervention in their clinical practice. This would typically require a business case from managers and the
support of colleagues and clinical leads. Participants acknowledged that there might need to be some
flexibility in relation to who delivers the intervention. There was also enthusiasm about the possibility of
delivering it to other patient groups. Although participants could envisage some changes to delivery, they
did not think that the intervention could be adapted in relation to the number of sessions and the topics
covered:
FG2: We were the same, I think it’d be a business case.
FG1: Yes, because [RAFT programme local principal investigator] is looking at a business case for us to
do it. [RAFT programme local principal investigator] bought into it but that’s as far as it’s got. I don’t
know how far [RAFT programme local principal investigator] has got with the business case.
FG3: Is that an OT manager or a . . . who is that?
FG1: [RAFT programme local principal investigator] our consultant.
And certainly, I don’t think they’d put our banding in either, because we’re band 7s, they’d probably
put lower bands in.
INT10
I just want to roll it out for everybody now, and I want to have CTD [connective tissue disease] groups
as well as the RA groups and general arthritis groups that would be good. And also fibromyalgia
patients as well, it would be interesting for everybody really.
INT12
. . . it’s difficult to think about things that could maybe be cut out to make it quicker because I think
actually the benefit of it has been that all of the areas have been covered.
INT11
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Models of training and support
Although participants valued their 4 days of central training, they acknowledged that this is unlikely to be
a feasible model to roll out. One option was new RAFT programme tutors observing the intervention being
delivered by experienced RAFT programme tutors, either in a live setting or on a digital versatile disc (DVD).
However, there was a strong sense that some face-to-face training with skills practice would be important.
Participants also stressed the need for clinical supervision to ensure a level of fidelity to the process:
I wondered if new people could maybe come and observe people who are already doing the course
perhaps, after the training?
FG3
. . . you’re reading through the manual and you think that you’ve got your head around what it is that
you’re doing and then when it comes to actually delivering that again which is why the practice is so
good because at least you get that practical element of it but trying to put those words into something
that made sense to me as a non-psychologist so having something like that [DVD], a kind of more visual
thing to use alongside it I think would be really useful.
FG7
I think you do need some supervision as well; you need somebody to come down, every now and
again to go through because you can get into bad habits.
INT8
I think you’d want to be supervised by people who’ve got experience in it and if there aren’t people
with experience in it, then a support network amongst each other, I think.
INT10
. . . it’s good to have some kind of structure and observation just to check that people are doing it
right because you can just assume can’t you and then it not being delivered . . . as required.
INT11
Wonderful seeing how patients can benefit
It was rewarding for participants to see patients benefit from taking part in the RAFT programme
intervention. They described how patients’ engagement with the intervention evolved during the seven
sessions and the satisfaction of seeing positive changes over time. There was the sense that some patients,
who had taken part in RAFT programme groups, might stay in contact and organise to meet up outside
the hospital and, subsequently, be an ongoing source of peer support:
. . . it was really lovely to see that light bulb moment for some patients, to click, I love that bit, that’s
really satisfying.
INT3
I can think of, well, quite a few patients said it’s been life-changing.
INT10
. . . after the last session they [patients] had already met up for coffee, they went shopping, they’re
giving each other lifts so it’s good to know that they had managed to find a group that they think
they can get support as well if they need to which is reassuring.
INT4
. . . it just gives you such a lift just seeing how well they look and how well . . . the groups interacted
and how they’re staying in touch and I think as a therapist that’s what you want to see, that’s why
you do your job really.
INT11
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Chapter 6 Discussion and conclusions
Reproduced from Dures et al.80 This is an Open Access article distributed in accordance with theterms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and formatting
changes to the original text.
Overall summary of findings
The RAFT programme, a seven-session group programme for RA fatigue self-management delivered by local
rheumatology nurses and OTs, when given as an adjunct to usual care, was effective in reducing the impact
of fatigue beyond usual care alone. The beneficial effect of the RAFT programme was sustained over 2 years
without further RAFT programme input beyond week 14. Improvements were also seen in emotional fatigue
and living with fatigue, as well as self-management processes of coping with fatigue and self-efficacy. No
harms were reported from the RAFT programme and patients had very high attendance rates and satisfaction
ratings and wished to recommend the programme to other patients. Although the costs were not significantly
different between trial arms, the primary economic evaluation using QALYs based on the EQ-5D-5L suggested
that the RAFT programme was unlikely to be cost-effective at conventional NICE thresholds. Rheumatology
clinicians delivering the RAFT programme felt that they had learned new skills that they subsequently used in
clinical patient care beyond the RAFT programme itself.
The key discussion points for the clinical and qualitative evaluations have previously been published.65
Clinical evaluation findings
Summary
The trial demonstrated that improvements in fatigue impact were made in both the control and RAFT
programme trial arms. However, the RAFT programme resulted in a greater improvement in fatigue impact
at 26 weeks than usual care alone (BRAF-NRS impact score adjusted mean difference –0.59; p = 0.03),
with treatment differences lasting for the 2 years of follow-up (BRAF-NRS impact score adjusted mean
difference –0.49; p = 0.01). A stronger effect on the primary outcome of fatigue impact was seen in those
patients who met the eligibility criteria of BRAF-NRS fatigue impact ≥ 6 at baseline, at both 26 weeks
(BRAF-NRS impact score adjusted mean difference –0.82 units; p = 0.01) and 2 years (BRAF-NRS impact
score adjusted mean difference –0.58 units; p = 0.02). Similar treatment differences lasting over the 2 years
were seen for overall impact of fatigue (BRAF-MDQ) and subscales emotional fatigue and living with fatigue;
in addition, self-efficacy and coping with fatigue also showed treatment differences at 26 weeks and over
the 2 years, respectively. There was no evidence of a treatment effect on fatigue severity, cognitive fatigue
or other clinical variables. Patient attendance at the RAFT programme sessions was high, as were satisfaction
with the programme and willingness to recommend it to other patients.
The RAFT programme targeted the impact of RA fatigue on patients’ lives and there was a treatment
difference between trial arms in favour of the RAFT programme for reducing fatigue impact as measured
by both the BRAF-NRS impact and BRAF-MDQ overall impact scales, as well as BRAF-MDQ subscales of
emotional fatigue and living with fatigue. Patients in the control arm also reported improvements in fatigue
impact, which was not seen in the previous RCT of this intervention in which the control was a group session
comprising 1 hour of didactic information on general self-management of RA.31 The usual-care booklet,
written after the first RCT and based on the results of that intervention,45 has been available in rheumatology
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units since 2011 and was therefore used as a ‘usual-care’ active control in the present study. Although the
booklet has never been subjected to rigorous effectiveness testing, a recent qualitative study88 suggested that
patients felt that it made them think differently about their fatigue. Patients in the study88 reported that
having a discussion of the booklet with a researcher made them consider taking responsibility for managing
some aspects of their fatigue and try the suggestions the booklet contained. Although the focus of the
qualitative study was for patients to review the booklet for research, it raises the possibility that the brief
booklet discussion with the health professional (usual care in this RCT) may have delivered an effect over and
above a patient simply picking the booklet up from the clinic display.
The trial demonstrated an effect size of 0.36 on fatigue impact. As recommended,62 in interpreting these
findings against the traditional 0.5 guideline for clinically meaningful effect sizes, the broader evidence
relating to the specific issue of RA fatigue (see Chapter 3, Interpretation of findings) was examined. The
level of change in fatigue impact that might be clinically important for people with RA is unknown, as
measurement of fatigue impact is relatively new. However, in terms of fatigue severity, a study to examine
the level at which patients reported a noticeable improvement in their RA-related fatigue demonstrated that
this occurred at effect sizes of 0.27–0.39 (three different anchors used for analysis).63 Non-pharmacological
interventions in RA are normally given in addition to pharmacological management, meaning that findings
must be placed in this context. For example, meta-analysis shows RA patient education to have an effect
size of 0.16 on painful joints compared with 0.66 seen in RCTs of non-steroidal anti-inflammatory drugs.
However, all patients in the patient education trials were already taking these; thus, the 0.16 effect size
represented additional benefits.89 Similarly, the RAFT programme study was conducted with patients who
were already receiving routine clinical management of their RA, that is pharmacological therapies to address
inflammatory activity, which meta-analysis shows to have an effect size of 0.43 on RA fatigue;16 therefore,
benefits in both intervention arms were over and above existing substantial improvements. Three studies
analysing the minimal clinically important difference (MCID) on a number of fatigue severity scales in RA
suggest that a change of between 7% and 11% would be clinically important.63,90,91 This approximate 10%
RA fatigue severity MCID might be a guide for meaningful change in RA fatigue impact, and comparable to
multiple sclerosis, for which results from two studies average a fatigue impact MCID of around 15%.92,93
The RAFT programme demonstrated an adjusted mean difference of 0.59 in BRAF-NRS fatigue impact
beyond the improvement seen in the usual-care arm, with the RAFT programme showing a 19% change
from baseline mean and the control arm showing a 12% change from baseline mean (fatigue impact
improving by 1.36 and 0.88 units, respectively).
The improvement of 0.59 in BRAF-NRS fatigue impact beyond the improvement seen in usual care is smaller
than the RCT was powered to detect, which was an improvement of 1.45 units. This had been based on
an assumption that the clinical team delivering CBT might achieve around 75% of the 1.95 fatigue impact
change seen in the earlier trial, in which delivery was by a clinical psychologist and in which the usual-care
arm experienced no change at all (usual care comprised a 1-hour group session of RA self-management
information delivered didactically by a nurse).31 The statistical significance of the 0.59 improvement would
have been enhanced by the lower than expected attrition rate. Therefore, taking the wider evidence from the
trial and the literature presented above, it seems likely that in the current RCT the improvement in fatigue
impact achieved by the RAFT programme beyond that of usual care may be clinically meaningful. This is
further supported by the high levels of patient satisfaction demonstrated in attendance rates, and satisfaction
and recommendation scores. However, further work to establish the MCID for the BRAF-NRS impact would
be beneficial.
The treatment differences for the primary outcome of fatigue impact were greater in those patients who were
eligible for the RAFT programme (i.e. had a fatigue severity score of ≥ 6 out of 10 at baseline). As with any
symptom, RA-related fatigue severity will naturally fluctuate slightly from week to week; therefore, it is not
surprising that, during the time it took to build cohorts in each centre, some patients’ fatigue severity over
the previous 7 days was ≥ 6 at screening, but was reported as < 6 at their later baseline assessment.
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However, the screening process also required that patients considered their fatigue to be a recurrent problem,
thereby allowing for normal short-term fluctuations in severity. The RAFT programme demonstrated significant
treatment effects even including those patients with less severe fatigue (i.e. using complete-case analysis).
This suggests that the RAFT programme is a pragmatic intervention to deliver clinically, as its timing in relation
to symptom severity may not be crucial; it still had an effect on a recurrent symptom even when intervention
delivery was delayed by the need to build an adequately sized group, or to accommodate patients’ personal
availability.
There was no treatment difference between trial arms for change in fatigue severity at 26 weeks, although
both trial arms had small reductions, which for the RAFT programme patients reached the proposed MCID63
for people with RA-related fatigue (MCID –0.82 to –1.12: control, –0.72; RAFT, –0.97). It is possible that the
RAFT programme participants made a shift in how they view and manage a persistent symptom, finding a
way to reduce the impact of fatigue on their lives.32 Large longitudinal observational studies of current best
practice pharmacological management aiming to control RA disease activity have demonstrated that fatigue
severity remains largely stable over the years,94 with the majority following either a persistent moderately
high or a persistently high fatigue trajectory and only a minority (one-third) having an improving fatigue
trajectory.95
Symptom severity and symptom impact are different concepts. For example, two studies have found that
RA patients can report low impact from high levels of disability, whereas others report that their low level
of disability has a high impact.96,97 Personal impact is likely to be a result of the interactions between
symptom severity, symptom importance in the individual context of a person’s life and perceived ability
to manage or cope with that symptom: the ‘impact triad’.98 There was a treatment difference in favour of
the RAFT programme in coping with fatigue over the 2 years (as measured on the BRAF-NRS coping). The
perceived ability to cope or manage fatigue better may reduce the importance of fatigue in an individual’s
life; thus, it is understandable that fatigue impact could still be changed by the RAFT programme even
without significant improvements in fatigue severity (the third side of the impact triad).
The effects of the RAFT programme lasted over 2 years without further RAFT programme input after the
1-hour group session at week 14, suggesting that patients’ newly acquired fatigue self-management skills
became embedded. This is supported by evidence of a treatment difference between intervention arms
for improvements in self-efficacy (the belief or confidence that one can successfully make behavioural
changes), perhaps translating into the improvements in perceived coping over the 2 years. Self-efficacy, a
key process underpinning behaviour change, was measured with the RASE56 scale (assessing beliefs about
RA self-management behaviours), and six of the RASE scale component items demonstrated differences
between trial arms for change over weeks 0–26 in favour of the RAFT programme, including key fatigue
self-management activities such as pacing and acceptance of fatigue. Problem-solving and goal-setting,
as a route to enhancing self-efficacy,25 are core self-management skills that patients learn in CBT and thus
these changes in coping and self-efficacy may reflect the CB approaches that the clinical rheumatology
tutors were trained to use in the RAFT programme.
The CB approaches were delivered by clinical rheumatology nurses and OTs after a brief training, rather than
clinical psychologists. This novel approach aimed to circumnavigate the lack of psychology support available
in most rheumatology units33 and shows similar results to a RAFT programme intervention delivered by the
usual clinical team for multiple sclerosis fatigue.99 A systematic review of nurse-led psychological interventions
for depression in people with long-term physical conditions demonstrated their effectiveness.100 In addition, a
systematic review of psychological interventions for people with diabetes showed generalist nurses/physicians
to be equally as effective as psychologists.101 Delivery of the RAFT programme intervention by the clinical
team was feasible, in that all RAFT programmes were delivered as planned and tutor sickness/absence could
be managed. Furthermore, the RAFT programme feasibility was supported by high patient attendance and
satisfaction rates; these suggest that the RAFT programme could be implemented in practice.
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Economic evaluation findings
Summary
The primary economic evaluation found no difference between intervention arms in either overall costs
(which incorporated intervention training and delivery costs) or QALY gains at 26 weeks or 2 years, and
there was no evidence that the RAFT programme reduced other health-care costs. However, there was
substantial uncertainty around the cost and QALY estimates. The primary cost–utility analyses suggested
that the RAFT programme is not very likely to be cost-effective at the conventional societal WTP values,
with probabilities below the 50% level (probability of 28% at the £20,000 NICE threshold and a probability
of 35% at the £30,000 NICE threshold) from the societal perspective. A subgroup analysis of those
patients who were eligible at baseline (i.e. BRAF-NRS impact ≥ 6/10) gave a 52% probability that the RAFT
programme was cost-effective at £20,000 per QALY, or 60% probability that the RAFT programme was
cost-effective at £30,000 per QALY.
The sustained improvement in fatigue impact seen clinically over 2 years was not reflected by increased
QALYs measured using the EQ-5D-5L. This may be indicative that the EQ-5D-5L is not responsive enough
to capture improvements in RA-related fatigue. Of the five EQ-5D domains (mobility, self-care, usual
activities, pain and mood), ‘usual activities’ is most likely be the domain to be affected by a fatigue
self-management intervention, a theory supported by the correlation demonstrated here between change
in EQ-5D-5L domains and change in BRAF-NRS impact score. However, ‘usual activities’ is the EQ-5D
domain that contributes least to the overall utility weights.102 The EQ-5D ‘usual activities’ domain includes
the ability to perform work, housework and family and leisure activities, and people with RA value doing
such ‘daily activities’ as the second most important of seven health domains, with fatigue as third, giving
highest weights to these two.103 This contrasts with the low weight for ‘usual activities’ and absence of
fatigue assessment in the EQ-5D, raising questions about the relevance of the EQ-5D for evaluating quality
of life in RA. Energy (or drive) and sleep have been identified as key domains for people with RA, and
these may be missed by the EQ-5D, leading to recommendations for further research to identify relevant
domains and weightings for the RA population for use in the EQ-5D.104
There is robust evidence to support the satisfactory psychometric performance of EQ-5D in RA.105 However,
it has also been shown that several commonly used quality-of-life measures for calculating QALYs in RA give
a wide range of results on the same data set, demonstrating cost–utility in favour of a bDMARD that varies
from 12% to 91% from four instruments (EQ-5D, 63%).106 Previous research has also suggested that the
EQ-5D is more responsive to worsening health states than to improving health states in RA patients.107
However, much of this research has not evaluated the more recent five-level EQ-5D (i.e. EQ-5D-5L) used in
this RCT, which might be more responsive to changes in health.
Economic evaluations of interventions designed to improve fatigue in RA are lacking, although
cost-effectiveness has been assessed in other long-term conditions. A short-term economic evaluation
of a fatigue management programme for patients with multiple sclerosis found similarly insignificant
between-arm differences in EuroQol-5 Dimensions, three-level version (EQ-5D-3L), derived QALYs,
despite significant improvement in fatigue in the intervention arm.99 A cost-effectiveness study comparing
a rehabilitation programme with a CBT intervention for patients with CFS over 12 months also found no
statistical differences in EQ-5D-3L-derived QALYs, despite a significant difference between the intervention
arms for fatigue severity.108 These studies support the view that the EQ-5D may not be responsive to
changes in fatigue in long-term conditions.
Work productivity was improved for patients in the RAFT programme intervention arm at 26 weeks and
2 years, although the difference between intervention arms was not statistically significant. However,
the number of patients in paid employment at baseline was small (n = 76, 23% of randomised patients),
suggesting that the power to capture a significant difference was low. There has been little research
on the effect of RA-related fatigue severity on work productivity, but a study of > 8000 RA patients in
32 countries demonstrates greater fatigue severity in patients who are work disabled than in those staying
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in work.109 The BRAF-NRS impact score is a relatively new measure and there have been no reported
quantitative studies examining the relationship between fatigue impact and work productivity. However,
qualitative studies consistently report that people with RA consider the impact of fatigue on work to be
significant;8,12 thus, improvement in work productivity could be consistent with the reduction seen in
fatigue impact with the RAFT programme. The EQ-5D scores are derived from surveys of the general
population. Recent work comparing people with RA with the general population found that both groups
placed a similar value on pain and function limitations, but the general population put a lower value on
the ability to work.110 This suggests that the EQ-5D scores may have been different had they been based
on values from people with RA rather than the general population, which is part of a wider debate on
obtaining better-informed population preferences for estimating QALYs.111
The algorithm for work productivity was based largely on items relating to hours lost (absenteeism) and
included just one item on presenteeism. Fatigue causes major difficulties for people while at work and may
mean that they are present but not functioning at full capacity (presenteeism).8,12 An uncontrolled pilot study
of a self-management programme specifically for fatigue at work for patients with inflammatory rheumatic
diseases examined presenteeism and demonstrated improvements in four domains of functioning while at
work: physical and mental demands, work scheduling and work outputs.112 It is possible that the weekly
review of daily activity diaries in the RAFT programme, accompanied by encouragement to break up large
periods of intense activity through factoring in short breaks, may help presenteeism.
Qualitative evaluation findings
Summary
Five themes were identified in the tutors’ data. The rheumatology nurses and OTs (tutors) were interested
and enthusiastic about being involved in the trial of a novel fatigue intervention. The tutors described
delivering the RAFT programme as a very rewarding experience, seeing patients make big changes to their
lives, although the process of becoming familiar with the material and gaining confidence in delivering it
proved hard work (theme 1). The tutors’ perceived personal benefits included a sense of professional
development and fulfilment, especially when they saw patients making life changes. Learning together and
rehearsing the RAFT programme elements as a group was helpful (theme 2). Challenges included using
an ‘ask don’t tell’ approach to prompt patients to generate their own ideas for behaviour change, as it
contrasted with tutors’ usual advice-giving and problem-solving approach. Tutors’ understanding of the
intervention was consolidated through re-reading and individualising their manuals (e.g. paraphrasing
sections), and feedback from the RAFT programme trainers during clinical supervision (theme 3). Over time,
tutors deepened their understanding of how a CB approach and the group setting could be used to support
patients in self-managing the impact of their fatigue. In addition, the usefulness of the skills gained by
tutors extended beyond the RAFT programmes and into their everyday clinical practice (theme 4). There
was widespread support for delivering the RAFT programme in clinical practice beyond the trial, as tutors
perceived that patients were benefiting (theme 5). Tutors valued their 4 days of central training, but
believed that it would not be a feasible future clinical model. Some face-to-face training with the
opportunity to role play key aspects of the intervention, along with some clinical supervision and quality
control, were deemed necessary in any future training of new tutors.
The qualitative findings support two key ideas about skills training and its subsequent transfer into clinical
practice. First is the importance of role play, a method of simulation commonly used to teach communication
skills.113 In the RAFT programme central training, role play was employed through both ‘role reversal’
(i.e. participants taking on the role of patients to develop insight into what the group dynamics might feel
like from a patient’s perspective) and ‘role training’ (i.e. participants practising the skills that can help them
become more expert in their professional role). Tutors identified both forms of role play as helpful for
learning. Second is the importance of clinical supervision, as although communication skills training
enhances skills, it has limited effect on clinical practice without subsequent clinical supervision.114–116
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Tutors were aware that they were delivering a standardised intervention and made great efforts to adhere
to the manual content. However, tutors also expressed their need to individualise the manual and to put
material into their own words. The RAFT programme trainers and fidelity observer often helped in this
process by feeding back on if and how tutors were incorporating essential techniques and approaches into
the sessions. Fidelity was recorded in the observer template (see Report Supplementary Material 1), and
confirmed that tutors were delivering the RAFT programme as intended. Fidelity to the RAFT programme is
an important consideration in any future roll-out. Inevitably, interventions are adapted to individual settings,
resources available, or practitioners’ beliefs and interpretations, once they are introduced into clinical practice.
Such changes may reduce or enhance outcomes seen in clinical practice and thus there is an argument for
capturing not only outcomes but implementation fidelity and adherence to delivery format, content and
underpinning CB theory in the roll-out of such interventions into clinical practice.117
Tutors’ perceptions that the RAFT programme training and subsequent delivery impacted and benefited
their wider clinical practice highlights the potential of up-skilling existing members of clinical teams to provide
low-level psychological support. Evidence from studies of other long-term conditions, such as diabetes,
cardiac rehabilitation and depression in long-term physical health conditions, shows that the incorporation
of psychological skills into the nursing role is viewed positively by both nurses and patients.100,118,119
However, the research evidence reiterates the finding that nurses and allied health professionals need time
and support to acquire and use these skills.
Strengths and limitations
The study’s external validity was strengthened by involving seven hospitals and 14 health professional tutors
with a range of previous experiences, broad entry criteria for people with RA fatigue and a control trial arm
providing usual care for fatigue. The trial design was pragmatic and reflected usual RA management (e.g.
medication changes, seeing other members of the multidisciplinary team), as well as natural fluctuations in
fatigue (some patients dropping below eligibility at baseline), natural variation in patient attendances (not
attending all the RAFT programme sessions), flexibility with regard to the RAFT programme group size, and
natural variations in ability to deliver clinical services (delivery by lone tutors, use of a locum tutor); yet the
RAFT programme still showed benefit with no reported harms. The usual-care fatigue booklet, based on the
original RCT,31,45 has been widely available in most UK rheumatology units for 3 years prior to recruitment.
Therefore, the timing and manner of its delivery to all participants was standardised in relation to the timing
of the outcome evaluation. Randomisation was performed by a clinical trials unit off-site, and those patients
randomised to the RAFT programme but unable to attend their next local programme were offered
subsequent programme dates, ensuring maximal accommodation of recruited trial patients and reflecting
future clinical practice. The integrity of data was supported by the checking of 100% of data entries by a
second person.
The trial was strengthened by the rounded evaluation which, in addition to assessing the quantitative
clinical outcomes, included intervention fidelity and cost-effectiveness. Furthermore, given that patient
perceptions of receiving the RAFT programme were explored in the previous RCT,32 this trial incorporated
examination of the tutors’ experiences of delivering a RAFT programme intervention and views on
the practicalities of future clinical implementation. The strengths of the clinical and economic evaluations
were the thorough approach taken to try and capture all relevant outcomes; the costs associated with
RA-related fatigue and with the RAFT programme intervention; the use of validated measures whenever
possible; and the continuation of data collection for 2 years. Data returns for the primary outcome were
very high, probably enhanced by collection of the question by telephone, which may also have increased
returns of the full questionnaire package posted the same day; consequently, patient loss to data
completion was very low.
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A strength of the qualitative evaluation was that almost all of the RAFT programme tutors took part,
ensuring a wide range of views and experiences. In light of the often limited understanding of what might
help or hinder the translation of a successful trial intervention into clinical practice, it is a strength of the
study that future roll-out of the RAFT programme will be underpinned by practical approaches based on
these combined perspectives of the nurses and OTs who delivered it across seven hospitals. The rigour of
the qualitative findings is strengthened by having the data analysed by multiple co-applicants (including a
patient co-applicant) before reaching a consensus.
Strong patient and public involvement was threaded throughout the trial. The two patient research partners
(CR and Frances Robinson) had received the fatigue intervention from a clinical psychologist during the
original trial31 and thus brought a wealth of knowledge and experience. Their input into methods of patient
recruitment and evaluation were insightful, including viewing drafts of questionnaire packs and patient
materials used in the RAFT programme handouts. The patient research partners’ participation and presentations
at the RAFT programme training event allowed tutors (and also principal investigators and research nurses)
to understand the impact of fatigue on daily life. One patient partner felt that the contribution to the trial
that they could offer primarily related to the set-up (e.g. reviewing and finalising patient materials ready for
the RAFT programme or the questionnaire pack), after which they decided to stand down; collaborating
with two patient partners enabled a continued patient perspective on the emerging results. This included
analysing a subset of the qualitative data, contributions to the trial reports and delivering presentations to
academic and lay audiences on the practicalities of patient involvement in research.
All trials have limitations. In terms of trial design, controlling for any social effect that might occur through
peer support by meeting other patients (i.e. the RAFT programme groups met on seven occasions) would
have been impractical: seven sessions of didactic information would not reflect current usual care for
RA-related fatigue and would be likely to have had high attrition. Furthermore, in the original RCT,31
qualitative evaluation with patients found that, although patients reported that interactions with, and the
experiences of, other patients in their group were helpful, it was the facilitative role of the tutors and the
use of CB techniques that were more important, otherwise the group of patients would simply have ‘pulled
one another down’.32
Delay between screening and baseline assessment was an inevitable result of the need to build cohorts in
each centre that were sufficiently large for randomisation. Even though patients were recruited with fatigue
as a recurrent problem, all symptoms fluctuate and a small proportion of patients in both trial arms did not
have eligible fatigue severity scores on the day of baseline assessment. However, the complete-case analysis
still showed that the RAFT programme was able to improve fatigue impact more than usual care alone
and a stronger effect was seen in those who were eligible at baseline. Furthermore, such delays would be
likely to be shorter in clinical practice as only sufficient patients for a RAFT programme need be recruited,
rather than double the number to allow for randomisation. Six patients who were randomised to the RAFT
programme could not attend their cohort’s programme dates and accepted a later programme, at which
point a new baseline assessment was performed, meaning that baseline data had been collected after
randomisation. During the trial, management of RA continued as usual and included necessary changes to
medication aimed to reduce disease activity, which might have had an effect on fatigue. However, these
changes did not differ between trial arms and it has been found that > 60% of patients on optimal
medication who achieve remission from disease activity continue to experience problematic fatigue.17
The RCT did not have follow-up data on the 25 patients who withdrew before the week 26 primary
outcome point. The majority comprised 14 patients randomised to receive the RAFT programme who were
unable to attend their original programme dates but expressed an intention to attend a later programme,
at which point a fresh baseline assessment would have been made and follow-up would have occurred
with the new cohort. By the end of local RAFT programme delivery, they had been unable to agree to any
suitable programme dates and no exit data were requested. However, imputing missing data made no
difference to the primary outcome analysis.
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The economic evaluation was limited by the large number of missing data (particularly at 2 years, when
> 30% of data had to be imputed), and possibly limited by the appropriateness of the EQ-5D in a RA
population, which is part of an ongoing debate in long-term conditions and fatigue. Several of the costly
bDMARDs have now come off patent and it was difficult to determine how much was actually paid for
the drugs during the RCT. Individual trust negotiations on list prices may have taken place, and with
clinical commissioners now encouraging/requiring trusts to switch patients to cheaper biosimilars120 these
medication costs may come down for this patient population (although they were not different between
trial arms).
The qualitative data on the tutors’ experiences of the RAFT programme were collected after tutors had
completed the RAFT programme delivery. Although this was necessary in order not to change their
practice (and can be seen as a strength as tutors had time to reflect), it meant that tutors were recalling
their experiences of the RAFT programme that occurred some months earlier, particularly in relation to
views on the central training that they had attended 2 years previously. It is possible that tutors’ responses
were influenced by ED or SH collecting the data, as tutors met both researchers during the central training
and were aware of their involvement in the design of the RAFT programme.
Implications for health care
The RAFT programme achieved a strong and sustained clinical effect on fatigue impact beyond usual care
with no adverse events. Cost-effectiveness was not demonstrated in the primary analysis, which might be
due to the lack of responsiveness of the EQ-5D to fatigue in long-term conditions. It is also possible that
additional benefits or savings may accrue later in a long-term condition. Although, overall, there was no
statistically significant difference in costs between the RAFT programme and usual care, nonetheless there
is an additional cost to delivering the RAFT programme. However, the use of the existing rheumatology
specialist nurses and OTs makes the RAFT programme both relatively easy to implement and low cost,
compared with utilising clinical psychologists, whose presence is rare in rheumatology departments. Balanced
against the paucity of other clinically effective interventions for fatigue in RA, and the importance of fatigue
to this population, the low-cost nature of the RAFT programme might prompt clinicians and commissioners
to consider implementation. The argument for implementation is supported by the subgroup analysis
showing higher probability of cost-effectiveness in patients with more severe fatigue (52–60% probability).
The NHS service costs for the RAFT programme delivery based on 175 randomised patients in 28 groups was
estimated at £322 per patient (assuming the one-off training becomes absorbed into routine training or a
means of health professionals obtaining mandatory continuing professional development hours). Increasing
group size to 8–10 patients in clinical practice would be both feasible and economically beneficial. The RAFT
programme appears to be generalisable across people with RA, as it had broad entry criteria (i.e. any RA
patient with notable fatigue severity). Furthermore, with patients in most inflammatory rheumatic diseases
reporting fatigue,121,122 the RAFT programme could be easily extended to include patients from all these
conditions, which could more rapidly fill programmes to capacity. This could be done without further costly
RCTs, as self-management mechanisms are likely to be similar across inflammatory rheumatic diseases.
To date, two of the seven RAFT programme centres are continuing to deliver the RAFT programme as part
of clinical practice and have extended it to include patients with other inflammatory rheumatic diseases.
The qualitative evaluation with RAFT programme tutors indicated that they were integrating the RAFT
programme skills gained (CB approaches; ‘ask don’t tell’) into their everyday clinical practice to great
effect, potentially improving patients’ ability to self-manage other aspects of their inflammatory rheumatic
disease, such as pain, stiffness or flares of inflammatory activity. This suggests that implementing the RAFT
programme and training clinicians in CB approaches could have clinical benefits beyond RAFT programmes.
It is increasingly advocated that training multidisciplinary team members in CB or motivational interviewing
techniques would enhance communication, collaboration and thus patient adaptation, acceptance and
behaviour change, all necessary for self-managing long-term conditions.123,124 Research evidence on the
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success of these techniques by non-psychologists as a way of supporting specific patient groups or specific
health problems is now emerging.30,125 All of these approaches reduce the reliance on traditional didactic
information or instruction-giving and consider the ‘whole person’, including how their beliefs affect
symptoms and behaviours. A number of health professional undergraduate programmes and hospital trusts
now include short training on these for students and staff, and detailed guidance on the use of some of
these open and reflective skills in patient encounters can be found.124
The RAFT programme was tested in seven different NHS hospital settings using existing clinicians, some of
whom had a degree of prior relevant experiences, such as CB training or group work, whereas others had
none at all (unlike other fatigue interventions in which clinical staff had to be experienced in group work in
order to deliver the intervention).99 The RAFT programme could be successfully delivered in terms of scheduling
the programmes and managing tutor absence and sickness. However, for implementation within current
NHS constraints, training would need to be shortened, as highlighted in the tutors’ qualitative data. Other
psychological interventions delivered by non-psychologists used training lasting only 1 or 2 days;99,100 therefore,
the RAFT programme training is currently being revised as two short online modules (covering preparatory
background reading; access to the RAFT programme manual, videos of a programme and podcasts), followed
by a single day of face-to-face group training (applying CB approaches in the RAFT programme, interpreting
the daily activity diaries, goal-setting and group management). As these are experienced rheumatology
clinicians, only occasional clinical supervision and support was required for the use of CB techniques, and this
should be able to be sourced within the local hospital.
Implications for future research
The first priority should be to address issues of widening accessibility to fatigue support through different
delivery routes, including different tutors and different patient populations. Delivery styles of the RAFT
programme could be further explored by testing co-delivery by a tutor pair comprising a rheumatology
professional and a lay (patient) volunteer, which combines professional knowledge with a patient’s
expertise of living with the condition, and has been shown to be supportive in the self-management of
long-term conditions.126 To prepare for such research, the allocation of the different RAFT programme
roles/topics in a way that would be most appropriate to the skills of either the professional or lay tutors
would first need to be agreed, then the RAFT programme training adapted to cover these different needs/
roles and any additional support or training needed for lay tutors. The RAFT programme could also be
tested in other physical long-term conditions that have a relapsing or remitting nature and fatigue similar
to RA (e.g. chronic obstructive pulmonary disease, multiple sclerosis, Parkinson’s disease), again, using the
principle of tutors with relevant clinical expertise. For those patients who do not wish or are not able to
attend group programmes, a brief one-to-one intervention by a rheumatology nurse or OT at the end of
routine appointments is currently being piloted, using the core RAFT programme principles of fatigue
validation, daily activity diaries and goal-setting.
Building on the exploratory analysis in this RCT, a study could be powered to test for dose response
(number and combinations of sessions required), and including an intervention arm that did not receive the
week 14 consolidation session would examine the impact and value of that final session. These research
proposals would clarify whether or not similar benefit to that seen in this RCT could be achieved with
lower cost to the NHS.
The second research priority would be to better understand change in fatigue impact that is meaningful to
patients and how this informs cost evaluation. Psychological interventions specifically targeting RA-related
fatigue have been identified as an under-researched area, with researchers encouraged to include cost
evaluation in future work.20,127 To better understand the importance of change in fatigue impact, further
research could usefully establish the level of change in fatigue impact (BRAF-NRS impact) that is meaningful
for patients. There is evidence that the impact of fatigue is particularly problematic in early RA2 and the
current trial population had a mean of 10-year disease duration; therefore, any improvements in fatigue
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impact from the RAFT programme may have greater potential for translating into improved quality of life
and economic benefit in a more recently diagnosed cohort. Future research also needs to explore whether
or not the EQ-5D and other utility measures capture what is important to people with RA,104 specifically
whether or not they capture fatigue, in order to better inform QALYs, on which NICE cost-effectiveness
thresholds are based.
The third research priority could be to better understand what happens to research interventions when
they are rolled out into clinical practice. Clinical implementation of the RAFT programme in RA, other
inflammatory rheumatic diseases or other physical long-term conditions would provide an opportunity to
evaluate not only outcome but also tutor fidelity to the RAFT programme content, principles and delivery
in clinical practice. This would clarify any changes to the RAFT programme that inevitably occur in clinical
practice and afford an opportunity to understand the clinical circumstances in which the intervention can
be effective.
A fourth research stream might be to build on the qualitative findings that tutors perceived that their
new CB skills fed into changes in their wider clinical practice. Trials could examine if training health-care
professionals and multidisciplinary team members in the use of CB approaches in their everyday practice
has a beneficial effect on patient outcomes.
Conclusions
The RAFT programme is a seven-session group intervention to help patients with RA manage their fatigue.
It uses CB approaches and is delivered for the first time by usual clinical teams and not psychologists.
Patient attendance and satisfaction were high. The RAFT programme demonstrates significant benefits
beyond usual care alone on RA-related fatigue impact, living with fatigue and emotional fatigue and these,
along with fatigue coping, are sustained over 2 years without further RAFT programme input. No harms
were identified. The RCT did not demonstrate that the RAFT programme is likely to be cost-effective at
NICE cost-per-QALY thresholds, although the EQ-5D may not be sufficiently responsive to capture changes
in fatigue. Although there was no statistically significant difference in costs, the RAFT programme supports
the management of a symptom considered important by patients and for which there is a paucity of
interventions. In addition, the RAFT programme is low cost and easy to implement. The RAFT programme
tutors believe the skills learned through delivery of the RAFT programme have had an impact on their
wider clinical practice and approach to supporting self-management in RA.
DISCUSSION AND CONCLUSIONS
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Appendix 1 Conceptual model of rheumatoid
arthritis fatigue
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FIGURE 5 Conceptual model of RA fatigue. Reproduced from Hewlett S, Chalder T, Choy E, Cramp F, Davis B,
Dures E, et al., Fatigue in rheumatoid arthritis: time for a conceptual model, Rheumatology (Oxford), 2011,
Volume 50, Issue 6, pp. 1004–6, by permission of Oxford University Press.19
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Appendix 2 Session content of the
RAFT programme
First hour Supporting materials Second hour
Week 1
Programme purpose and expectations Energy management:
l Boom-and-bust behaviour
l Rewards/pitfalls of this
l Prioritise, pace, plan
l Choice is possible
H: achieving balance
H: activity cycling
T: activity/rest diaries
Ground rules:
l Commitment, confidentiality, homework
Validating fatigue:
l Share and discuss fatigue experiences
(difference from flare)
H: setting our course (groups’ ideas)
Self-management strategies, struggles and
difficulty of changing habits
Week 2
What are your priorities for change that
would increase QoL?
T: wheel of life (priority areas) Goal-setting (two groups):
l Short-/long-term goals
l Use peer group for ideasWhat are your drainers and energisers?
Week 3
Self-sabotage on the programme H: best ways of self-sabotage Goal-setting review
Successes/barriers
New goals
Sleep and rest:
l Hours needed? Quality vs. quantity
l Sleep hygiene strategies
H: getting a better night’s sleep
T: sleep diary (if needed)
Week 4
Stress and relaxation:
l Personal stressors, bodily reactions
l Relaxation rationale and techniques
H: effects of stress
H: relaxation practice guide
T: relaxation CD
Goal-setting review
Successes/barriers
New goals
Week 5
Assertiveness and communication: Goal-setting review
Successes/barriers
New goals
l Passive, manipulative, assertive? M: cartoon examples
l Other people’s reactions to these?
l Communicating your needs H: saying ‘no’
Week 6
Review self-help tools
l What have you learnt?
l Review each topic
M: fatigue pit – falling in/digging out Goal-setting review
Successes/barriers
New goals
Dealing with setbacks – what could you do?
l Negative self-talk, automatic thoughts
l Rumination
H: the pit
H: coping with setbacks
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First hour Supporting materials Second hour
Week 14
Review last 8 weeks:
l Skills; dealing with setbacks
M: islands – were on a desert island
(passive) looking at the mainland
(100% health, i.e. unrealistic). Now
on adaptive coping island (realistic)
New goals
CD, compact disc; H, handout; M, metaphor; QoL, quality of life; T, tools.
Note
Reproduced from Hewlett et al.40 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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Appendix 3 Recruitment to the RAFT programme
across centres
Centre Number of patients randomised
Bristol Royal Infirmary 43
University Hospital of Wales, Cardiff 44
St Peter’s Hospital, Chertsey 53
Southmead Hospital Bristol 46
Poole Hospital 41
Torbay Hospital 58
Weston General Hospital 48
Total 333
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Appendix 4 Data completion rates for all
follow-up time points
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Clinical variable
Time point, n (%)a
Baseline
(N= 333, 100%)
Week 6
(N= 314, 94%)
Week 10
(N= 312, 94%)
Week 18
(N= 311, 93%)
Week 26
(N= 308, 92%)
Week 52
(N= 305, 92%)
Week 78
(N= 302, 91%)
Week 104
(N= 300, 90%)
Fatigue
BRAF-NRS impact 333 (100) 312 (94) 308 (92) 305 (92) 308 (92) 305 (92) 300 (90) 296 (89)
BRAF-NRS severity 333 (100) 283 (85) 268 (80) 275 (83) 294 (88) 264 (79) 249 (75) 261 (78)
BRAF-NRS coping 333 (100) 283 (85) 268 (80) 274 (82) 294 (88) 264 (79) 248 (75) 261 (78)
BRAF-MDQ overall impact 333 (100) 282 (85) 267 (80) 274 (82) 294 (88) 260 (78) 247 (74) 261 (78)
BRAF-MDQ physical 333 (100) 283 (85) 268 (80) 275 (83) 294 (88) 264 (79) 249 (75) 261 (78)
BRAF-MDQ emotional 333 (100) 282 (85) 267 (80) 274 (82) 294 (88) 263 (79) 247 (74) 261 (78)
BRAF-MDQ cognitive 333 (100) 282 (85) 267 (80) 274 (82) 294 (88) 262 (79) 248 (75) 261 (78)
BRAF-MDQ living 333 (100) 282 (85) 267 (80) 274 (82) 294 (88) 261 (78) 248 (75) 261 (78)
Pain: NRS 333 (100) 283 (85) – – 294 (88) 264 (79) 248 (75) 261 (78)
Disability: MHAQ 332 (100) 282 (85) – – 294 (88) 264 (79) 249 (75) 261 (78)
Quality of life: AIMS VAS 332 (99) 283 (85) – – 294 (88) 264 (79) 248 (75) 261 (78)
Disease activity
Assessed: DAS28 332 (100) – – – 293 (88) – – –
Self-reported: sPDAS2 293 (88) 281 (84) – – 294 (88) 263 (79) 246 (74) 259 (78)
Anxiety: HADS 333 (100) 282 (85) – – 293 (88) 264 (79) 246 (74) 260 (78)
Depression: HADS 333 (100) 282 (85) – – 293 (88) 264 (79) 247 (74) 260 (78)
Valued life activities: VLA 332 (100) 282 (85) – – 294 (88) 264 (79) 248 (75) 261 (78)
Helplessness: AHI 333 (100) 282 (85) – – 294 (88) 264 (79) 245 (74) 260 (78)
Self-efficacy: RASE scale 333 (100) 281 (84) – – 293 (88) 260 (78) 245 (74) 254 (76)
Sleep quality 332 (99) 276 (83) – – 292 (88) 258 (78) 241 (72) 253 (76)
a For all percentages, the denominator is the total number randomised (n = 333).
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Appendix 5 Baseline demographic data of
patients who did and did not complete to 26 weeks
Demographic variable
Trial arm
Did not complete
(N= 25)Control (N= 152) RAFT (N= 156)
Female, n (%) 121 (79.6) 125 (80.1) 20 (80)
Age (years), median (lower and upper quartile) 61.8 (54.4, 69.6) 63.7 (54.2, 69.9) 69 (61.3, 72)
Disease duration (years), median (lower and upper
quartile)
10 (3, 20) 10 (5, 19) 10 (5, 11)
Comorbidity, n (%) 119 (78.8) 124 (80.0) 20 (80.0)
Fatigue, mean (SD)
Severity (BRAF-NRS, 0–10)a 6.85 (1.57) 6.89 (1.57) 6.64 (1.47)
Impact (BRAF-NRS, 0–10)a 7.23 (1.6) 7.10 (1.7) 6.96 (1.54)
Other self-management programmes, n (%) 21 (14.0) 16 (10.3) 1 (4.0)
Years since programme, median (lower and upper
quartile)
8 (5, 11) 5 (3, 10) 2
Socioeconomic status, n (%)
England
Deprived 28 (21.1) 23 (17.2) 6 (27.3)
Moderate 60 (45.1) 65 (48.5) 10 (45.5)
Affluent 45 (33.8) 46 (34.3) 6 (27.3)
Wales
Deprived 7 (41.2) 7 (35.0) 2 (66.6)
Moderate 3 (17.7) 5 (25.0) 1 (33.3)
Affluent 7 (41.2) 8 (45.0) 0
Ethnicity, n (%)
White 147 (98.0) 151 (96.8) 24 (96.0)
Asian/Asian British 3 (2.0) 5 (3.2) 1 (4.0)
a High score is worse.
Note
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Appendix 6 Baseline clinical data of patients who
did not complete to 26 weeks
Clinical variable
Mean score (SD) for those participants who
did not completea (n= 25)
Fatigue
BRAF-NRS impact (0–10) 6.96 (1.5)
BRAF-NRS severity (0–10) 6.64 (1.5)
BRAF-NRS coping (0–10)b 4.88 (2.0)
BRAF-MDQ overall impact (0–70) 41.80 (11.8)
BRAF-MDQ physical (0–22) 15.52 (2.7)
BRAF-MDQ emotional (0–12) 7.28 (3.1)
BRAF-MDQ cognitive (0–15) 8.64 (3.2)
BRAF-MDQ living (0–21) 10.36 (5.4)
Pain: NRS (0–10) 6.08 (2.3)
Disability: MHAQ (0–3) 0.87 (0.6)
Quality of life: AIMS VAS (0–100) 52.40 (22.4)
Disease activity
Assessed: DAS28 (0.96+) 4.25 (1.4)
Self-reported: sPDAS2 (2.4–7.9) 4.57 (1.0)
Anxiety: HADS (0–21) 8.88 (3.8)
Depression: HADS (0–21) 7.00 (3.9)
Valued life activities: VLA (0–3) 1.17 (0.7)
Helplessness: AHI (5–30) 17.86 (5.7)
Self-efficacy: RASE scale (28–140)b 101.19 (11.9)
Sleep qualityc
Very good 0 (0%)
Fairly good 11 (44%)
Fairly bad 7 (28%)
Very bad 7 (28%)
a Similar to those who did complete (see Table 5).
b Higher score = better outcome.
c Percentage of questionnaires returned.
Note
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Appendix 7 Treatment effect on BRAF-NRS
impact score at 26, 52, 78 and 104 weeks
Time pointa
BRAF-NRS impact score,
adjusted mean differenceb,c 95% CI p-value
26 weeks (n = 308) –0.58 –1.07 to –0.09 0.02
52 weeks (n = 305) –0.62 –1.12 to –0.13 0.01
78 weeks (n = 300) –0.22 –0.71 to 0.28 0.39
104 weeks (n = 296) –0.52 –1.02 to –0.02 0.04
a Estimated from the repeated measures linear mixed model.
b Adjusted for baseline BRAF-NRS impact score and for centre.
c Negative score demonstrates improvement in BRAF-NRS impact.
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Appendix 8 Change in secondary outcomes at
26 weeks
Clinical outcome
Trial arm
Control RAFT
n (%)a
Mean change
in score (SD) n (%)a
Mean change
in score (SD)
Fatigue
BRAF-NRS severity (0–10) 142 (89.9) –0.72 (2.27) 152 (86.9) –0.97 (2.53)
BRAF-NRS coping (0–10)b 142 (89.9) 0.48 (3.07) 152 (86.9) 0.09 (2.82)
BRAF-MDQ overall impact (0–70) 142 (89.9) –5.64 (12.75) 152 (86.9) –8.91 (14.55)
BRAF-MDQ physical (0–22) 142 (89.9) –1.79 (4.77) 152 (86.9) –2.40 (5.13)
BRAF-MDQ emotional (0–12) 142 (89.9) –1.35 (3.14) 152 (86.9) –2.18 (3.18)
BRAF-MDQ cognitive (0–15) 142 (89.9) –1.03 (3.88) 152 (86.9) –1.65 (3.78)
BRAF-MDQ living (0–21) 142 (89.9) –1.47 (4.20) 152 (86.9) –2.68 (5.09)
Pain: NRS (0–10) 142 (89.9) –0.33 (2.44) 152 (86.9) –0.22 (2.32)
Disability: MHAQ (0–3) 142 (89.9) –0.06 (0.34) 151 (86.3) –0.04 (0.39)
Quality of life: AIMS VAS (0–100) 141 (89.2) –2.19 (25.37) 152 (86.9) –1.93 (25.63)
Disease activity
Assessed: DAS28 (0.96+) 145 (91.8) –0.13 (0.93) 147 (84.0) –0.09 (1.18)
Self-reported: sPDAS2 (2.4–7.9) 142 (89.9) –0.03 (0.95) 151 (86.3) –0.01 (1.09)
Anxiety: HADS (0–21) 142 (89.9) –0.45 (2.76) 151 (86.3) –0.64 (2.77)
Depression: HADS (0–21) 142 (89.9) –0.37 (2.98) 151 (86.3) –0.96 (2.88)
Valued life activities: VLA (0–3) 142 (89.9) –0.01 (0.40) 151 (86.3) –0.07 (0.48)
Helplessness: AHI (5–30) 142 (89.9) –1.51 (4.67) 152 (86.9) –2.11 (5.22)
Self-efficacy: RASE scale (28–140)b 142 (89.9) 0.29 (10.71) 151 (86.3) 3.77 (12.54)
Sleep quality 142 (89.9) 149 (85.1)
Categories improved: –3c 0 (0%) 2 (1.3%)
Categories improved: –2c 6 (4.2%) 9 (6.0%)
Categories improved: 1c 37 (26.1%) 45 (30.2%)
No change: 0c 77 (54.2%) 75 (50.3%)
Categories worsened: 1c 21 (14.8%) 18 (12.1%)
Categories worsened: 2c 1 (0.7%) 0 (0%)
Categories worsened: 3c 0 (0%) 0 (0%)
a Percentage of total randomised (control, n = 158; RAFT, n = 175).
b Higher score = better outcome.
c Percentage of questionnaires returned.
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Appendix 9 Secondary clinical outcomes at the
26-, 52-, 78- and 104-week follow-up
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Clinical outcome
Time point
26 weeks 52 weeks 78 weeks 104 weeks
Control RAFT Control RAFT Control RAFT Control RAFT
na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD)
Fatigue
BRAF-NRS severity (0–10) 142
(89.9)
6.13
(2.30)
152
(86.9)
5.91
(2.22)
127
(80.4)
6.05
(2.18)
137
(78.3)
5.80
(2.19)
120
(75.9)
6.05
(2.24)
129
(73.7)
5.91
(2.19)
124
(78.5)
5.72
(2.12)
137
(78.3)
5.85
(2.25)
BRAF NRS coping (0–10)b 142
(89.9)
5.32
(2.42)
152
(86.9)
5.25
(2.33)
127
(80.4)
5.02
(2.40)
137
(78.3)
5.83
(2.10)
119
(75.3)
5.10
(2.55)
129
(73.7)
5.57
(2.32)
124
(78.5)
5.28
(2.33)
137
(78.3)
6.03
(2.16)
BRAF-MDQ overall impact (0–70) 142
(89.9)
34.74
(16.41)
152
(86.9)
31.51
(16.02)
125
(79.1)
34.67
(15.54)
135
(77.1)
31.04
(15.59)
118
(74.7)
34.61
(16.04)
129
(73.7)
32.45
(16.08)
124
(78.5)
33.31
(14.94)
137
(78.3)
31.60
(16.41)
BRAF-MDQ physical (0–22) 142
(89.9)
14.40
(5.23)
152
(86.9)
13.72
(4.91)
127
(80.4)
14.36
(4.81)
137
(78.3)
13.39
(5.01)
120
(75.9)
14.41
(4.94)
129
(73.7)
13.92
(4.77)
124
(78.5)
14.06
(4.79)
137
(78.3)
13.56
(5.01)
BRAF-MDQ emotional (0–12) 142
(89.9)
5.36
(3.79)
152
(86.9)
4.37
(3.51)
126
(79.7)
5.18
(3.37)
137
(78.3)
4.20
(3.45)
118
(74.7)
5.31
(3.62)
129
(73.7)
4.40
(3.47)
124
(78.5)
5.07
(3.54)
137
(78.3)
4.20
(3.48)
BRAF-MDQ cognitive (0–15) 142
(89.9)
6.55
(4.16)
152
(86.9)
5.89
(4.35)
125
(79.1)
6.86
(4.15)
137
(78.3)
6.09
(4.27)
119
(75.3)
6.31
(4.04)
129
(73.7)
5.98
(4.20)
124
(78.5)
6.19
(4.00)
137
(78.3)
5.82
(4.01)
BRAF-MDQ living (0–21) 142
(89.9)
8.43
(5.68)
152
(86.9)
7.53
(5.43)
126
(79.7)
8.38
(5.21)
135
(77.1)
7.47
(5.46)
119
(75.3)
8.52
(5.50)
129
(73.7)
8.14
(5.76)
124
(78.5)
7.98
(5.03)
137
(78.3)
7.81
(6.00)
Pain: NRS (0–10) 142
(89.9)
5.24
(2.41)
152
(86.9)
5.47
(2.22)
127
(80.4)
5.21
(2.33)
137
(78.3)
5.34
(2.38)
119
(75.3)
5.23
(2.23)
129
(73.7)
5.28
(2.42)
124
(78.5)
5.37
(2.27)
137
(78.3)
5.32
(2.35)
Disability: MHAQ (0–3) 142
(89.9)
0.70
(0.51)
152
(86.9)
0.71
(0.54)
127
(80.4)
0.74
(0.52)
137
(78.3)
0.74
(0.60)
119
(75.3)
0.76
(0.55)
130
(74.3)
0.78
(0.63)
124
(78.5)
0.78
(0.53)
137
(78.3)
0.77
(0.62)
Quality of life: AIMS VAS (0–100) 142
(89.9)
47.70
(22.96)
152
(86.9)
47.22
(23.46)
127
(80.4)
45.54
(22.21)
137
(78.3)
46.61
(24.01)
119
(75.3)
46.60
(23.99)
129
(73.7)
48.43
(23.40)
124
(78.5)
47.77
(22.32)
137
(78.3)
44.10
(24.68)
Disease activity: sPDAS2 (2.4 to 7.9) 142
(89.9)
4.33
(1.04)
152
(86.9)
4.44
(1.13)
127
(80.4)
4.50
(1.09)
136
(77.7)
4.60
(1.15)
117
(74.1)
4.48
(1.12)
129
(73.7)
4.66
(1.11)
123
(77.8)
4.67
(1.09)
136
(77.7)
4.57
(1.21)
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Clinical outcome
Time point
26 weeks 52 weeks 78 weeks 104 weeks
Control RAFT Control RAFT Control RAFT Control RAFT
na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD) na (%)
Mean
(SD)
Anxiety: HADS (0–21) 142
(89.9)
7.56
(4.48)
151
(86.3)
6.65
(4.36)
127
(80.4)
7.57
(4.58)
137
(78.3)
6.69
(4.50)
116
(73.4)
7.56
(4.64)
130
(74.3)
6.76
(4.57)
123
(77.8)
7.36
(4.26)
137
(78.3)
6.34
(4.64)
Depression: HADS (0–21) 142
(89.9)
6.42
(4.06)
151
(86.3)
6.22
(3.76)
127
(80.4)
6.44
(3.91)
137
(78.3)
6.28
(3.99)
117
(74.1)
6.84
(3.94)
130
(74.3)
6.76
(4.57)
123
(77.8)
7.36
(4.26)
137
(78.3)
6.34
(4.64)
Valued life activities: VLA (0–3) 142
(89.9)
1.07
(0.62)
152
(86.9)
1.08
(0.67)
127
(80.4)
1.00
(0.61)
137
(78.3)
1.09
(0.70)
118
(74.7)
1.08
(0.65)
130
(74.3)
1.08
(0.67)
124
(78.5)
1.08
(0.66)
137
(78.3)
1.09
(0.71)
Helplessness: AHI (5–30) 142
(89.9)
17.47
(5.46)
152
(86.9)
16.92
(5.06)
127
(80.4)
17.41
(5.38)
137
(78.3)
17.40
(5.60)
116
(73.4)
17.41
(5.43)
129
(73.7)
18.13
(5.62)
123
(77.8)
17.68
(5.22)
137
(78.3)
17.33
(5.12)
Self-efficacy: RASE scale (28–140)b 142
(89.9)
104.67
(13.31)
151
(86.3)
106.26
(14.78)
125
(79.1)
104.94
(12.51)
135
(77.1)
105.08
(13.39)
117
(74.1)
105.62
(12.99)
128
(73.1)
103.89
(12.55)
121
(76.6)
104.69
(12.77)
133
(76.0)
105.40
(15.41)
Sleep qualityc
Very good 9 (6.3) 17
(11.3)
10
(8.1)
10
(7.5)
7 (6.1) 15
(11.9)
7 (5.8) 13
(9.9)
Fairly good 65
(45.8)
65
(43.3)
52
(41.9)
61
(45.5)
55
(47.8)
52
(41.3)
51
(42.2)
57
(43.2)
Fairly bad 51
(35.9)
51
(34.0)
45
(36.3)
45
(33.6)
40
(34.8)
33
(26.2)
46
(38.0)
46
(34.9)
Very bad 17
(12.0)
17
(11.3)
17
(13.7)
18
(13.4)
13
(11.3)
26
(20.6)
17
(14.1)
16
(12.1)
a Percentage of total randomised (control, n = 158; RAFT, n = 175).
b Higher score = better outcome.
c Number of patients (percentage of questionnaires returned).
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Appendix 10 Patients making major medication
changes during the trial
Time pointa
Trial arm
p-value (from
chi-squared test)
Control RAFT
N n (%)b N n (%)b
Weeks 0–26 152 37 (24.3) 156 32 (20.5) 0.42
Weeks 26–52 151 27 (17.9) 154 32 (20.8) 0.52
Weeks 52–78 148 28 (18.9) 154 31 (20.1) 0.79
Weeks 78–104 147 21 (14.3) 153 22 (14.4) 0.90
a Major medication change = start, stop or change dose of DMARD, bDMARD or glucocorticoid.
b Percentage of patients remaining in trial.
Note
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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Appendix 11 Complier-average causal effect
analysis
Reproduced from Hewlett et al.65 This is an Open Access article distributed in accordance with theterms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and formatting
changes to the original text.
The CACE analysis used instrumental variable regression to estimate the efficacy of the RAFT programme
in reducing RA-related fatigue impact compared with usual care alone. One of the assumptions of CACE
analysis is exclusion restriction, that is, the offer of the intervention does not affect the outcome. In the current
study, those individuals randomised to the RAFT programme but who could not make the programme dates
and did not attend had no follow-up data collected. Therefore, outcome data were not available for a group
of individuals who would be considered non-compliant and contribute information to the CACE analysis,
and it also violates the exclusion restriction assumption. If individuals in the RAFT programme arm were only
considered participants if they attended the first CBT session (which could then impact their outcome), then
the offer of the intervention does affect outcome.
In an attempt to address this issue, the two stages of the 2SLS CACE estimation were conducted separately to
allow for loss to follow-up, which is dependent on adherence. This first-stage regression uses all individuals
randomised to predict adherence. Second-stage regression involves only those individuals with available
outcomes, but models these using the predicted values of adherence obtained from the ‘complete’ first stage.
The results of the CACE analyses are shown in Table 30, along with the primary analysis results for
comparison. The CACE analyses showed that there was a larger effect of the RAFT programme in those
individuals who adhered to the intervention (defined as attending at least two CBT sessions), compared
with the standard primary analysis effectiveness estimate of the ‘offer’ of the intervention (see Table 30).
It should be noted that in the current study, due to the exclusion of individuals who did not attend the first
CBT session, there is no one correct ideal approach; therefore, the results of the CACE analysis should be
interpreted as part of a general sensitivity analysis and as exploratory in nature.
TABLE 30 The BRAF-NRS fatigue impact at 26 weeks: primary and CACE analyses
Analysis Coefficient (95% CI) p-value
Primary –0.59 (–1.11 to –0.06) 0.03
CACE –0.69 (–1.30 to –0.07) 0.03
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Appendix 12 Clinical outcomes at 6 weeks
Clinical outcome
Trial arm
Control RAFT
n (%)a Mean (SD) n (%)a Mean (SD)
Fatigue
BRAF-NRS impact (0–10) 156 (98.7) 6.62 (2.03) 156 (89.1) 5.94 (1.95)
BRAF-NRS severity (0–10) 139 (88.0) 6.45 (1.91) 144 (82.3) 6.17 (1.76)
BRAF-NRS coping (0–10)b 139 (88.0) 4.81 (2.26) 144 (82.3) 6.05 (1.90)
BRAF-MDQ overall impact (0–70) 139 (88.0) 37.89 (13.63) 143 (81.7) 33.30 (13.34)
BRAF-MDQ physical (0–22) 139 (88.0) 15.29 (3.89) 144 (82.3) 13.83 (4.02)
BRAF-MDQ emotional (0–12) 139 (88.0) 6.23 (3.33) 143 (81.7) 5.07 (3.13)
BRAF-MDQ cognitive (0–15) 139 (88.0) 7.22 (3.83) 143 (81.7) 6.32 (3.85)
BRAF-MDQ living (0–21) 139 (88.0) 9.14 (5.16) 143 (81.7) 8.13 (5.37)
Pain: NRS (0–10) 139 (88.0) 5.63 (2.18) 144 (82.3) 5.69 (2.07)
Disability: MHAQ (0–3) 139 (88.0) 0.73 (0.52) 142 (81.1) 0.75 (0.59)
Quality of life: AIMS VAS (0–100) 138 (87.3) 50.64 (21.02) 144 (82.3) 47.63 (21.50)
Disease activity: sPDAS2 (2.4–7.9) 139 (88.0) 4.55 (1.06) 141 (80.6) 4.67 (1.07)
Anxiety: HADS (0–21) 139 (88.0) 8.21 (4.37) 143 (81.7) 7.54 (4.28)
Depression: HADS (0–21) 139 (88.0) 6.89 (3.84) 143 (81.7) 6.94 (3.69)
Valued life activities: VLA (0–3) 139 (88.0) 1.12 (0.58) 142 (81.1) 1.19 (0.61)
Helplessness: AHI (5–30) 139 (88.0) 18.70 (4.79) 143 (81.7) 18.20 (4.58)
Self-efficacy: RASE scale (28–140)b 138 (87.3) 102.97 (12.74) 143 (81.7) 105.00 (11.86)
Sleep quality 136 (86.1) 139 (79.4)
Very goodc 7 (5.1%) 18 (12.9%)
Fairly goodc 53 (39.0%) 53 (38.1%)
Fairly badc 55 (40.4%) 45 (32.4%)
Very badc 21 (15.4%) 23 (16.6%)
a Percentage of total randomised (control, n = 158; RAFT, n = 175).
b Higher score = better outcome.
c Number of patients (percentage of questionnaires returned).
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Appendix 13 Change in clinical outcomes from
0 to 6 weeks
Clinical outcome
Trial arm
Control RAFT
n (%)a Mean change (SD) n (%)a Mean change (SD)
Fatigue
BRAF-NRS impact (0–10) 156 (98.7) –0.61 (1.99) 156 (89.1) –1.17 (2.24)
BRAF-NRS severity (0–10) 139 (88.0) –0.35 (1.89) 144 (82.3) –0.78 (2.08)
BRAF-NRS coping (0–10)b 139 (88.0) –0.09 (2.59) 144 (82.3) 0.92 (2.64)
BRAF-MDQ overall impact (0–70) 139 (88.0) –2.75 (10.25) 143 (81.7) –7.17 (11.84)
BRAF-MDQ physical (0–22) 139 (88.0) –0.87 (3.44) 144 (82.3) –2.35 (4.35)
BRAF-MDQ emotional (0–12) 139 (88.0) –0.62 (2.77) 143 (81.7) –1.51 (3.01)
BRAF-MDQ cognitive (0–15) 139 (88.0) –0.43 (3.31) 143 (81.7) –1.10 (3.24)
BRAF-MDQ living (0–21) 139 (88.0) –0.84 (4.09) 143 (81.7) –2.15 (4.59)
Pain: NRS (0–10) 139 (88.0) 0.04 (2.17) 144 (82.3) –0.03 (2.05)
Disability: MHAQ (0–3) 139 (88.0) –0.03 (0.30) 142 (81.1) 0.00 (0.36)
Quality of life: AIMS VAS (0–100) 138 (87.3) 0.83 (21.74) 144 (82.3) –1.64 (24.43)
Disease activity: sPDAS2 (2.4–7.9) 139 (88.0) 0.19 (0.88) 141 (80.6) 0.21 (0.95)
Anxiety: HADS (0–21) 139 (88.0) 0.19 (3.03) 143 (81.7) 0.11 (2.60)
Depression: HADS (0–21) 139 (88.0) 0.11 (2.34) 143 (81.7) –0.30 (2.61)
Valued life activities: VLA (0–3) 139 (88.0) 0.04 (0.34) 142 (81.1) 0.02 (0.36)
Helplessness: AHI (5–30) 139 (88.0) –0.25 (3.87) 143 (81.7) –0.97 (4.24)
Self-efficacy: RASE scale (28–140)b 138 (87.3) –1.43 (9.08) 143 (81.7) 2.97 (11.45)
Sleep quality 136 (86.1) 139 (79.5)
Categories improved: –3c 0 (0%) 1 (0.7%)
Categories improved: –2c 1 (0.7%) 7 (5.0%)
Categories improved: 1c 23 (16.9%) 41 (29.5%)
No change: 0c 94 (69.1%) 74 (53.2%)
Categories worsened: 1c 17 (12.5%) 16 (11.5%)
Categories worsened: 2c 1 (0.7%) 0 (0%)
Categories worsened: 3c 0 (0%) 0 (0%)
a Percentage of total randomised (control, n = 158; RAFT, n = 175).
b Higher score = better outcome.
c Number of patients (percentage of questionnaires returned).
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Appendix 14 Fatigue outcomes at 10 weeks
Fatigue outcomea
Trial arm
Control RAFT
n (%)b Mean (SD) n (%)b Mean (SD)
BRAF-NRS impact (0–10) 153 (96.8) 6.59 (2.03) 155 (88.6) 6.05 (2.15)
BRAF-NRS severity (0–10) 131 (82.9) 5.93 (2.02) 137 (78.3) 5.93 (2.08)
BRAF-NRS coping (0–10)c 131 (82.9) 5.47 (2.15) 137 (78.3) 5.96 (2.07)
BRAF-MDQ overall impact (0–70) 130 (82.3) 34.20 (14.50) 137 (78.3) 31.91 (14.21)
BRAF-MDQ physical (0–22) 131 (82.9) 14.27 (4.32) 137 (78.3) 13.59 (4.44)
BRAF-MDQ emotional (0–12) 130 (82.3) 5.35 (3.26) 137 (78.3) 4.53 (3.32)
BRAF-MDQ cognitive (0–15) 130 (82.3) 6.48 (3.83) 137 (78.3) 6.01 (4.11)
BRAF-MDQ living (0–21) 130 (82.3) 8.09 (5.50) 137 (78.3) 7.77 (5.20)
a Using data from patients who completed both 0- and 10-week data.
b Percentage of total randomised (control, n = 158; RAFT, n = 175).
c Higher score = better outcome.
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Appendix 15 Change in fatigue outcomes from
0 to 10 weeks
Fatigue outcomea
Trial arm
Control RAFT
n (%)b Mean change (SD) n (%)b Mean change (SD)
BRAF-NRS impact (0–10) 153 (96.8) –0.66 (2.03) 155 (88.6) –1.06 (2.63)
BRAF-NRS severity (0–10) 131 (82.9) –0.86 (2.09) 137 (78.3) –0.96 (2.53)
BRAF-NRS coping (0–10)c 131 (82.9) 0.61 (2.79) 137 (78.3) 0.84 (2.97)
BRAF-MDQ overall impact (0–70) 130 (82.3) –6.22 (10.83) 137 (78.3) –8.47 (13.94)
BRAF-MDQ physical (0–22) 131 (82.9) –1.89 (3.98) 137 (78.3) –2.47 (5.12)
BRAF-MDQ emotional (0–12) 130 (82.3) –1.33 (2.87) 137 (78.3) –1.98 (3.51)
BRAF-MDQ cognitive (0–15) 130 (82.3) –1.17 (3.24) 137 (78.3) –1.47 (3.50)
BRAF-MDQ living (0–21) 130 (82.3) –1.81 (4.04) 137 (78.3) –2.56 (4.95)
a Using data from patients who completed both 0- and 10-week data.
b Percentage of total randomised (control, n = 158; RAFT n = 175).
c Higher score = better outcome.
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Appendix 16 Fatigue outcomes at 18 weeks
Fatigue outcomea
Trial arm
Control RAFT
n (%)b Mean (SD) n (%)b Mean (SD)
BRAF-NRS impact (0–10) 151 (95.6) 6.42 (2.22) 154 (88.0) 5.77 (2.08)
BRAF-NRS severity (0–10) 137 (86.7) 6.13 (2.17) 138 (78.9) 5.86 (2.10)
BRAF-NRS coping (0–10)c 136 (86.1) 5.22 (2.35) 138 (78.9) 5.95 (2.20)
BRAF-MDQ overall impact (0–70) 137 (86.7) 34.84 (16.11) 137 (78.3) 32.35 (15.15)
BRAF-MDQ physical (0–22) 137 (86.7) 14.19 (4.94) 138 (78.9) 13.34 (4.62)
BRAF-MDQ emotional (0–12) 137 (86.7) 5.54 (3.51) 137 (78.3) 4.73 (3.42)
BRAF-MDQ cognitive (0–15) 137 (86.7) 6.73 (3.93) 137 (78.3) 5.96 (4.06)
BRAF-MDQ living (0–21) 137 (86.7) 8.38 (5.60) 137 (78.3) 8.28 (5.57)
a Using data from patients who completed both 0- and 18-week data.
b Percentage of total randomised (control, n = 158; RAFT, n = 175).
c Higher score = better outcome.
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Appendix 17 Change in fatigue outcomes from
0 to 18 weeks
Fatigue outcomea
Trial arm
Controla RAFTa
n (%)b Mean change (SD) n (%)b Mean change (SD)
BRAF-NRS impact (0–10) 151 (95.6) –0.80 (2.27) 154 (88.0) –1.35 (2.51)
BRAF-NRS severity (0–10) 137 (86.7) –0.72 (2.24) 138 (78.9) –1.13 (2.50)
BRAF-NRS coping (0–10)c 136 (86.1) 0.44 (3.13) 138 (78.9) 0.86 (2.91)
BRAF-MDQ overall impact (0–70) 137 (86.7) –5.53 (13.15) 137 (78.3) –8.41 (14.94)
BRAF-MDQ physical (0–22) 137 (86.7) –1.96 (4.43) 138 (78.9) –2.91 (5.14)
BRAF-MDQ emotional (0–12) 137 (86.7) –1.14 (2.98) 137 (78.3) –1.91 (3.55)
BRAF-MDQ cognitive (0–15) 137 (86.7) –0.93 (4.03) 137 (78.3) –1.49 (3.77)
BRAF-MDQ living (0–21) 137 (86.7) –1.50 (4.79) 137 (78.3) –2.09 (5.47)
a Using data from patients who completed both 0- and 18-week data.
b Percentage of total randomised (control, n = 158; RAFT, n = 175).
c Higher score = better outcome.
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Appendix 18 Rheumatoid Arthritis Self-Efficacy
Scale: individual item mean scores (0 and 26 weeks)
RASE scale itema
Trial arm, mean score
Control RAFT
Week 0 Week 26 Week 0 Week 26
Use relaxation techniques to help with pain 3.70 3.64 3.61 3.72
Think about something else to help with pain 3.37 3.46 3.33 3.45
Use my joints carefully to help with pain 3.58 3.81 3.60 3.76
Think positively to help with pain 3.59 3.66 3.47 3.71
Avoid doing things that cause pain 3.54 3.79 3.65 3.61
Wind down, relax before bed, to improve sleep 3.51 3.65 3.50 3.68
Hot drink before bed to improve sleep 3.20 3.39 3.17 3.39
Use relaxation before bed to improve sleep 3.61 3.57 3.50 3.66
Pace myself, take RA into account to deal with tiredness 3.78 3.76 3.73 4.09
Accept fatigue as part of my arthritis 3.58 3.70 3.53 3.93
Use gadgets to help with mobility, tasks, personal care 3.90 3.94 3.83 4.01
Ask for help to deal with difficulties of doing everyday things 3.87 3.85 3.64 3.88
Do exercises to deal with difficulties of doing everyday tasks 3.56 3.63 3.56 3.66
Plan/prioritise to deal with difficulties of doing everyday tasks 3.78 3.76 3.74 3.90
Educate family/friends about my RA to help with relationships 3.71 3.75 3.63 3.76
Explain to friends and family when I do or do not need help 3.80 3.78 3.78 3.82
Discuss any problems with my partner or family 4.02 3.99 3.87 3.97
Make time for leisure activities, hobbies or socialising 3.65 3.73 3.78 3.84
Save energy for leisure activities, hobbies or socialising 3.35 3.49 3.34 3.51
Focus on the positive when I am feeling down 3.72 3.82 3.69 3.86
Use relaxation to deal with worries 3.47 3.60 3.54 3.54
Allocate time for relaxation 3.72 3.70 3.78 3.81
Use relaxation tape or instructions to help me relax 3.54 3.37 3.41 3.56
Use regular exercise 3.63 3.72 3.63 3.79
Be aware of my limits in exercise 3.97 3.98 3.99 4.05
Manage medication, knowing how and when to take it 4.24 4.25 4.18 4.23
Look out for and avoid side effects of medication 3.92 3.88 4.02 4.01
Seek help with persistent side effects 4.03 4.02 4.04 4.04
a Scored 1–5, with higher score meaning greater self-efficacy.
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Appendix 19 Social contact with other people for
support with fatigue or arthritis
Response
Time point, n (%)a
52 weeks 104 weeks
Control RAFT Control RAFT
Data returned 113 (71.5) 125 (71.4) 104 (65.8) 118 (67.4)
Made contact in past year 21 (13.3) 12 (6.9) 21 (13.3) 16 (9.1)
Face-to-face meetings 10 (6.3) 7 (4.0) 13 (8.2) 9 (5.1)
Still in touch 15 (9.5) 8 (4.6) 16 (10.1) 10 (5.7)
Made contact with RAFT programme group 35 (20.0) 16 (9.1)
Face-to-face with RAFT programme group 18 (10.3) 11 (6.3)
Still in touch with RAFT programme group 22 (12.6) 10 (5.7)
a Percentage of total randomised (control, n = 158; RAFT, n = 175).
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Appendix 20 Baseline work productivity
In the past 7 daysa
Trial arm, mean (SE)
p-valueControl (n= 158) RAFT (n= 175)
Employed at baselineb 37 (23.42%) 39 (22.29%) 0.81c
Hours lost due to arthritis fatigued 1.97 (0.46) 2.82 (1.19) 0.52e
Hours actually workedd 24.57 (2.51) 25.56 (2.57) 0.78e
Perceived effect on work productivity while at workd,f 4.19 (0.40) 3.85 (0.40) 0.55e
a WPAI scale.
b Number (%) of those randomised (control, n = 158; RAFT, n = 175).
c Chi-squared statistic.
d Calculated on those in employment only.
e t-test.
f Patient opinion, NRS 0–10, high is greatest effect.
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Appendix 21 Correlations between change in
individual dimensions of the EuroQol-5 Dimensions
and change in BRAF-NRS impact
EQ-5D-5L domain
BRAF-NRS impact, correlation (95% CI)a
26 weeks 104 weeks
Mobility 0.25 (0.14 to 0.36) 0.29 (0.18 to 0.40)
Self-care 0.21 (0.10 to 0.32) 0.22 (0.10 to 0.34)
Usual activities 0.25 (0.14 to 0.36) 0.41 (0.31 to 0.51)
Pain 0.29 (0.18 to 0.39) 0.37 (0.26 to 0.47)
Anxiety/depression 0.36 (0.26 to 0.46) 0.24 (0.12 to 0.35)
a Pearson’s correlation coefficient.
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Appendix 22 Complete-case health economics
sensitivity analysis
TABLE 31 Cost-effectiveness statistics from a societal perspective at 26 weeks
Costs and outcomes
Trial arm
Difference (95% CI) p-value
Control (n= 134) RAFT (n= 140)
Mean SE Mean SE
Unadjusted costs from the societal
perspective (£)
3343 355 3817 333
Adjusted costs from the societal
perspective (£)a
3379 336 3784 328 405 (–517 to 1327) 0.39
Unadjusted QALYs over 26 weeks of
follow-up
0.276 0.009 0.275 0.009
Adjusted QALYs over 26 weeks of
follow-upb
0.273 0.006 0.277 0.006 0.004 (–0.012 to 0.020) 0.63
ICER 101,561
Net monetary benefit at £20,000 (£) –325 (–1367 to 716)
Net monetary benefit at £30,000 (£) –285 (–1416 to 846)
Probability that the RAFT programme is cost-effective at £20,000 per QALY 0.27
Probability that the RAFT programme is cost-effective at £30,000 per QALY 0.31
a Adjusted for centre.
b QALYs adjusted for baseline utility and centre.
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FIGURE 6 Cost-effectiveness acceptability curve: variation in probability of RAFT programme cost-effectiveness at a
range of societal WTP thresholds – complete-case analysis.
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Appendix 23 Cost-effectiveness and BRAF-NRS
impact outcome
Cost-effectiveness threshold (£000)
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FIGURE 7 Cost-effectiveness acceptability curve: variation in probability of RAFT programme cost-effectiveness at a
range of societal WTP thresholds for BRAF-NRS impact. Secondary analysis: NHS/PSS perspective BRAF-NRS outcome.
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